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ABSTRACT
Self-Reported Physician Prescribing Behavior and Factors Related to
Antidepressant Prescribing to Children and Adolescents with Major Depressive
Disorder
Andrea R. Pfalzgraf, MPH
Major depressive disorder is a serious public health problem and impacts
approximately 2% of children and 4-8% of the adolescents in the United States (Birmaher
et al., 1996). There are risks associated with untreated major depressive disorder and no
sound epidemiological basis for treating children and adolescents with this disorder
(Brent, 2005). The purpose of this study was to examine physician treatment preferences
for children and adolescents with major depressive disorder and to examine the factors
which impact these choices.
The study was conducted in two phases. Phase I involved identifying pediatricians
who treat child and adolescents for major depressive disorder and who were willing to
participate in the larger Phase II survey, regarding specific treatment practices.
Survey methodology was utilized in both phases and a national random sample of
pediatricians (n= 2,000) and child psychiatrists (n= 2,250) was employed.
Approximately 40.00% of the pediatricians who returned surveys indicated they treat
children and/or adolescents. Of those 163 pediatricians who treat children and/or
adolescents, only 67.48% (n=110) were willing to participate in the Phase II survey.
Phase II of this study determined the majority of the child psychiatrists indicated they
utilize a combination of antidepressants and counseling to treat children (52.19%) and
adolescents (76.95%) with major depressive disorder. A preponderance of pediatricians
also use a combination of antidepressants and counseling to treat children (63.46%) and
adolescents (87.72%) with major depressive disorder. In the event physicians utilize an
antidepressant medication for the first-line of treatment for children or adolescents, they
indicated they most commonly prescribe medication was either Prozac® or Zoloft®.
It was found that child psychiatrists and pediatricians monitor both children and
adolescents significantly less (p=0.000) than the U.S. FDA recommendations during the
first and second months of antidepressant therapy. During month three, pediatricians still
monitor children and adolescents significantly less (p=0.000) than the U.S. FDA
recommendations. However, the frequency with which child psychiatrists monitor
children (p=0.098) and adolescents (p=0.101), who are on antidepressant treatment,
during the third month of treatment, does not differ significantly from the U.S. FDA
recommendations
It was found the type of physician, age of the physician, and geographic region in
which the physician practiced was associated with prescribing antidepressant medication
for a child with major depressive disorder. Exploratory factor analysis revealed four
underlying factors; socio-economic status of patient, disease severity, medication cost,
and drug profile. Based on this analysis, it was concluded that these four factors
influence child psychiatrists’ decision of whether or not to prescribe antidepressant
medication to a child or adolescent who had been newly diagnosed with major depressive
disorder.

In the absence of empirical research to guide the selection of treatment of children and
adolescents with major depressive disorder this study determined physicians prefer to
treat children and/or adolescents with a combination of antidepressants and counseling.
Physicians reported an adequate course of treatment to help prevent relapse of depressive
symptoms. However, physicians need to increase the amount of monitoring to be in line
with U.S. FDA monitoring recommendations. Limitations to the study are those inherent
with any research utilizing survey methodology. The rationales behind physician
preferences for treatment and monitoring choices for children and adolescents with major
depressive disorder were not studied and are subject to future research. Further
investigation is also warranted to better understand the associations between physician
characteristics (specialty, age, and geographic location) and the treatment prescribed.
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CHAPTER ONE: INTRODUCTION
Chapter one provides an introduction for this dissertation. The statement of the research
problem and the specific research objectives follow. The chapter concludes with a discussion of
the significance and limitations of the study.
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Major depressive disorder in children and adolescents is a serious public health problem in
the United States (U.S.). Studies indicate that between ten and 15 percent (%) of all children and
adolescents in the U.S. show at least some symptoms of depression (United States Department of
Health and Human Services-SAMHSA, 2004). Major depressive disorder in children under the
age of six years is rare, but does occur (American Academy of Child and Adolescent Psychiatry,
2007; National Alliance for the Mentally Ill, 2004). However, as age increases so does the
prevalence of major depressive disorder. Approximately, two percent of all children between the
ages of six and 12 years have been diagnosed with major depressive disorder, while between four
and 8.3% of adolescents (13-18 years) in the U.S. are affected by major depressive disorder
(Birmaher, Ryan, & Williamson, 1996; National Alliance for the Mentally Ill, 2004). Before
children reach puberty, the rates of depression among males and females indicate that they are
equally impacted by the disorder (American Academy of Child and Adolescent Psychiatry, 2007;
Costello, Mustillo, Erkanli, Keeler, & Angold, 2003). Once an individual reaches adolescence,
females are twice as likely as males to have major depressive disorder (American Academy of
Child and Adolescent Psychiatry, 2007; Costello et al., 2003). It is estimated that 14-25% of
children and adolescents will experience at least one episode of major depressive disorder before
adulthood (Lewinsohn, Rohde, & Seeley, 1998; Ryan, 2005).
Globally, depression is among the leading cause of disability (World Health Organization,
2007). Although the cost in children and adolescents is unknown, the economic cost of
depression in adults is large (Haby, Tonge, Littlefield, Carter, & Vos, 2004; Lynch & Clarke,
2006; World Health Organization, 2007). Researchers calculated the economic burden of
depression in the U.S. in 2000 to be $83.1 billion (Greenberg et al., 2003). This amount included
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$26.1 billion in direct medical costs and $51.5 billion in associated workplace costs (Greenberg
et al., 2003).
Major depressive disorder is diagnosed in both adults and youth by utilizing the criteria (See
Table 2.1) set forth by the American Psychiatric Association’s Diagnostic and Statistical Manual
of Mental Disorders (DSM). A diagnosis of major depressive disorder is made if the patient has
at least five of the nine symptoms specified in the DSM, for a period of at least two weeks
(American Psychiatric Association, 2000).
There are risks associated with untreated major depressive disorder. Studies indicate that
major depressive disorder in children and adolescents tends to be a chronic and recurring
disorder, which may persist into adulthood (Costello et al., 2002; Emslie et al., 1997; Lewinsohn,
Rohde, Klein, & Seeley, 1999). Additionally, children and adolescents with major depressive
disorder have a greater risk for drug abuse, difficulties in school, impaired functioning, and even
suicide (Lewinsohn et al., 1999; Weissman et al., 1999). Given that there are serious
consequences associated with major depressive disorder, treatment of children and adolescents
with this disorder becomes crucial.
Statement of the Problem
Unfortunately, for physicians the optimal treatment for children and adolescents who have
major depressive disorder is not a clear decision. There is no sound epidemiological basis for
choosing antidepressant treatment in children and adolescents with major depressive disorder
(Brent, 2005). Even the most recently updated Practice Parameters published by the American
Academy of Child and Adolescent Psychiatry are intended to provide physicians with some
guidelines for their treatment decisions (American Academy of Child and Adolescent Psychiatry,
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2007). These Practice Parameters are not meant to serve as or define the standard of care for
children and adolescents with major depressive disorder (American Academy of Child and
Adolescent Psychiatry, 2007).

Only in the last several decades has major depressive disorder

in children and adolescents been recognized as a problem in the scientific community (Costello
et al., 2002). Thus, the scientific literature demonstrating efficacy of antidepressant treatment in
children and adolescents with major depressive disorder is limited and physicians have a limited
number of positive controlled trials upon which to base antidepressant treatment (Ryan, 2005).
Currently, only one antidepressant, Prozac®, is approved by the U.S. Food and Drug
Administration (FDA) to treat major depressive disorder in children and adolescents, but much,
off-label use of other antidepressants occurs (Brent, 2005). Furthermore, all antidepressant
treatments, even those demonstrating efficacy, have been the subject of debate because of a U.S.
FDA Public Health Advisory (U.S. FDA, 2004b).
On October 15, 2004 the U.S. FDA directed manufacturers of antidepressants to revise the
labels of these medications (U.S. FDA, 2004b). It was recommended that a black-box warning
indicating that the use of antidepressant medications increased the risk of suicidality (suicidal
thinking and suicidal behavior) in children and adolescent patients (U.S. FDA, 2004b). In
addition to the warning, the U.S. FDA has suggested certain monitoring should accompany
antidepressant treatment (U.S. FDA, 2005). Ideally, a child or adolescent receiving
antidepressant treatment should be seen by the physician one time per week for the first four
weeks of treatment (U.S. FDA, 2005). During the second and third months of treatment, the
patient should be seen biweekly and at week 12, respectively (U.S. FDA, 2005).
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However, scientific evidence is not the only factor that impacts physicians’ antidepressant
prescribing decisions to children and adolescents with major depressive disorder. Other factors
impacting physicians’ prescribing decisions include, patient-related (e.g., patient’s age),
physician-related (e.g., physician’s specialty), marketing-related (e.g., advertisements), and drugrelated (e.g., drug cost) factors (Benson, 1983; Cates, 2001; Eisenberg, 1979).
The majority of the scientific literature which examines prescribing patterns of medication
to children and adolescents encompass all psychotropic medications (Elfron, 2003; Goodwin,
Gould, Blanco, & Olfson, 2001; Haapasalo-Pesu, Erkolahti, Saarijarvi, & Aalberg, 2004;
Harpaz-Rotem & Rosenheck, 2006; Hugtenburg, Heerdink, & Tso, 2005; Hong & Shepherd,
1996; Jensen et al., 1999; Kaplan & Busner, 1997; Lekhwani, Nair, Nikhinson, & Ambrosini,
2004; Najjar et al., 2004; Olfson, Gameroff, Marcus, & Waslick, 2003; Rushton & Whitmire,
2001; Safer, 1997; Zito et al., 2000; Zito et al., 2003), all mental illness diagnoses (Elfron, 2003;
Goodwin et al., 2001; Haapasalo-Pesu et al., 2004; Harpaz-Rotem & Rosenheck, 2006;
Hugtenburg et al., 2005; Hong & Shepherd, 1996; Jensen et al., 1999; Kaplan & Busner, 1997;
Lekhwani et al., 2004; Najjar et al., 2004; Rushton & Whitmire, 2001; Safer, 1997; Zito et al.,
2000; Zito et al., 2003), and examine prescribing trends over time (Goodwin et al., 2001;
Haapasalo-Pesu et al., 2004; Hong & Shepherd, 1996; Lekhwani et al., 2004; Najjar et al., 2004;
Olfson et al., 2003; Rushton & Whitmire, 2001; Safer, 1997; Zito et al., 2000; Zito et al., 2003).
These studies have limited generalizability because of geographic limitations (Elfron, 2003;
Haapasalo-Pesu et al., 2004; Hugtenburg et al., 2005; Kaplan & Busner, 1997; Lekhwani et al.,
2004; Najjar et al., 2004; Rushton & Whitmire, 2001; Safer, 1997). For example, the Rushton &
Whitmire (2001) study was limited to the state of North Carolina. Several other studies are not
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generalizable to the U. S. because they examine prescribing trends in European countries or
Australia (Elfron, 2003; Haapasalo-Pesu et al., 2004; Hugtenburg et al., 2005; Kaplan & Busner,
1997).
Fewer studies focus only on antidepressant prescribing to children and adolescents (Bramble,
1995; Fegert, Kolch, Zito, Glaeske, & Janhsen, 2006; Kurian et al., 2007; Murray, deVries, &
Wong, 2004; Murray, Thompson, Santosh, & Wong, 2005; Nemeroff et al., 2007; Rushton,
Clark, & Freed, 2000; Vitiello, Zuvekas, & Norquist, 2006; Zito et al., 2002). These studies do
limit their analysis to only antidepressant medications but no studies were located that limited the
patient diagnosis to major depressive disorder. The majority of the scientific literature, which
examines the prescribing of antidepressants to children and adolescents, has utilized large
databases. The exception being three studies, Bhatia et al., 2008, Bramble, 1995, and Rushton,
Clark, & Freed, 2000, which used surveys to obtain prescribing information directly from
physicians who prescribe antidepressants to children and adolescents. Thus, most of these
studies capture information about antidepressant utilization, and not data regarding the decisionmaking process. A few studies examined antidepressant use in relation to the demographic
characteristics of patients (Fegert et al., 2006; Rushton et al., 2000; Vitiello et al., 2006; Zito et
al., 2002). No studies were located which examined predictors of antidepressant prescribing in
the U.S. after the 2004 FDA warning, however a few studies did examine the impact of the 2004
warnings on the number of prescriptions for antidepressants to children and adolescents (Bhatia
et al., 2008; Kurian et al., 2007; Nemeroff et al., 2007).
In the absence of empirical research to guide the selection of antidepressant treatment
additional research needs to be conducted to examine: 1) what physicians consider to be the

6

most appropriate antidepressant treatment, 2) physicians’ recommended course of treatment, and
3) the factors which impact physicians’ decisions to treat major depressive disorder in children
and adolescents with antidepressants. Thus, the purpose of this study is designed to examine
physician antidepressant choices for children and adolescents with major depressive disorder and
to examine the factors which impact these choices.
Study Objectives
The study will be conducted in two phases. Phase I will consist of a national survey to
determine the proportion of pediatricians who treat children and adolescents with major
depressive disorder, in the U.S. These physicians will also be asked to participate in phase II of
this study. The specific objectives of phase I are as follows:
Phase I Objectives:
Objective 1: To determine the proportion of pediatricians who treat children and adolescents
with major depressive disorder.
Objective 2: To determine the proportion of pediatricians who refer children and adolescents
with major depressive disorder.
Objective 3: To determine the health care provider to whom pediatricians refer a child or
adolescent with major depressive disorder.
Objective 4: To determine geographic differences in pediatricians’ willingness to treat versus
referral of children and/or adolescents with major depressive disorder.
Null Hypothesis 4.0: There is no difference in the geographic locations of pediatricians who
treat versus refer children and/or adolescents for major depressive disorder.
Phase II of this study will survey the pediatricians identified in phase I plus a random sample
of child psychiatrists. This phase is designed to ascertain information about physicians’
treatment and prescribing patterns of antidepressants to both newly diagnosed children (five
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through 12 years of age) and adolescents (13 through 18 years of age) with major depressive
disorder. The specific objectives address each age category separately.
Phase II Objectives:
Objectives 5 through 13 focus on the treatment and prescribing patterns of children (five
through 12 years of age) with major depressive disorder.
Objective 5: To determine the demographic characteristics of physicians who treat newly
diagnosed children with major depressive disorder.
Objective 6: To determine physicians’ first line of treatment for newly diagnosed children with
major depressive disorder by: a) type of treatment, b) drug category, and c) specific
antidepressant prescribed.
Objective 7: To determine physicians’ second and third lines of treatment for newly diagnosed
children with major depressive disorder by: a) drug category, and b) specific antidepressant
prescribed.
Objective 8: To determine the difference in first, second, and third lines of antidepressant
treatment prescribed by physicians to newly diagnosed children with major depressive disorder
by a) the pharmacotherapy category and b) specific antidepressant prescribed.
Null Hypothesis 8.a: There is no difference in the pharmacotherapy category prescribed by
physicians for first, second, and third lines of antidepressant treatment for newly diagnosed
children with major depressive disorder.
Null Hypothesis 8.b: There is no difference in the specific antidepressant prescribed by
physicians for first, second, and third lines of treatment for newly diagnosed children with major
depressive disorder.
Objective 9: To predict which physician characteristics effect the treatment prescribed for
children with major depressive disorder.
Objective 10: To determine the average length of antidepressant treatment for newly diagnosed
children with major depressive disorder.
Objective 11: To determine the types of pharmacotherapy monitoring in newly diagnosed
children with major depressive disorder.
Objective 12: To determine differences in antidepressant monitoring for newly diagnosed
children with major depressive disorder and the U.S. FDA recommendations for monitoring
children treated with antidepressants.
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Null Hypothesis 12.0: There is no difference in pharmacotherapy monitoring for newly
diagnosed children with major depressive disorder and the U.S. FDA recommendations for
monitoring children treated with antidepressants.
Objective 13: To determine whether there are differences, by physician type, in the average
number of times per month physicians monitor children with major depressive disorder.
Null Hypothesis 13.0: There is no difference, by physician type, in the average number of times
per month physicians monitor children with major depressive disorder.
Next, Objectives 14 through 22 address these same issues but in the adolescents (13 through
18 years of age) population.
Objective 14: To determine the demographic characteristics of physicians who treat newly
diagnosed adolescents with major depressive disorder.
Objective 15: To determine physicians’ first line of treatment for newly diagnosed adolescents
with major depressive disorder by: a) type of treatment, b) drug category, and c) specific
antidepressant prescribed.
Objective 16: To determine physicians’ second and third lines of treatment for newly diagnosed
adolescents with major depressive disorder by: a) drug category, and b) specific antidepressant
prescribed.
Objective 17: To determine the difference in first, second, and third lines of antidepressant
treatment prescribed by physicians to newly diagnosed adolescents with major depressive
disorder by a) the pharmacotherapy category and b) specific antidepressant prescribed.
Null Hypothesis 17.a: There is no difference in the pharmacotherapy category prescribed by
physicians for first, second, and third lines of antidepressant treatment for newly diagnosed
adolescents with major depressive disorder.
Null Hypothesis 17.b: There is no difference in the specific antidepressant prescribed by
physicians for first, second, and third lines of treatment for newly diagnosed adolescents with
major depressive disorder.
Objective 18: To predict which physician characteristics effect the treatment prescribed for
adolescents with major depressive disorder.
Objective 19: To determine the average length of antidepressant treatment for newly diagnosed
adolescents with major depressive disorder.
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Objective 20: To determine the types of pharmacotherapy monitoring in newly diagnosed
adolescents with major depressive disorder.
Objective 21: To determine differences in antidepressant monitoring for newly diagnosed
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring
adolescents treated with antidepressants.
Null Hypothesis 21.0: There is no difference in pharmacotherapy monitoring for newly
diagnosed adolescents with major depressive disorder and the U.S. FDA recommendations for
monitoring children treated with antidepressants.
Objective 22: To determine whether there are differences, by physician type, in the average
number of times per month physicians monitor adolescents with major depressive disorder.
Null Hypothesis 22.0: There is no difference, by physician type, in the average number of times
per month physicians monitor adolescents with major depressive disorder.
Phase II of this study also utilizes survey methodology to determine factors which influence
child psychiatrists’ decisions to prescribe antidepressant therapy to children and adolescents who
have been diagnosed with major depressive disorder. The relative importance of the factors,
which influence these physicians’ decisions regarding antidepressant treatment, will also, be
determined. The specific objectives for this portion of the study are listed below.
Objective 23: To determine the relative importance which physicians place on each factor prior
to prescribing antidepressants to newly diagnosed children and adolescents with major
depressive disorder.
Objective 24: To determine the factors associated with physicians’ antidepressant prescribing
behavior for children and adolescents newly diagnosed with major depressive disorder.
Significance of the Study
The current study will be a valuable addition to the literature because it will be the first study,
in the U.S. to determine, on a national scale, which factors physicians consider when making
decisions to treat children and adolescents with major depressive disorder. This will also be the
first U.S. study to determine physicians’ first, second, and third-lines of antidepressant treatment
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by category and specific drug; the length of treatment; and monitoring practices in the treatment
of newly diagnosed children and adolescents with major depressive disorder.
Additionally, little is known about the variables which influence child psychiatrists’ decision
to prescribe antidepressant medication to children and adolescents with major depressive
disorder. Thus, by examining the variables which influence child psychiatrists’ antidepressant
prescribing decisions, the results may be utilized as the basis for future studies to research
prescribing decisions in greater detail.
The results of the current study will also be beneficial to health care organization and
pharmaceutical manufactures in the creation of marketing and educational strategies aimed at
physicians who utilize antidepressants to treat children and adolescents with major depressive
disorder. By taking into consideration what physicians deem important in the prescribing
decision, newly created marketing, promotional, and educational materials may incorporate this
information and create advertising and educational messages which better appeal to physicians.
Another benefit of this study is the identification of the most appropriate treatment for
children and adolescents with major depressive disorder. Child psychiatrists are the experts in
treating children and adolescents for major depressive disorder. According to the American
Academy of Child and Adolescent Psychiatry, child psychiatrists undergo two years of
specialized training beyond that of an adult psychiatrist (American Academy of Child and
Adolescent Psychiatry, 2001). Although other physicians may treat children and adolescents
with major depressive disorder child psychiatrists should be the experts based on their training.
Thus, the information gleaned from this study will not only provide guidance to other physician
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specialties, but also to parents about the best treatment options for children and adolescents with
major depressive disorder.
Limitations of the Study
Limitations to the current study are similar to other studies that employ survey methodology.
These limitations include errors such as sampling error, measurement error, and non-response
error. Sampling error will be minimized by conducting a national survey and utilizing the most
comprehensive mailing lists of physicians available. Non-response error should be minimized
by repeated mailings and the identification of pediatricians who treat children and adolescents in
Phase I of the study. Chapter two will discuss the literature reviewed for the basis of this study.
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CHAPTER TWO: LITERATURE REVIEW
Chapter two discusses the treatment of major depressive disorder in children and adolescents.
The chapter begins with the topic of diagnosis, clinical course of major depressive disorder, and
the risk factors associated with untreated major depressive disorder. Next, the stages of major
depressive disorder treatment are described. This is followed by a discussion of the different
classes of antidepressant treatment, their mechanism of action, and their efficacy for the
treatment of major depressive disorder in children and adolescents. Efficacy of psychotherapy
and the combination of antidepressant treatment and psychotherapy are then reviewed. An
examination of the factors which influence physicians’ prescribing decisions, with specific
attention given to the scientific literature regarding antidepressant prescribing to children and
adolescents follows. The chapter concludes with a summary of these factors and additional
factors which have been found to influence other prescribing decisions.
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Diagnosis of Major Depressive Disorder
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a standard classification
of mental disorders and is written and published by the American Psychiatric Association. The
American Psychiatric Association is an organization that represents United States (U.S.)
psychiatrists (American Psychiatric Association, 2006a). The last revisions to the DSM were
made when the DSM-IV-TR edition was published in July 2000 (American Psychiatric
Association, 2006c). The DSM is utilized by mental health professionals to help diagnose
mental disorders. It contains a list of psychiatric disorders, diagnostic criteria, text describing the
disorder and its epidemiology, and a diagnostic code that corresponds to each of these disorders
(American Psychiatric Association, 2006c). Institutions, agencies, and researchers may use these
codes for data collection and billing purposes (American Psychiatric Association, 2006c). These
diagnostic codes have been derived from the International Statistical Classification of Diseases
and Related Health Problems (ICD) (American Psychiatric Association, 2006c). No information
about treatment is included in the DSM (American Psychiatric Association, 2006c).
According to the DSM-IV-TR a patient can be diagnosed with major depressive disorder if
five or more of the nine specified symptoms have been present during the same two-week period
and represent a change from previous functioning (American Psychiatric Association, 2000).
These nine symptoms are described in Table 2.1.
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Table 2.1: Nine Symptoms from DSM-IV-TR Utilized to Diagnose Major Depressive
Disordera
1. Depressed mood most of the day, nearly every day, as indicated by either
subjective report (e.g., feels sad or empty) or observation made by others (e.g.,
appears tearful). Note: In children and adolescents, can be irritable mood.
2. Markedly diminished interest or pleasure in all, or almost all, activities most of
the day, nearly every day (as indicated by either subjective account or observation
made by others)
3. Significant weight loss when not dieting or weight gain (e.g. a change of more
than 5% of body weight in a month) or decrease or increase in appetite nearly
every day. Note: In children, failure to make expected weight gains
4. Insomnia or hypersomnia nearly every day
5. Psychomotor agitation or retardation nearly every day (observable by others, no
merely subjective feelings of restlessness or being slowed down)
6. Fatigue or loss of energy nearly every day
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be
delusional) nearly every day (not merely self-reproach or guilt about being sick)
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day
(either by subjective account or as observed by others)
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation
without a specific plan, or a suicide attempt or a specific plan or committing
suicide.

a

Adapted from DSM-IV-TR(American Psychiatric Association, 2000)

It should be noted the DSM-IV-TR requires that either depressed mood or loss of interest or
pleasure in activities be a present symptom for the patient to be diagnosed with major depressive
disorder (American Psychiatric Association, 2000). Additionally, the DSM-IV-TR requires that
certain symptoms may not be utilized to make a diagnosis of major depressive disorder. These
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symptoms are as follows: any symptom that is due to a general medical condition, moodincongruent delusions, or hallucinations (American Psychiatric Association, 2000). The DSM
indicates that for children and adolescents the irritable mood symptom may replace the depressed
mood symptom, which is usually present in adults who are diagnosed with major depressive
disorder (American Psychiatric Association, 2000). Also, children may fail to make expected
weight gains when they have major depressive disorder (American Psychiatric Association,
2000).
Clinical Course of Major Depressive Disorder
A major depressive episode is defined by utilizing the diagnostic criteria set forth by the
American Psychiatric Association and are listed in Table 2.1 (American Psychiatric Association,
2000). It is estimated that between 14-25% of children and adolescents experience at least one
episode of major depressive disorder before adulthood (Lewinsohn, Rhode, & Seeley, 1998;
Ryan, 2005). The median duration of a major depressive episode for youth is between seven to
nine months (American Academy of Child and Adolescent Psychiatry, 1998; Kovacs, Obrosky,
Gatsonis, & Richards, 1997). Several terms have been frequently utilized by clinicians and
researchers to describe the clinical course of an episode of major depressive disorder.
Unfortunately, these terms have not always been utilized in a standardized manner. Frank et al.
(1991) proposed standard definitions for these terms so that research results regarding the
clinical course of major depressive disorder in children and adolescents might be compared. The
American Academy of Child and Adolescent Psychiatry has adapted these terms and utilized
them in their 1998 practice parameters (American Academy of Child and Adolescent Psychiatry,
1998). The terms and definitions can be found in Table 2.2.
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Table 2.2: Terms and Definitions Describing the Clinical Course of Major Depressive
Disordera
Term:
Definition:
1. Response

2. Remission
3. Partial remission

4. Recovery
5. Relapse
6. Recurrence

a

Significant improvement of depressive
symptoms during the initial or acute
treatment phase. In general, response
coincides with the onset of remission.
A period of at least two weeks and less
than two months with no more than one
clinically significant symptom.
A period of at least two weeks and less
than two months with more than one
clinically significant symptom but fewer
symptoms than the full syndrome.
An asymptomatic period of more than two
months.
An episode of depression during the period
of remission.
The emergence of symptoms of major
depressive disorder during the period of
recovery (a new episode).

Adapted from Frank et al., 1991

Emslie et al. (1997) assessed remission, recovery, and recurrence of major depressive disorder in
hospitalized children and adolescents, utilizing the definitions established by Frank et al. (1991).
The average time to remission was 59.5 days with a range of 14 to 246 days (Emslie et al, 1997).
Recovery was achieved in 98% of the patients within one year and recurrence occurred in 61%
of the children and adolescents (Emslie et al, 1997). Of those with a recurrence of major
depressive disorder, 47.2% had the recurrence within the first year, while another 22.2% (a total
of 69.4%) had the recurrence of major depressive disorder by the end of year two (Emslie et al.,
1997).
Other studies have indicated that depression is chronic and most children and adolescents who
have experienced an episode of major depressive disorder will have a recurrence of the disorder
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within five years (Kovacs et al., 1984; Ryan, 2005). Additionally, depressed youth have
recurrences of depression into adulthood at rates of 30%-50% (Angst, Gamma, Sellaro, Lavori,
& Zhang, 1990; Costello et al., 2002; Lewinsohn, Rhode, Klein, & Seeley, 1999). Since major
depressive disorder can be chronic and recur, treatment of this disorder in children and
adolescents becomes important. Treatment is also important as there are various risk factors
associated with major depressive disorder in children and adolescents. The next section
discusses some of the risk factors associated with major depression in children and adolescents.
Risk Factors Associated with Major Depressive Disorder
Major depressive disorder in children and adolescents is associated with a high degree of
morbidity and mortality. Children and adolescents with major depressive disorder, compared to
normal controls are at greater risk for drug and alcohol abuse, tend to experience significantly
greater difficulty in school and work, and have greater impairment in overall functioning
(Lewinsohn et al., 1999; Weissman et al., 1999). Left untreated, major depressive disorder is
likely to recur in children and adolescents (Lewinsohn et al., 1999). Research indicates that
untreated depression, which began during childhood or adolescence, tends to persist into
adulthood (Lewinsohn et al., 1999; Weissman et al., 1999).
Left untreated major depressive disorder can a have serious impact on the lives of children
and adolescents. Major depressive disorder is associated with a higher risk of substance abuse,
impaired functioning, and even suicide. Although not all depressed youth commit suicide, it has
been estimated that between 40-80% of youth with depression have experienced thoughts of
suicide (American Psychiatric Association & American Academy of Child and Adolescent
Psychiatry, 2004). As age increases so does the risk of suicide, from 1.3/100,000 for youth aged
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10-14 years to 8.2/100,000 for adolescents aged 15-19 years (National Institute of Mental Health,
2004). Furthermore, research indicates that over 50% of those children and adolescents
diagnosed with depression will attempt suicide, and at least 7% will take their lives as a result of
depression (Ringold, 2005).
Untreated major depressive disorder tends to recur in youth and continue into adulthood.
Furthermore, there are serious risks related to untreated major depressive disorder. Therefore, it
is imperative that this disorder be treated in children and adolescents.
Stages of Major Depressive Disorder Treatment
Treatment is commonly referred to in the literature as being divided into three stages or
phases (Agency for Health Care Policy and Research, 1993). The Agency for Healthcare
Research and Quality (AHRQ), formerly the Agency for Healthcare Policy and Research
(AHCPR) defined the three phases for the treatment of major depressive disorder (Karasu,
Gelenberg, Merriam, & Wang, 2000; Agency for Health Care Policy and Research, 1993). The
aim of each phase is the “attainment of a stable, fully asymptomatic state and full restoration of
psychosocial function” (Agency for Health Care Policy and Research, 1993). The first or initial
phase of treatment is the acute treatment phase. This phase uses formal procedures to reduce or
remove the symptoms and signs of depression and helps to restore the patient’s psychosocial
function (Agency for Health Care Policy and Research, 1993). The patient is considered a
responder and remission is induced when the patient improves with the use of treatment. The
next phase is the continuation phase of treatment. The purpose of the continuation phase of
treatment is to prevent a relapse and maintain remission (Agency for Health Care Policy and
Research, 1993). Based on the AHRQ definition, the continuation phase continues until the

19

patient has maintained remission for six months (Agency for Health Care Policy and Research,
1993). Some physicians may discontinue treatment at the end of the continuation phase;
however treatment may be continued into the maintenance phase of treatment (Agency for
Health Care Policy and Research, 1993). The purpose of maintenance treatment is to prevent a
recurrence or a new episode of major depressive disorder in the patient (Agency for Health Care
Policy and Research, 1993).
Treatment of Major Depressive Disorder in Children and Adolescents
Antidepressant medication and psychotherapy have each been found to be beneficial in the
treatment of major depressive disorder. The research on the efficacy of major depressive
disorder treatments for children and adolescents has only been conducted in the more recent
years and literature in this area is limited when compared to the literature in the treatment of
major depressive disorder in the adult population. Additionally, some of the treatments that have
proved helpful in the adult population are not efficacious when treating children and adolescents
with major depressive disorder. Therefore, the adult research results should not be generalized to
the child and adolescent population and additional research needs to be conducted in this area.
The following two sections of this dissertation will be devoted to antidepressant treatments
for children and adolescents with major depressive disorder. First, each class of antidepressant
medication will be reviewed. Second, the randomized clinical trials of antidepressant medication
for major depressive disorder in children and adolescents will be examined.
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Antidepressant Treatment of Major Depressive Disorder
Mechanism of Action
Although the mechanism of antidepressants is not completely understood, the general action
of these medications is believed to be the following: Neurotransmitters, including
norepinephrine, serotonin, and dopamine, are released from one neuron or the presynaptic
neuron into the synapse, or space between two neurons (Lieberman, 2003; Trujillo & Chinn,
1996). Once in the synapse neurotransmitters can be deactivated by being reabsorbed by the
presynaptic neuron or by being broken down by an enzyme called monoamine oxidase (Trujillo
& Chinn, 1996). It is thought that depression results from a decrease in the concentration of
neurotransmitters within the synapse. Therefore, antidepressants act to increase concentrations
of neurotransmitters within the synapse by either blocking the reuptake or re-absorption of
neurotransmitters from the synapse or by preventing the enzymatic action of monoamine oxidase
with the synapse.
Each class of antidepressants, their mechanism of action, and their side effects will be
discussed in the following section. Randomized controlled trials related to each class of
antidepressant will be discussed later in this chapter.
Monoamine Oxidase Inhibitors (MAOIs)
Monoamine Oxidase Inhibitors (MAOIs) are a class of antidepressant medication and include
the drugs Marplan® (isocarboxazid), Nardil® (phenelzine sulfate), and Parnate® (tranlcypromine
sulfate). These medications were among the first antidepressants to be synthesized and their
utilization began in the early 1950’s (Lieberman, 2003; Plestscher, 1991; Trujillo & Chinn,
1996).
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The MAOIs operate by inhibiting the action of the enzyme, monoamine oxidase which breaks
down neurotransmitters, including norepinephrine, serotonin, and dopamine, within the synaptic
cleft (Lieberman, 2003; Plestscher, 1991; Trujillo & Chinn, 1996). Because the MAOIs block
the action of monoamine oxidase these neurotransmitters are not destroyed and they build up in
the synapse. It is thought that the decreased levels of neurotransmitters are associated with
depression. Therefore, MAOIs increase neurotransmitter concentrations, and this higher
concentration is believed to relieve depressive symptoms.
Although, MAOIs can be effective in treating depression these medications have the potential
for serious side effects and numerous drug and food interactions. Side effects range from
dizziness, blurred vision, and weight gain to hypertensive crisis (National Institutes of Health,
2005). Patients taking MAOIs must avoid foods and drugs that have a high tyramine content
including cheeses, poultry, alcoholic beverages, coffee, tea, and chocolate (National Institutes of
Health, 2005). This trend seems to be related to the potentially serious side effects and
dangerous interactions with any food or drug which contains tyramine (McCrabe, 1986).
Tyramine aids in regulating blood pressure (Mayo Clinic, 2004). MAOIs prevent the normal
destruction of tyramine, which results in a high level of this amino acid to build up in the human
body (Mayo Clinic, 2004). Higher than normal levels of tyramine may cause a severe increase in
blood pressure and the results can be fatal (Mayo Clinic, 2004).
It has been noted in the literature that MAOIs have not been widely utilized in the child and
adolescent population (Emslie, Walkup, Pliszka, & Ernst, 1999). In fact due to the potential for
side effects and interactions some psychiatrists never prescribe MAOIs (Fiedorowicz & Swartz,
2004).
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Tricyclic Antidepressants (TCAs)
Concurrent to the development and utilization of the MAOIs was the synthesis and use of the
class of antidepressants known as TCAs (Lieberman, 2003; Pletscher, 1991). The first TCA to
be synthesized was Tofranil® (imipramine HCl) (Lieberman, 2003; Pletscher, 1991; Trujillo &
Chinn, 1996). By the 1960’s other TCAs, including Norpramin® (desipramine HCl) and Elavil®
(amitriptyline HCl), were developed (Lieberman, 2003). These newer TCAs were relatively safer
and better tolerated by patients than the older Tofranil® (Lieberman, 2003; Pletscher, 1991).
The TCAs act by blocking the reuptake of neurotransmitters into neurons (Pletscher, 1991).
The disadvantage of this class of antidepressants is that they are associated with undesirable side
effects including dry mouth, dizziness, and weight gain (Hazell, O’Connell, & Heathcote, 1995).
Additionally, the TCAs may cause more serious adverse effects including cardiovascular events
and the potential for overdose (Hazell et al., 1995).
Tetracyclic Antidepressants
In 1980, the U.S. Food and Drug Administration (FDA) approved Ludiomil® (maprotiline
HCl) for use in the treatment of depression (United States Food and Drug Administration, 2007).
The other tetracyclic antidepressant Remeron® (mirtazpine) was not approved by the U.S. FDA
until 1996 (MedicineNet.com, 1999; United States Food and Drug Administration, 2007).
Tetracyclic antidepressants increase the amount of the neurotransmitters, norepinephrine and
serotonin (MedicineNet.com, 1999). Like the MAOIs and TCAs, the tetracyclic antidepressants
have relatively more side effects than some of the other antidepressants developed in the last two
decades. The more prominent side effects of the tetracyclic antidepressants include sedation and
risk of overdose (HealthyPlace, 2006).
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Selective Serotonin Reuptake Inhibitors (SSRIs)
The next major class of antidepressants to be developed was the SSRIs (Pletscher, 1991). In
1987, Prozac® (fluoxetine HCl), was the first SSRI to be approved and launched in the
U.S.(United States Food and Drug Administration, 2007). It should be noted that Prozac® is the
only antidepressant that has been approved for use in the child and adolescent population, and
the U.S. FDA granted this approval in 2003 (United States Food and Drug Administration,
2007). The 1990’s and early 2000’s brought the development and launch of other SSRIs
including Celexa® (citalopram HBr), Lexapro® (escitalopram oxalate), Paxil® (paroxetine HCl),
Luvox ® (fluvoxamine maleate), and Zoloft® (sertraline HCl) (United Stated Food and Drug
Administration, 2007). As their name suggests, the SSRIs act by selectively inhibiting the
reuptake of the neurotransmitter serotonin (Pletscher, 1991). This results in an increase in
serotonin levels which helps to treat depressive symptoms (Pletscher, 1991).
This class of antidepressants has the advantage of an improved safety and tolerability profile,
relative to the MAOIs or TCAs (Emslie et al., 1999; Lieberman, 2003; Pletscher, 1991).
Additionally, the SSRIs have the advantage of being safer to the patient if taken in excess, such
as in an attempt at a drug overdose (Emslie et al., 1999). Common side effects of the SSRIs
include agitation, sleep difficulties, and gastrointestinal upset (Emslie et al., 1999).
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
The SNRIs were developed during the same time period as the SSRIs. By 1993, the U.S.
FDA approved, the first SNRI, Effexor® (venlafaxine HCl) for the treatment of depression
(United States Food and Drug Administration, 2007). Cymbalta® (duloxetine HCl) was
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approved in 2004, in the U.S., for use in the treatment of depression (United States Food and
Drug Administration, 2007).
The SNRIs have an action similar to that of the TCAs, as these antidepressants block the
reuptake of both norepinephrine and serotonin. However, SNRIs have an improved side effect
profile compared to TCAs including less risk of cardiovascular events and less potential for
overdose (United States Food and Drug Administration, 2007).
Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs)
Wellbutrin® (buproprion HCl) is an NDRI and is unique as its mechanism of action mainly
affects the neurotransmitter dopamine (GlaxoSmithKline, 2006). However, this NDRI inhibits
the reuptake of serotonin, norepinephrine, and dopamine (GlaxoSmithKline, 2006). Wellbutrin®
was initially approved by the U.S. FDA for use in the treatment of depression in 1985 (United
States Food and Drug Administration, 2007). Since that time two other dosage forms of
Wellbutrin® have gained approval for the treatment of depression. In 1996 Wellbutrin SR® was
approved and in 2003 Wellbutrin XL® gained approval (United States Food and Drug
Administration, 2007). The SR or sustained-release and XL or extended-release versions of
Wellbutrin® both release bupropion at a slower rate.
This antidepressant seems to be well-tolerated and is relatively safe, even in overdose
situations (Carson, Butcher, & Mineka, 2002). Common side effects with this antidepressant are
agitation, insomnia, dizziness, headache, rapid heartbeat, and weight loss (GlaxoSmithKline,
2006).
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Other Antidepressants
Two chemically related antidepressants Desyrel® (trazodone HCl) and Serzone® (nefazodone
HCl), which are unrelated to other classes of antidepressants, were approved by the U.S. FDA to
treat depression, in 1982 and 1994 respectively (United States Food and Drug Administration,
2007). Desyrel® is believed to inhibit the reuptake of serotonin, while Serzone® inhibits the
reuptake of serotonin and norepinephrine (MedicineNet.com, 1997; MedicineNet.com, 2003).
Desyrel® can be helpful in treating patients that are depressed but also have symptoms of
anxiety, as it has a sedative effect (MedicineNet.com, 2003). Serzone® has been associated with
side effects such as low blood pressure, sleepiness, dry mouth, nausea, dizziness, vision
problems, and confusion (United States Food and Drug Administration, 2005c). More critically,
Serzone® has been associated with liver failure. Serzone® has been removed from many markets
including the European, Australian, New Zealand, and Canadian markets (United States Food
and Drug Administration, 2005c; WebMD, 2004). As of June 14, 2004, Bristol-Myers Squibb
stopped selling Serzone®, however generic versions of the antidepressant are still available
(United States Food and Drug Administration, 2005c; WebMD, 2004). The U.S. FDA now
requires that nefazodone’s label carry a black box warning of life-threatening liver damage
(United States Food and Drug Administration, 2007; WebMD, 2004).
Outcome Measures Utilized in Randomized Clinical Trails
The randomized clinical trials (RCTs) for antidepressants and psychotherapy have utilized
several different outcome measures to quantify patients’ response to treatment. Table 2.3
provides an overview of the measures utilized in the antidepressant and psychotherapeutic RCTs,
which will be described in the following section.
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Table 2.3: Instruments Utilized to Measure Patient Outcomes in Randomized Clinical
Trials
Scale

Reference

Number of Items
on the Scale

Age for which
Scale is
Appropriate
Adolescents and
Adults (13-80 yrs.)

Beck Depression
Inventory (BDI)

(Beck & Steer,
1987)

21

Child Behavior
Checklist (CBCL)

(Achenbach &
Rescorla, 2001)

118 plus 2 openended questions

Children (6-18
yrs.)

Children’s
Depression
Inventory (CDI)
Children’s
Depression Rating
Scale (CDRS-R)

(Kovacs, 1992)

27

(Poznanski &
Mokros, 1996)

17

Children and
Adolescents (7-17
yrs.)
Children (6-12
yrs.) and
Adolescents

Children’s Global
Assessment Scale
(CGAS)

(American
Psychiatric
Association, 2000)

Numeric Scale
1-100

Children and
Adolescents (< 18
yrs.)

Clinical Global
Impressions (CGI)

(Guy, 1979)

3

Appropriate for all
Ages

Hamilton
Depression Rating
Scale (HAM-D)

(Hamilton, 1960)

21

Adults (> 18 yrs.)

Raskin Depression
Scale

(Rush, 2000)

3

Adults (> 18yrs.)

Social Adjustment
Scale Self Report
(SAS-SR)

(Weissman &
Bothwell, 1976)

54

17 yrs. and older

27

Purpose of Scale
Self-inventory
scale designed to
measure
depressive
symptoms
Parent-report scale
designed to
measure the child’s
behavior and social
competency
Self-reported
inventory to assess
depression
Semi-structured
interview to
diagnose
depression or
monitor treatment
response
Utilized by
clinicians to rate
the general
functioning of a
child
Utilized by
clinicians to assess
a patient’s
response to
treatment
Semi-structured
interview to
designed to rate
the severity of
depressive
symptoms
Utilized by
clinicians to assess
the severity of
depression
Self-report
inventory designed
to assess
individuals ability
to adapt and be
satisfied with their
social situation

Efficacy of Antidepressants in Children and Adolescents with Major Depressive Disorder
Few studies regarding the efficacy of MAOIs in treating any psychiatric disorder in the child
and adolescent population can be found in the literature (Emslie et al., 1999). Ryan et al. (1988)
conducted a published chart review of 23 adolescent patients who had been diagnosed with
depression and treated with MAOIs. While this study demonstrated some improvement in
depressive symptoms among patients, the authors concluded that the potential risks associated
with these antidepressants outweighed the therapeutic benefit (Ryan et al., 1988).
Despite the fact that TCAs have demonstrated efficacy in adults, this has not proved to be the
case in the child and adolescent population (Hazell et al., 1995; Geller, Reising, Leonard, Riddle,
& Walsh, 1999). Unlike the MAOI class of antidepressant, where there have been few scientific
studies conducted in the child and adolescent population, many RCTs have been conducted for
TCAs. Unfortunately, the results of these trials have not proved TCAs to be efficacious in the
treatment of major depressive disorder in children and adolescents. Included in the literature is a
meta-analysis conducted by (Hazell et al., 1995). This study includes 12 RCTs of TCAs, such as
amitriptyline, desipramine, impramine, and nortriptyline (Hazell et al., 1995). The conclusion of
this study was that TCAs are no more effective than placebo in treating child and adolescent
depression (Hazell et al., 1995). Geller et al. (1999) conducted a systematic review of tricyclic
antidepressant use in children and adolescents. This review also concluded that the TCAs did
not demonstrate efficacy in the treatment of child and adolescent depression (Geller et al., 1999).
Although the literature contains no published RCTs of the tetracyclic antidepressants, there
are results of two unpublished, multi-center, double-blind, placebo controlled trials of Remeron®
in outpatient children and adolescents with major depressive disorder (Dubitsky, 2004). The two

28

trials (hereafter, referred to as Trial #1 and Trial #2) had identical protocols (Medicines and
Healthcare Products Regulatory Agency, 2004).

Trial #1 randomized 126 children and

adolescents, while Trial #2 randomized 133 children and adolescents seven to17 years of age to a
dose of 15 milligram (mg) to 45 mg of Remeron® or placebo for eight weeks (Dubitsky, 2004;
Medicines and Healthcare Products Regulatory Agency, 2004). Patients randomized to the
Remeron® arm began treatment with a 15 mg dose of the antidepressant (Dubitsky, 2004). The
investigators had the option of increasing the dose in 15 mg increments to a maximum of 45 mg
(Dubitsky, 2004). The primary efficacy measure was the change in the score on the Children’s
Depression Rating Scale-Revised from baseline to the eight-week study endpoint (Medicines and
Healthcare Products Regulatory Agency, 2004; Emslie, Ryan, & Wagner, 2005). There was no
statistically significant difference between treatment groups in either of these trials (Emslie et al,
2005; Medicines and Healthcare Products Regulatory Agency, 2004).
The SSRIs have been shown to have greater efficacy than other antidepressants in the
treatment of child and adolescent depression, and have subsequently been studied more in this
population than other classes of antidepressants (Emslie et al., 2005). However, efficacy has not
been consistently demonstrated across RCTs in which children and adolescents diagnosed with
major depressive disorder have been treated with SSRIs (Emslie et al., 2005).
Simeon, Denicola, Ferguson, & Copping (1990) conducted a placebo-controlled double-blind
trial of fluoxetine. The study population consisted of 40 outpatients and inpatients between the
ages of 13 and 18 years who had been diagnosed with major depressive disorder (Simeon et al.,
1990) The 40 adolescents were randomized to a seven-week treatment period (Simeon et al.,
1990). The fluoxetine treatment was 20 mg per day, increased to 40 mg daily after four to seven
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days, and then increased to 60 mg during the second week of treatment (Simeon et al., 1990).
Outcome measures for this study included the following: Hamilton Rating Scale for Depression,
Clinical Global Impression, and Raskin Depression Scale (Simeon et al., 1990). The researchers
found that fluoxetine was not a statistically superior treatment to placebo based on any of these
outcome measures (Simeon et al., 1990).
Emslie et al. (1997) conducted an eight-week double-blind randomized, placebo-controlled
trial to evaluate the efficacy, safety, and tolerability of fluoxetine (20 mg per day) compared to
placebo in a child and adolescent population. The study population consisted of outpatients
between the ages of seven and 17 years who met the DSM-III-R criteria for major depressive
disorder (Emslie et al., 1997). After a one week, single-blind placebo run-in period, 96 children
were randomized to either an eight-week treatment of fluoxetine or placebo (Emslie et al., 1997).
Primary outcome measures were the Clinical Global Impressions and the Children’s Depression
Rating Scale-Revised (Emslie et al., 1997). At the completion of the treatment period, the
fluoxetine arm was found to be statistically significant to the placebo arm, on both of the primary
outcome measures (p = .02 Clinical Global Impressions; p<.001 Children’s Depression Rating
Scale-Revised) (Emslie et al., 1997). In the fluoxetine arm, 27 of the 48 patients compared to 16
of the 48 patients in the placebo arm responded to treatment (χ2 =5.097, df = 1, p = .02) (Emslie
et al., 1997).
Keller et al. (2001) conducted an eight-week trial, which randomized 275 patients 12 to 18
years of age who had been diagnosed with major depressive disorder, to three treatment arms.
The three treatments included paroxetine (20 mg – 40 mg per day), imipramine (gradual titration
to 200 mg -300 mg per day), and placebo (Keller et al., 2001). The primary outcome measure
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was the Hamilton Rating Scale for Depression and the authors defined a response to treatment as
a Hamilton Rating Scale for Depression score of less than or equal to eight, or a greater than or
equal to 50% reduction in baseline Hamilton Rating Scale for Depression score at end of
treatment (Keller et al., 2001). The percentage of patients who achieved a Hamilton Rating
Scale for Depression score of less than or equal to eight were as follows: paroxetine 63.3%,
imipramine 50.0%, and placebo 46.0% (Keller et al., 2001). There were significantly more
“responders” in the paroxetine treatment groups than in the placebo group (p = 0.02) (Keller et
al., 2001). The percentage of patients who achieved a Hamilton Rating Scale for Depression of
less than or equal to eight or a greater than or equal to 50% reduction in baseline Hamilton
Rating Scale for Depression score were as follows: paroxetine 66.7%, imipramine 58.5%, and
placebo 55.2% (Keller et al., 2001). On this second measure of response neither the paroxetine
group nor the imipramine group was statistically significant when compared to the placebo group
(Keller et al., 2001).
Emslie et al. (2002) conducted a second RCT in children and adolescents, eight to 18 years of
age, who had been diagnosed with major depressive disorder. This trial included a three-week
screening period, then a single-blind, placebo run-in period (Emslie et al., 2002). Those patients
(n = 219) who did not respond to placebo were randomized to either treatment with Prozac® or
placebo (Emslie et al., 2002). The primary outcome measure was a treatment response as
measured by the Children’s Depression Rating Scale-Revised. A treatment response was defined
as a greater than or equal to 30% decrease in Children’s Depression Rating Scale-Revised score
from week zero to study endpoint (Emslie et al., 2002). A treatment remission was defined as an
endpoint Children’s Depression Rating Scale-Revised score of less than 28 (Emslie et al., 2002).
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The mean change in Children’s Depression Rating Scale-Revised score was statistically
significant (p < 0.001) for fluoxetine as compared to placebo (Emslie et al., 2002). The response
rate for patients treated with fluoxetine (65.1%) compared to those treated with placebo (53.5%)
was not statistically significant (Emslie et al., 2002). The remission rate for patients treated with
fluoxetine (41.3%) compared to those treated with placebo (19.8%) was statistically significant
(p < 0.01) (Emslie et al., 2002).
Mandoki, Tapia, Tapia, Sumner, & Parker (1997) conducted a six-week, double-blind,
placebo-controlled trial with 40 patients between the ages of eight and 17 years who had major
depressive disorder (Mandoki et al., 1997). Among patients receiving Effexor® the dose varied
from 37.5 mg per day for children and 75 mg per day for adolescents (Mandoki et al., 1997).
Response was measured by the Hamilton Depression Rating Scale, and the Children’s
Depression Rating Scale, Children’s Depression Inventory, and the Children’s Behavioral
Checklist (Mandoki et al., 1997). All rating scales indicated an improvement in depressive
symptoms, but there were no statistically significant differences found between treatment groups
(Mandoki et al., 1997). Therefore, this study did not demonstrate efficacy of Effexor® in
children and adolescents with major depressive disorder (Mandoki et al., 1997). The authors
stated that the insignificant findings could be a result of the fact that all of the patients received
cognitive-behavioral therapy along with the antidepressant or placebo, which might have
obscured any treatment effect (Mandoki et al., 1997). Also, the insignificant result may have
been a result of the small doses of Effexor® (Mandoki et al., 1997). However, later trials of this
antidepressant have not shown efficacy in the treatment of children and adolescents with major
depressive disorder.
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Two unpublished eight-week, double-blind, placebo-controlled trials evaluated the efficacy of
Effexor ER® in children and adolescents with major depressive disorder (Medicines and
Healthcare Products Regulatory Agency, 2004). Patients began on a dose of 37.5 mg per day
and then were titrated up to a maximum of 225 mg per day (Medicines and Healthcare Products
Regulatory Agency, 2004). Primary efficacy measurement for both trials was the change in
Children’s Depression Rating Scale-Revised score (Medicines and Healthcare Products
Regulatory Agency, 2004). There was no statistically significant difference between treatment
groups, therefore Effexor ER® did not demonstrate efficacy in the treatment of children and
adolescents with major depressive disorder (Medicines and Healthcare Products Regulatory
Agency, 2004).
Emslie, Findling, Yeung, Kunz, & Li (2007) conducted an eight-week, double-blind, placebocontrolled trial evaluated the efficacy of Effexor ER®. Patients seven to seventeen years of age
were randomized to a flexible dose of Effexor ER® or placebo (Emslie et al., 2007). The primary
outcome was change from baseline on the Children’s Depression Rating Scale (Emslie et al.,
2007). There was no statistical significant improvement between the treatment and placebo
groups (Emslie et al., 2007). A post-hoc analysis showed greater improvement for adolescents
(p=0.022) based on the Children’s Depression Rating Scale, but no significant improvement for
children (Emslie et al., 2007). Therefore, this analysis indicates efficacy for Effexor ER® in the
adolescent population (Emslie et al., 2007).
The NDRIs’ efficacy have not been tested for children and adolescents with major depressive
disorder. Although these antidepressants have been studied for the treatment of children and
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adolescents with other disorders, no RCTs of Wellbutrin®, Wellbutrin SR®, or Wellbutrin XL®
exist in the literature involving children and adolescents with major depressive disorder.
Only one unpublished trial was located for the “Other Antidepressants”, including Desyrel®
and Serzone®. Rynn, Riddle, Yeung, & Kunz, (2007) conducted a trial to determine the efficacy
of Serzone® in the treatment of major depressive disorder in children and adolescents before liver
damage warnings were made public (Rynn et al., 2007). However, this study did not
demonstrate the antidepressant’s efficacy in this population (Rynn et al., 2007). The lack of
RCTs for this group of antidepressants may be a result of the liver damage that has been
associated with their use and Bristol Myers Squibb pulled Serzone® from the U.S. market,
however the generic version nefazodone HCL is still available (U.S. FDA, 2008).
Psychotherapy Treatment for Major Depressive Disorder
According to the 1998 American Academy of Child and Adolescent Psychiatry Practice
Parameters, psychotherapy is an appropriate treatment for depressive disorders in both children
and adolescents (American Academy of Child and Adolescent Psychiatry, 1998). There are
many different types of psychotherapy and some of these are utilized to treat children and
adolescents with major depressive disorder. These types are defined in Table 2.4.
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Table 2.4: Definitions of Psychotherapy

Cognitive Behavioral Therapy (CBT) teaches the patient to identify and counteract cognitive
distortions. CBT is based on the premise that people with depression have cognitive distortions of
themselves, the world, and the future; that these cognitive distortions contribute to their depression
(American Academy of Child and Adolescent Psychiatry, 1998).
Interpersonal Therapy (IPT) focuses on the clarification and resolution of problem areas such as
prolonged grief, interpersonal roles, role disputes, role transitions, and personal difficulties
(Agency for Health Care Policy and Research, 1993; American Academy of Child and Adolescent
Psychiatry, 1998).
Supportive Counseling establishes and maintains rapport with the patient and provides support to
the patient and helps the patient identify and express feelings. The health care provider can
achieve these goals through the use of reflective listening, empathy, and discussions of personal
problems (Brent, 1997).
Play Therapy utilizes the therapeutic powers of play to help patients prevent or resolve
psychosocial difficulties and achieve optimal growth and development (O’Connor, 2000).
Family Therapy is a treatment approach that makes the assumption that the within-family
behavior of a particular family member is largely influenced by the behaviors and communication
patterns of other family members (Carson, 2002).

Unfortunately, efficacy of psychotherapy for the treatment of major depressive disorder in
children and adolescents is difficult to assess due to the limited number of RCTs in the scientific
literature. Of those RCTs conducted the sample sizes have been small (Ryan, 2005). Small
samples sizes and high placebo rates make the results of these existing studies difficult to
interpret (Ryan, 2005). Studies found in the literature are described in the next section.
Although there are no empirically validated psychotherapy treatments for children with major
depressive disorder (Bridge, Salary, Birmaher, Asare, & Brent, 2005) there is some support for
two different psychotherapeutic approaches in the treatment of major depressive disorder in
adolescents (Dopheide, 2006; Bridge et al., 2005; Ryan, 2005; Compton et al., 2004). These two
approaches are cognitive behavioral therapy (CBT) and interpersonal therapy (IPT). Brent et al.
(1997) conducted a trial in which 107 adolescents who had been diagnosed with major
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depressive disorder were randomized to receive 12 to 16 sessions of CBT, family therapy, or
supportive therapy. Those patients treated with CBT showed a more rapid treatment response (p
= 0.03) and a higher remission rate than family therapy (p = 0.03) or supportive therapy (p =
0.04) than patients in other treatment arms (Brent et al., 1997). Remission was defined as
absence of major depressive disorder as defined by the DSM-III-R and three consecutive scores
of nine or less on the Beck Depression Inventory (Brent et al., 1997).
Mufson, Weissman, Moreau, & Garfinkel (1999) conducted a randomized controlled clinical
trial in which 48 adolescents aged 12 to 18 years were randomized to 12-weeks of IPT or clinical
monitoring. The clinical monitoring consisted of therapists reviewing patients’ depressive
symptoms, school attendance, supportive listening, and assessing the patients’ suicidality
(Mufson et al., 1999). The adolescents who received interpersonal therapy had a higher rate of
recovery than the control group (p = 0.04). The recovery criterion was a score of six or less on
the Hamilton Rating Scale for Depression at the end of the 12-weeks of treatment (Mufson et al.,
1999).
In 2004 Mufson et al. conducted another RCT in which 63 adolescents aged 12 to 18 years
who had been diagnosed with major depressive disorder were randomized to 16 weeks of IPT or
treatment as usual (Mufson et al., 2004). At the end of the 16 weeks, the adolescents who had
received IPT had significantly fewer depressive symptoms as measured by the Hamilton
Depression Rating Scale (p = 0.04), significantly better functioning on the Children’s Global
Assessment Scale (p = 0.04), significantly better overall social functioning on the Social
Adjustment Scale-Self-Report (p = 0.01), significantly greater clinical improvement (p = 0.03)
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and greater decrease in clinical severity (p = 0.03) as measured by the Clinical Global
Impressions Scale (Mufson et al., 2004).
Combination Therapy for Major Depressive Disorder
Another strategy is the combination of pharmacotherapy and psychotherapy. However,
effectiveness for this treatment combination has been established only for adolescents who have
been diagnosed with major depressive disorder (March & The Treatment for Adolescents with
Depression Study (TADS) Team, 2004). A description of the only RCT, sponsored by the
National Institute of Mental Health, which supports this type of therapy, follows.
The TADS team conducted an RCT which randomized 439 adolescents 12 to 17 years of age,
who were diagnosed with major depressive disorder (March & TADS Team, 2004). The
adolescents received one of four treatments for 12-weeks. These treatments included fluoxetine
(10 mg per day for week one, then increased to 20-40 mg per day), CBT, a combination of
fluoxetine and CBT, or placebo (March & TADS Team, 2004). The primary outcome measures
consisted of the Children’s Depression Rating Scale-Revised and the Clinical Global
Impressions improvement score (March & TADS Team, 2004). This study found that the
combination treatment of fluoxetine and CBT was superior and statistically significant to placebo
as measured by the Children’s Depression Rating Scale-Revised (p = 0.001) (March & TADS
Team, 2004). Additionally, treatment with fluoxetine and CBT was superior to either fluoxetine
(p = 0.02) or CBT (p = 0.01) alone, as measured by the Children’s Depression Rating ScaleRevised (March & TADS Team, 2004).
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Physician Prescribing Decisions
As the reviewed studies in the above sections indicate, some types of antidepressant therapy
and psychotherapy have been shown to have efficacy in the treatment of major depressive
disorder in children and/or adolescents. However, opinions vary as to which of these treatments
should be offered as a first-line of treatment or whether they should be offered as a combination
treatment (American Academy of Child and Adolescent Psychiatry, 1998). Ideally the choice of
antidepressant medication should rely on Evidence-Based Medicine (EBM) (Depont et al.,
2003). Evidence- Based Medicine has been defined as the “use of current best evidence in
making decisions about the care of individual patients” (Sackett, Rosenberg, Gray, Haynes, &
Richardson, 1996).
Fluoxetine is the only antidepressant approved by the U.S. FDA for the treatment of major
depressive disorder in children and adolescents (United States Food and Drug Administration,
2007). However, 40% of patients will not respond to this antidepressant and off-label use of
other antidepressants for the treatment of major depressive disorder in children and adolescents
is common (Brent, 2005; March & TADS Team, 2004). Therefore, EBM is not the only factor
to influence physicians’ decision to prescribe antidepressants to children and adolescents.
According to the American Academy of Child and Adolescent Psychiatry, the choice of initial
therapy depends in part on “clinical”, “psychosocial factors”, and the “therapist’s expertise”
(American Academy of Child and Adolescent Psychiatry, 1998). Since the choice of
antidepressant treatment for children and adolescents is not based solely on empirical research, it
is important to explore other factors that influence physicians’ decision-making.
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Prescribing Decisions for Adult Populations
Characteristics of physicians’ decisions is that they tend to be made quickly, require an
enormous amount of information, and differ in style depending on the physician and the clinical
problem (Eisenberg, 1979). Researchers have proposed models that depict factors which
influence physicians’ prescribing decisions. However, the majority of these studies focused on
prescribing any type of medication to adults rather than focusing on antidepressant prescribing
decisions to children and adolescents. One study did focus on antidepressant prescribing to
adults and will be discussed first. Sleath & Shih (2003) demonstrated that Eisenberg’s model of
sociological influences on physicians’ prescribing could be applied to antidepressant prescribing
to depressed adults. In 1979 Eisenberg’s theory of decision-making by clinicians stated that in
addition to the scientific criteria (EBM and clinical information) upon which physicians’
decisions are based, there are four types of sociological factors which influence physicians’
decision-making (Eisenberg, 1979). These sociological factors are as follows: characteristics of
the patient, characteristics of the physician, the physician’s interaction with his profession and
the health care system, and the physician’s relationship with the patient (Eisenberg, 1979).
Sleath & Shih (2003) determined that patients’ age, patients’ depression severity (any type of
depression was examined, not only major depressive disorder), patients’ insurance, geographic
location, and physicians’ specialty influenced physicians’ prescribing of antidepressants to
adults.
Benson (1983) modeled the relative influence of patient characteristics, physician
characteristics, and treatment setting characteristics on antipsychotic drug prescribing by North
Carolina psychiatrists. Patients’ level of functional impairment, patients’ diagnosis, physicians’
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board certification, psychiatrists’ professional activism, psychiatrists’ comfort with their
knowledge of psychopharmacology, and the treatment setting were factors Benson (1983)
determined to influence the antipsychotic prescribing decision.
Cates (2001) suggested that when considering an antidepressant for the treatment of major
depressive disorder, drug-related factors should be considered. These factors include efficacy,
adverse effects, drug interactions, dosing, and cost (Cates, 2001). Other researchers have
suggested that marketing and promotional efforts influence physicians’ prescribing decisions
(Caplow & Raymond, 1954; Chew et al., 2000; Freeman, Barnes, Summers, & Szeinbach, 1993).
Chew et al. (2000) demonstrated that the availability of drug samples influenced physicians’
decisions to prescribe antidepressants.
Freeman et al. (1993) determined that side effects, efficacy, and patient characteristics were
most influential to physicians’ prescribing decisions for the treatment of panic disorder.
Additionally, Freeman et al. (1993) demonstrated that product attributes and promotional
influences were also influential, but to a lesser extent.
A more recent study by Nutescu et al. (2005) demonstrated the importance of some drugrelated factors to physicians’ prescribing decisions. Nutescu et al. (2005) suggested that the
decision to prescribe one drug instead of another within a specific therapeutic class (lowmolecular-weight-heparins) is influenced by a variety of factors. Nutescu et al. (2005)
determined that drug efficacy, drug formulary status, restrictions on prescribing, physicians’
personal experience, safety, cost, prescribing guidelines, and U.S. FDA approval were important
factors in the physicians’ decision-making process. Nutescu et al. (2005) determined that
marketing and promotional factors such as face-to-face detailing by pharmaceutical
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representatives, samples of drugs, free drugs to indigent patients, and advertising efforts were
somewhat influential to physicians’ decision-making process. However, these factors were
much less influential than other drug-related factors which physicians considered when making a
decision to prescribe one drug instead of another within the same therapeutic class (Nutescu et
al., 2005).
Prescribing Decisions for Children and Adolescents
Chen & Chang (2002) determined that specific patient factors are related to increased
utilization of prescription medications. It was determined that race, insurance status, and family
income levels had significant impact on child and adolescent prescription drug utilization (Chen
& Chang, 2002). Children who were white, had private insurance, and were from high-income
families were more likely to use prescription medications (Chen & Chang, 2002). This study
focused on all prescription medications whereas, other studies have focused specifically on the
prescribing patterns associated with psychotropic medications in children and adolescents. The
sections that follow will review the scientific literature pertaining to factors associated with
physicians prescribing medication to children and adolescents. The first section will consist of a
review of the scientific literature pertaining to factors associated with physicians prescribing of
psychotropic medication to children and adolescents. The second section will consist of a review
of the literature pertaining to factors associated specifically with physicians prescribing of
antidepressants to children and adolescents.
Psychotropic Prescribing to Children and Adolescents
Hong & Shepherd (1996) examined prescription drug benefit data for children and
adolescents during the 1992-1993 time-period. The researchers found that children and
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adolescents were more likely to take psychotropic medication if their parents took them (Hong &
Shepherd, 1996). Males were more likely to take psychotropic medications at younger ages,
while females were more likely to take psychotropic medications at older ages (Hong &
Shepherd, 1996). For the antidepressant drug class, children and adolescents from single parent
homes were less likely than children from two parent homes to utilize antidepressants (Hong &
Shepherd, 1996). Additionally, parental use of antidepressants was associated with child and
adolescent utilization of antidepressants (Hong & Shepherd, 1996).
Kaplan & Busner (1997) compared the psychotropic medication prescribing practices of
inpatient child psychiatrists at a state hospital, a private hospital, and a county-university hospital
in New York during 1991. The percentage of patients at the state, private and county-university
hospital who received psychotropic medications were 79%, 76%, and 68%, respectively (Kaplan
& Busner, 1997). Of those patients who received medication, more children and adolescents at
the private hospital (80%) compared with those patients at the state (26%), or county-university
(26%) hospital received antidepressants (p < 0.001) (Kaplan & Busner, 1997). Additionally,
significantly more county-university patients (74%) received antipsychotic medications than
those patients in the private (35%) hospital (Kaplan & Busner, 1997).
Safer (1997) examined the records of outpatient children and adolescents (their outpatient
information was supplemented with inpatient records, if available) who were seen by child
psychiatrists at four community mental health care centers in Maryland. Safer (1997) found that
from 1988 to 1994 there was an increase in psychotropic medication treatment for children and
adolescents. There was also an increase in SSRI utilization (Safer, 1997). Additionally, it was
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found that most children and adolescents who were prescribed psychotropic medications
discontinued this treatment within three months (Safer, 1997).
Jensen et al. (1999) conducted a study which utilized prescribing data from the 1995 National
Ambulatory Medical Care Survey (NAMCS) and the 1995 National Disease and Therapeutic
Index (NDTI) to determine national trends for prescribing psychotropic medications to children
18 years and younger. Jensen et al. (1999) determined that stimulants are the most commonly
prescribed psychotropic medication for this population (Jensen et al., 1999). Stimulant
prescriptions were followed in frequency by SSRIs, anticonvulsant mood stabilizers, TCAs,
central adrenergic agonists, antipsychotics, benzodiazepines, and lithium (Jensen et al., 1999).
Zito et al. (2000) utilized two Medicaid databases and one health maintenance organization
(HMO) database to determine the prevalence and utilization trends of psychotropic medication
use in children aged two through four. Zito et al. (2000) determined that psychotropic
medication utilization trends increased for children aged two through four during the years 1991
to1995 (Zito et al., 2000). All three databases indicated that stimulants were the most widely
utilized psychotropic medication for children aged two through four (Zito et al., 2000).
Stimulant use frequency was followed by antidepressants, clonidine, and neuroleptics in both of
the Medicaid populations (Zito et al., 2000). The HMO database indicated that clonidine was the
second most frequently utilized psychotropic medication followed by antidepressants and
neuroleptics (Zito et al., 2000). It should be noted that the TCA class of antidepressants
represented the majority of the antidepressant use in this population during the years 1991-1995
(Zito et al., 2000).
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Goodwin, Gould, Blanco, & Olfson (2001) utilized the National Ambulatory Medical Care
Survey from 1992 - 1996 to determine prescribing patterns, patient characteristics, and clinical
management of physicians who prescribed psychotropic medications to children and adolescents.
It was found that a majority (84.8%) of psychotropic medications were prescribed by
pediatricians and general practitioners (Goodwin et al., 2001). It was also determined that
stimulants (53.9%) were the most often prescribed psychotropic medication prescribed
(Goodwin et al., 2001). Antidepressants (30%) were the second most commonly prescribed
psychotropic medication (Goodwin et al., 2001). This study demonstrated that there are
significant differences by gender, age, payment source, and race among those children and
adolescents receiving prescriptions for psychotropic medications (Goodwin et al., 2001).
Rushton & Whitmire (2001) conducted a study utilizing the North Carolina Medicaid
database to describe prescription trends for SSRIs and stimulants in children. Stimulants and
SSRI utilization increased during the 1992 to 1998 timeframe (Rushton & Whitmire, 2001). For
the year 1998, SSRI utilization was also higher for white males (2.8%) than it was for black
females (0.6%) (Rushton & Whitmire, 2001).
Elfron et al. (2003) conducted a survey of pediatricians and child and adolescent psychiatrists
in Australia to determine the prescribing patterns for psychotropic medications. Stimulants and
clonidine were the most frequently prescribed medications (Elfron et al., 2003). Child
psychiatrists were more likely than pediatricians to indicate prescribing SSRIs (93% versus 75%)
(Elfron et al., 2003).
Olfson, Gameroff, Marcus, & Waslick (2003) utilized the Medical Expenditure Panel Survey
(MEPS) from 1996 through 1999 to describe treatment patterns of children and adolescents
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(aged six to 18 years) with depression. More than half (56.9%) of the children and adolescents
were prescribed an antidepressant medication and most of these patients were treated with an
SSRI (Olfson et al., 2003). Children and adolescents who were treated with an antidepressant
were more likely (as compared to those patients not treated with an antidepressant) to have
parents who graduated from high school, have health insurance, and live in large communities
(Olfson et al., 2003).
Zito et al. (2003) utilized information from two Medicaid (a Midwestern state Medicaid
database (MWM) and a mid-Atlantic state Medicaid database (MAM)) and one health
maintenance organization (HMO) databases over a ten year period (1987 – 1996) to examine the
changes in the prevalence and utilization trends of psychotropic medication use in children and
adolescents less than 20 years of age. During the ten year period, there was a three-fold increase
in total psychotropic medication prevalence in the MWM and HMO population, and a two-fold
increase in total psychotropic medication prevalence in the MAM (Zito et al., 2003). By 1996,
stimulants followed by antidepressants were the most commonly prescribed psychotropic
medications for children and adolescents in all three populations (Zito et al., 2003). Additionally
in 1996, ten to 14 year old children and adolescents were utilizing more psychotropic
medications in both Medicaid populations, while 15 to 19 year olds were utilizing more
medications in the HMO population (Zito et al., 2003). In 1996, antidepressant utilization was
highest in the 15 to 19 year old group for the HMO population, and highest in the ten to 14 year
old group in both Medicaid populations (Zito et al., 2003). In 1996, the antidepressant utilization
rate for males was two times that of the female rate (Zito et al., 2003). Over the ten year period,
males increased their utilization of antidepressants more than females in the MAM population,
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and males and females had similar antidepressant utilization rates in the MWM population (Zito
et al., 2003). In the HMO population, during the same ten-year period, more males than females
utilized antidepressants in the zero to four, five to nine, and ten to 14 year olds (Zito et al., 2003).
However, in the 15 to 19 year old group more females than males utilized antidepressants during
this ten year period (Zito et al., 2003). There were race disparities among whites and African
American patients in the MAM population, as shown by a greater utilization of antidepressant
among white patients (Zito et al., 2003).
Haapasalo-Pesu, Erkolahti, Saarijarvi, & Aalberg (2004) assessed adolescent psychiatrists’
prescribing practices in hospital settings in Finland. The researchers sent a questionnaire to
adolescent psychiatrists in 1991 and again in 1999 (Haapaslo-Pesu et al., 2004). It was
determined by these surveys that 30% of inpatients in 1991 and 68% in 1999 received a
psychotropic medication (Haapaslo-Pesu et al., 2004). The researchers conclude that this
increase may be related to availability of newer antidepressants (Haapaslo-Pesu et al., 2004).
Lekhwani, Nair, Nikhinson, & Ambrosini (2004) conducted a chart review of inner city
children, age nine or younger, receiving public assistance, and who were admitted as inpatients
during the 1998 to 2001 time period. The study objective was to determine prescribing patterns
of psychotropic medications to these patients (Lekhwani et al., 2004). It was determined that
51.8% of the children were taking a psychotropic medication when they were admitted to the
hospital, and 78.7% of the patients were taking a psychotropic medication at the time of
discharge (Lekhwani et al., 2004). Additionally, stimulants were the most widely utilized
psychotropic medication (Lekhwani et al., 2004).
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Najjar et al. (2004) examined inpatient prescribing patterns of psychotropic medications for
children and adolescents utilizing hospital pharmacy dispensing data from 1991 through 1998.
Researchers found that there was a 73.0% increase in use of psychotropic medications during the
1991 to 1998 time frame (Najjar et al., 2004). Additionally, there was a significant increase in
the use of antidepressants from 35.6% to 77.3% during the same time frame (Najjar et al., 2004).
Hugtenburg, Heerdink, & Tso (2005) conducted a survey of child psychiatrists in the
Netherlands to gain more information about the prescribing patterns of psychoactive
medications. This survey gathered information regarding the preferred medication treatment for
various disorders (Hugtenburg et al., 2005). For depressive disorders (including major
depressive disorders, dsythymia, and bipolar disorder), child psychiatrists reported a preference
for paroxetine (Hugtenburg et al., 2005).
Harpaz-Rotem & Rosenheck (2006), in the year 2000, compared prescribing practices of
psychiatrists and primary care physicians (PCP) for children and adolescents with any mental
illness. Utilizing MarketScan®, a national claims database from private insurance plans, HarpazRotem and Rosenheck determined that PCPs were more likely to see younger children and
psychiatrists were more likely to see adolescents (Harpaz-Rotem & Rosenheck, 2006).
However, no differences were found in psychotropic prescribing practices including the
proportion of patients receiving psychotropic medication, types of psychotropic medications
prescribed, or the dosages of psychotropic medications prescribed (Harpaz-Rotem & Rosenheck,
2006).
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Antidepressant Prescribing to Children and Adolescents
Other studies have focused specifically on the prescribing of antidepressant medications to
children and adolescent patients. Bramble (1995) conducted a mail survey of child psychiatrists
in Britain to gain information about prescribing patterns of antidepressants. Of those
psychiatrists who responded 85% had prescribed antidepressants to their patients (Bramble,
1995). The most frequently prescribed antidepressants were amitriptyline and imipramine, and
SSRIs were prescribed only “very rarely” at the time of this survey (Bramble, 1995).
Rushton, Clark, & Freed (2000) conducted a survey of North Carolina pediatricians and
primary care physicians to determine the prescribing patterns of SSRIs in the child and
adolescent population. This study determined that 72% of the surveyed physicians had
prescribed an SSRI to a child or adolescent patient (Rushton et al., 2000). Physicians indicated
that depression was the most frequent reason for prescribing an SSRI to these patients (Rushton
et al., 2000). Furthermore, primary care physicians were more likely to prescribe SSRIs to
adolescents than young children, with only 6% of the physicians surveyed indicating that they
had prescribed an SSRI to a child less than six years of age (Rushton et al., 2000). Additionally,
primary care physicians were also more likely than pediatricians to prescribe SSRIs to an
adolescent (41% versus 26%) (Rushton et al., 2000). Primary care physicians were more likely
than pediatricians (91% versus 58%) to prescribe SSRIs to all youth (including both children and
adolescent patients) (Rushton et al., 2000). Primary care physicians also indicated a greater
belief in the effectiveness (40% versus 32%) and safety (63% versus 48%) of the SSRI
medication, and indicated they were more comfortable with the management of depression in the
child and adolescent population (22% versus 11%) as compared to pediatricians (Rushton et al.,
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2000). This study also indicated that physicians were more likely to prescribe an SSRI to
children and adolescents if they were primary care physicians, could not refer patients to another
health care provider, felt comfortable managing depressed patients, and believed in the safety
and efficacy of SSRIs (Rushton et al., 2000).
Bhatia et al. (2008) conducted a survey of prescribing clinicians (child psychiatrists, general
psychiatrists, pediatricians, family practice physicians, nurse practitioners, and physician
assistants) within the state of Nebraska, to evaluate the impact of the U.S. FDA black box
warning on physician prescribing. Almost all (96.8%) of the clinicians were aware of the black
box warning (Bhatia et al., 2008). Of the responding clinicians 76.9% prescribed antidepressants
to children and/or adolescents before the 2004 warning. Of the clinicians, who prescribed before
the warning, 15.5% reported a decrease in prescribing antidepressants to children after the
warning, while 36.6% reported a decrease in prescribing to adolescents (Bhatia et al., 2008).
Some clinicians reported making modifications to their monitoring, with 31.9% of the clinicians
reporting increasing contacts with the patients (Bhatia et al., 2008). Slightly more than a third
(36.0%) of the clinicians reported increasing referrals to mental health professionals (Bhatia et
al., 2008).
Zito et al. (2002) examined changes in antidepressant utilization and factors associated with
antidepressant utilization in the child and adolescent population by examining two Medicaid and
one HMO database. Between the years 1988 and 1994 antidepressant use increased among this
population (Zito et al., 2002). Additionally, the study indicated a modest significant difference
in utilization associated with male gender (58.0% versus 49.5%; p<.001) (Zito et al., 2002).
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Murray, deVries, & Wong (2004) examined prescribing patterns of antidepressants to
children and adolescents in the United Kingdom during the 1992 to 2001 time frame. Murray et
al. (2004) utilized the United Kingdom Practice Research Database to determine that 55.7% of
all antidepressant prescriptions were for TCAs, 41.3% for SSRIs, and 2.9% for other
antidepressants. Overall, antidepressant prevalence increased 1.7 times from 1992 to 2001
(Murray et al., 2004). During the same time frame, prevalence of TCAs decreased from 3.6 to
2.5 per 1000, and SSRI prevalence increased from 0.5 to 4.6 per 1000 (Murray et al., 2004).
Murray, Thompson, Santosh, & Wong (2005) compared the prevalence and incidences of
children and adolescents who were prescribed antidepressant treatment in the United Kingdom
during the 2000 to 2004 time frame. The researchers utilized information from Mediplus
database, which contains records from primary care visits (Murray et al., 2005). Antidepressant
prevalence increased from 5.4 to 6.6 patients per 1000 people during the 2000 to 2002 time
frame (Murray et al., 2005). Additionally, prevalence decreased from 6.6 to 5.7 patients per
1000 people during the 2002 to 2004 time frame (Murray et al., 2005).
Fegert, Kolch, Zito, Glaeske, & Janhsen (2006) examined prescription patterns of
antidepressants (including St. John’s Wort, an herb with antidepressant properties) for patients
less than 20 years of age in Germany. The researchers utilized prescription data from a HMO for
the years 2000 to 2003 (Fegert et al., 2006). It was determined that prevalence of antidepressants
increased from 3.43 per 1000 in 2000, to 3.74 per 1000 in 2003 (Fegert et al., 2006). Fegert et
al. (2006) defined prevalence as the dispensing of one or more prescriptions for an antidepressant
per calendar year per 1000 continuously enrolled children and adolescents. St. John’s Wort and
TCAs accounted for approximately 80% of the antidepressant use (Fegert et al., 2006). Females
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were two times as likely as males to use an antidepressant, and females aged 15 to19 years of age
accounted for most of the antidepressant use in Germany during the 2000 to 2003 time frame
(Fegert et al., 2006).
Vitiello, Zuvekas, & Norquist (2006) analyzed the Medical Expenditure Panel Survey
database for the 1997 to 2002 time frame to determine the utilization of antidepressants among
children and adolescents (patients less than 19 years of age). During this time period, the
percentage of children and adolescents receiving an antidepressant increased significantly from
1.3% to 1.8% (p < 0.01) (Vitiello et al., 2006). Utilization was highest in the 13 to 18 year olds
and lowest among children less than six year of age (Vitiello et al., 2006). In 1996, utilization
was highest among male children and adolescents when compared to females (Vitiello et al.,
2006). However, by 2002 utilization of antidepressants was similar between males and females
(Vitiello et al., 2006). In 2002, there was significantly more utilization among whites than
blacks or Hispanics (Vitiello et al., 2006). Between 1997 and 2002, utilization of antidepressants
increased among blacks and Hispanics (Vitiello et al., 2006). There were significant increases in
utilization for children and adolescents from poor families and among those children and
adolescents who had public insurance (Vitiello et al., 2006). Additionally, there was a
significant increase in the utilization of SSRIs and other “newer antidepressants” but no increase
for TCAs during the 1997 to 2002 time-frame (Vitiello et al., 2006).
Kurian et al. (2007) utilized Tennessee’s Medicaid database to evaluate the impact of the
2004 warnings on prescriptions of antidepressants to pediatric patients. Data from 2002 to 2005
was analyzed and it was found there was a 33% decrease in antidepressant users after the
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warnings (Kurian et al., 2007). Non-fluoxetine SSRIs and SNRIs showed the greatest decrease
(54%) in use, while new users of fluoxetine, actually increased 60% (Kurian et al., 2007).
Nemeroff et al. (2007) utilized retail pharmacy database, Verispan, to investigate prescribing
trends in the United States. This study found that the number of children and adolescents
prescribed an antidepressant after the 2004 warnings decreased significantly (p=0.02) (Nemeroff
et al, 2007). The other impacts of the warnings seem to be a shift away from “generalist” care to
“specialist” care for patients seeking antidepressants (Nemeroff et al., 2007). Also, the study
showed a slight shift or increase in prescriptions of Wellbutrin® to children and adolescents
(Nemeroff et al., 2007).
Summary of Factors Influencing Physician Prescribing Decisions
Based on the studies above, factors related to antidepressant prescribing in children and
adolescents include patients’ gender (Fegert et al., 2006; Vitiello et al., 2006) patients’ race
(Goodwin et al., 2001; Olfson et al., 2003; Vitiello et al., 2006), type of insurance (Goodwin et
al., 2001; Olfson et al., 2003), patients’ age (Fegert et al., 2006; Goodwin et al., 2001; Vitiello et
al., 2006; Zito et al., 2002), geographic location (Olfson et al., 2003) and physicians’ specialty
(Rushton et al., 2000). Additional factors were found to influence physicians’ decisions
regarding antidepressant prescriptions to children and adolescents. These factors were family
income (Olfson et al., 2003), parents education level (Olfson et al., 2003), parental use of
antidepressant medication (Hong & Shepherd, 1996), single parent household (Hong &
Shepherd, 1996), physicians’ comfort level in managing depression (Rushton et al., 2000), and
physicians’ belief in the safety and efficacy of antidepressants for youth (Rushton et al., 2000).
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The reviewed randomized clinical trials illustrate that there is no sound epidemiological basis
for choosing antidepressant treatment in children and adolescents with major depressive disorder
(Brent, 2005). Even those antidepressants demonstrating efficacy in the treatment of major
depressive disorder in children and adolescents have been subject to the 2004 U.S. FDA black
box warning. However, scientific evidence is not the only factor to impact physicians’
prescribing decisions. The last part of this chapter reviewed research regarding factors which
impact physicians’ prescribing decisions. The purpose of the current study is to examine
physician antidepressant choices for children and adolescents with major depressive disorder and
to examine the factors which impact these choices. The methods to accomplish these goals will
be the focus of the next chapter.
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CHAPTER THREE: METHODOLOGY
The purpose of this study was to examine physician antidepressant choices for children and
adolescents with major depressive disorder and to examine the factors which impact these
choices. The study consisted of two phases. Thus, this chapter outlines the conceptual
framework for each phase of the study, the study population, sample size, and data collection.
This will be followed by a description of the development and validation of each survey
instrument. The chapter concludes with a description of the data analysis for each objective.

54

Conceptual Framework
The optimal treatment for children and adolescents who have major depressive disorder is not
a clear decision for physicians. There is no empirical basis for choosing antidepressant treatment
in children and adolescents with major depressive disorder (Brent, 2005). In the absence of
empirical research to guide the selection of antidepressant treatment, additional research needs to
be conducted to examine what physicians consider to be the most appropriate antidepressant
treatment and recommended course of treatment. These goals were accomplished in Phase I and
Phase II of this study.
It has been suggested that ideally the choice of antidepressant treatment could be based on
evidence-based medicine (Depont et al., 2003). However, this would exclude other factors
which may influence physicians’ antidepressant prescribing decisions to newly diagnosed
children and adolescents with major depressive disorder. The current literature has highlighted
some patient and physician-related factors that influence physicians’ prescribing decisions,
including decisions to prescribe antidepressants (Benson, 1983; Sleath & Shih, 2003).
Additionally, research suggests that drug-related factors, including marketing-related factors,
also influence prescribing decisions of physicians, but may be less influential, at least in some
situations, than patient and physician-related factors (Freeman et al., 1993; Nutescu et al., 2005).
Furthermore, prescribing decisions have been conceptualized as a two-stage process (Benson,
1983; Sleath & Shih, 2003). First, the physician makes a decision about whether or not to
prescribe an antidepressant (Benson, 1983; Sleath & Shih, 2003). Second, the decision of which
specific antidepressant to prescribe must be made (Benson, 1983; Sleath & Shih, 2003).
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Phase II of the current study examined variables/factors associated with the first stage,
“whether or not to prescribe an antidepressant” to children and adolescents with major
depressive disorder. This study is a more comprehensive examination of variables associated
with the decisions to prescribe an antidepressant, than any found in the scientific literature to
date and allowed for the relative influence of these factors to be determined.

The conceptual

framework for each study phase is depicted below.
Phase I: Identification of Physicians
Phase I of this study consisted of a short survey to a sample of pediatricians to determine
which physicians treat children and adolescents with newly diagnosed major depressive disorder.
Figure 3.1a shows a visual representation of the conceptual framework for Phase I.
Figure 3.1: Conceptual Framework for Phase I
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Phase II: Determination of Physician Prescribing Behavior
Phase II of the study surveyed pediatricians and child psychiatrists. This portion of the study
determined treatment behavior and specific antidepressant prescribing behavior for children and
adolescents with newly diagnosed major depressive disorder. A visual representation of the
conceptual framework for Phase II can be seen in Figure 3.1b.
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Figure 3.2: Conceptual Framework of Phase II
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Phase II: Variables Influencing Physicians’ Decisions to Prescribe Antidepressants
Additionally, Phase II of this study determined the variables, and the importance of the variables
which influence pediatricians’ and child psychiatrists’ antidepressant prescribing behavior. A listing
of the 28 variables examined in this portion of the study and subjected to exploratory factor analysis
are listed in Table 3.1.

Table 3.1: 28 Variables Utilized in Exploratory Factor Analysis
Variables
Advertisements to physicians via journals
Availability of patient education materials
Clinical experience with prescribing antidepressants
Co-existing conditions of patients (eg. OCD)
Comfort in managing MDD in youth
Direct-to-consumer advertising
Drug efficacy
Drug safety
Face-to-face detailing by medical sciences liaison and/or pharmaceutical
representatives
Familiarity with an antidepressant being prescribed
FDA approval
Formulary inclusion
Frequency in dosing
Generic form of drug available
Manufacturer provides free drugs to indigent patients
Medication cost
Monitoring requirements
Parents’ education level
Parental use of antidepressants
Patient’s ability to perform daily activities
Patient’s age
Patient’s family income
Patient’s gender
Patient’s insurance
Potential adverse events
Sample drugs available
Severity of MDD symptoms
Suicidal Thinking
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Study Population
In any study the reference, target, or study population “is the group we wish to study” and the
random sample “is selected from the study population” (Rosner, 2000). The random sample is a
“sample in which each group member has the same probability of being selected” (Rosner, 2000).
The population in the current study consisted of all pediatricians and child psychiatrists in the United
States (U.S.). Child psychiatrists, undoubtedly treat children and adolescents with major depressive
disorder, as they are trained to do so (American Academy of Child and Adolescent Psychiatrists,
2006). Since there is currently a shortage of child psychiatrists in the U.S., it has been documented
in the literature that some children and adolescents with major depressive disorder receive treatment
from other types of physicians such as pediatricians (American Academy of Child and Adolescent
Psychiatry, 2006). However, all pediatricians are not willing to treat children and adolescents with
major depressive disorder (American Academy of Child and Adolescent Psychiatry, 2006). To
obtain adequate responses for Phase II, it was important to first identify which physicians treat these
patients.
The SK&A Informational Services, Inc. maintains databases of over two million medical records,
including records of 615,000 physicians. Another database is the American Medical Association’s
Member list. This database served as the sampling frame for the current study. This database was
chosen because it is a more exhaustive list of physicians (compared to others that were identified) in
the U.S. The specialty count includes 59,237 pediatricians and 7,496 child and adolescent
psychiatrists for a total of 66,733 physicians.
The sample for Phase I consisted of a random sample of pediatricians in the U. S. selected from
the total population of these specialty areas. The information collected from Phase I of this survey
provides an estimate of the number of pediatricians who are currently treating major depressive
disorder in newly diagnosed children and/or adolescents in the U.S. The sample for Phase II
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consisted of those pediatricians who indicated they treat children and/or adolescents with major
depressive disorder, and who were willing to participate in a follow-up survey designed to gain
information about prescribing habits to newly diagnosed children and adolescents with major
depressive disorder. The sample for Phase II also included a random sample of child psychiatrists
from the SK&A database.
Sample Size Estimation
The sample size was calculated using the following formula:
n = Z2 * (p * 1-p)
C2
n = the sample size
Z = the Z value for the confidence interval, or the number of standard errors away from the mean
p = the true proportion of the population
C = the confidence interval
Several samples were utilized for this study. First, it was necessary to calculate the sample size
for Phase I of the study. This sample size was estimated utilizing a 95% confidence level and a
confidence interval equal to 5%, so that C = 0.05 and Z = 1.96. This means that the researcher is
95% confident that an estimate of the true proportion of the variable of interest will be no more than
+ 5% (Salant & Dillman, 1994). No prior knowledge of the true proportion of the population is
known. Since this was the case, a conservative estimate was assumed and p = 0.5 (Salant &
Dillman, 1994). Substituting these values (Z = 1.96, p = 0.5, and C = 0.05) in the formula above, a
sample size of 384 was calculated.
Research suggests that response rates for physicians are low compared to the response rates of the
general public and this may impair the generalizability of the results of the survey (Kellerman &
Herold, 2001). A study which reviewed the medical literature during a one year time frame
indicated that the physician response rate was 54% (Martin, 1974). Another study, which examined
survey methodology of physician surveys from 1967 through 1999 found response rates to range
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from 38% to 84% (Kellerman & Herold, 2001). The current study assumed a much more
conservative response rate of 20%. Therefore, 2,000 ((1, 920 = 384 * 5) plus an additional 80 for
incorrect addresses) randomly selected pediatricians were sent a survey, for a total of 2,000 surveyed
in Phase I of this study.
The sample for Phase II consisted of those pediatricians who indicated they treat children and/or
adolescents with major depressive disorder, and who indicated they were willing to participate in
Phase II of this study. In addition, a random sample of 2,500 (384*5 = 1,920 plus an additional 580
for incorrect addresses and non-responses) child psychiatrists were surveyed.
When conducting factor analysis it is usually suggested that a sample size of between 10 and 20
subjects for each variable being measured be utilized (Thompson, 2004). An absolute minimum of
five subjects per measured variable has also been suggested (Gorsuch, 1983). The current study had
28 variables. Therefore, a minimum sample size of 28*5 = 140 was needed for conducting the factor
analysis in this study.
Data Collection
This study utilized primary data for both phases. Primary data may be collected by telephone,
face-to-face, internet, or mail surveys. Mail surveys have some advantages over some other data
collection methods. These advantages include the facts that mail surveys typically require less time,
money, and research staff than other primary data collection methods (Salant & Dillman, 1994). The
major reason mail surveys were utilized for this study was to reach physicians nationally. Research
indicates that phone surveys yield only slightly higher, but not statistically significant, response rates
as compared to response rates of mail surveys of physicians (Kellerman & Herold, 2001).
Furthermore, personal interviews of physicians yield significantly higher response rates than mail
surveys of physicians (Kellerman & Herold, 2001). However, to conduct personal interviews on a
national basis, for this study, was not feasible. Therefore, mail surveys were utilized.
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Research suggests a survey mailing procedure that consists of four separate mailings (Salant &
Dillman, 1994). This begins with an initial letter sent to all sample participants. The purpose of this
letter is to alert the participants who have been selected for the survey and to make them aware that
they will be receiving a questionnaire (Salant & Dillman, 1994). The next mailing, which should
take place approximately a week after the initial letter, consists of a cover letter providing the details
of the survey, the questionnaire, and a return postage-paid envelope (Salant & Dillman, 1994).
Approximately four to eight days after the questionnaire is sent, a postcard thanking those who have
responded and asking for a response from those participants who have not responded should be
mailed (Salant & Dillman, 1994). The fourth mailing occurs approximately three weeks after the
questionnaire was sent (Salant & Dillman, 1994). This mailing entails mailing to those people who
have not returned the first questionnaire and consists of a new cover letter which again asks for their
participation and includes a replacement questionnaire and return postage-paid envelope (Salant &
Dillman, 1994). According to Salant & Dillman (1994) this procedure should yield a 50-60%
response rate from the general public. Due to limited resources, the current study varied Salant &
Dillman’s (1994) recommendations slightly. Data for each phase was collected via two survey
mailings. The first mailing for each phase consisted of a cover letter, survey, and return postagepaid envelope to each physician. The second mailing consisted of a cover letter, survey, and return
postage-paid envelop to each physician who did not respond to the first mailing.
Approval for the research protocol, cover letters, survey for Phase I, and survey for Phase II, was
obtained from the Institutional Review Board of West Virginia University.
Instrument Development
Surveys for this study were developed by obtaining information from reviews of the scientific
literature and from informal discussions with psychiatrists who treat children and adolescents.
Instrument development for each phase of the study will be discussed in detail.
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Phase I
The survey for Phase I (See Appendix A) was designed to determine which physicians treat
newly diagnosed children and adolescents with major depressive disorder. Additionally, the
information gathered from this survey combined with demographic information discerned from the
physician database allowed the researcher to detect whether there are geographical differences in
pediatricians’ willingness to treat children or adolescents with major depressive disorder. The
survey also asked physicians if they would be willing to participate in a more in-depth questionnaire
in the next phase of this study.
Phase II
The survey utilized in Phase II consisted of eight sections. The questions were designed to obtain
information about prescribing habits to newly diagnosed children and adolescents with major
depressive disorder. A copy of the survey can be found in Appendix B and each section will be
discussed in detail. The first section of the survey gathered information regarding whether or not
physicians treated and/or referred children and adolescents for the treatment of major depressive
disorder, as it was possible that physicians treated only one of these groups of patients. The second
section of the survey gathered information about physicians’ preferred first-line of treatment for
newly diagnosed children and adolescents with major depressive disorder. This section also
determined a physicians’ antidepressant prescribing habits regarding these patients, including
dosage, titration, and length of treatment. Section three of the survey obtained information regarding
the physicians’ preferred second-line of treatment (in the event of a treatment failure with the firstline of treatment). The fourth section asked physicians to indicate their preferred third-line of
treatment assuming the second-line of treatment is a failure. The fifth section gathered some basic
information about physicians’ counseling and psychotherapy practices. Section six collected
information regarding pharmacotherapy monitoring of children and adolescents receiving
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antidepressants. Section seven consisted of a listing of variables which may influence the
physicians’ decision to prescribe an antidepressant medication to a child or adolescent who has been
newly diagnosed with major depressive disorder. The physicians were asked to indicate how much
influence each factor has when making the decision to prescribe an antidepressant medication to
children and adolescents. A four point, Likert scale (where 1 = not influential and 4 = extremely
influential) was utilized to determine the degree of influence each variable has on the physicians’
decision to prescribe antidepressant medication. The last section of the instrument collected
physician demographic information, including age, gender, specialty, practice location, practice
volume, and training.
Instrument Validation
In general, the validity of a measurement has to do with the correctness or accuracy of the
measurement. More specifically, the validity of an instrument or measurement reflects the extent to
which scores on the instrument are reflective of the true differences of the measured characteristic
among individuals (Churchill, 1991). One type of validity is content validity. Content validity is the
ability of the measurement or instrument to capture all of the content, or all domains of the
characteristic the researchers wants to measure (Churchill, 1991). Face validity refers to what an
instrument appears to measure (Churchill, 1991).
Content and face validity were assessed for both surveys utilized in this study. During the
development of the surveys, the input of experts in psychiatry and faculty members with expertise in
health outcomes research at West Virginia University was sought. The psychiatry experts and
researchers assessed the readability, clarity of the questions, and the relevance of the questions in
this survey.
Non-response bias was assessed by comparing the responses of early responders to those of late
responders. This method of assessing non-response bias involves viewing non-response bias as a
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continuum, with early respondents at one end and late responders at the other. It is also assumed that
late responders are more like non-responders and may be used as proxy for non-respondents.
Therefore, a comparison of the responses from the early responders to the late responders (i.e., Nonresponders) can be made as a method for assessing non-response bias (Armstrong & Overton, 1977).
A pilot study was conducted for Phase II of the study. The pilot study consisted of a random
sample equal to 10% (or 250 subjects) of the sample size for Phase II. This study allowed the
researchers to determine the clarity of the survey questions. Based on the feedback from the pilot
study, final adjustments to the content of the survey instrument were made, prior to the first mailing.
A copy of the survey utilized in the pilot study can be found in Appendix C.
Data Analysis
Objectives for each of the two phases are stated and followed by the data analysis to be utilized in
this study. All statistical analyses were conducted utilizing either Statistical Package for the Social
Sciences, SPSS® Version 16.0 or Statistical Analysis Software, SAS® Version 9.1.
Phase I :
The overall goal of Phase I was to identify pediatricians who treat children and/or adolescents
with major depressive disorder. There were four specific objectives for this phase.
Objective 1: To determine the proportion of pediatricians who treat children and adolescents with
major depressive disorder.
The Phase I survey asked pediatricians to indicate all age groups they treat for major depressive
disorder. The choices were “children (5-12 years old)”, “adolescents (13-18 years old)”, or “do not
treat”. Descriptive statistics were calculated for the responses. More specifically the frequencies
and proportions of pediatricians who treat children and/or adolescents with major depressive
disorder were calculated based on physicians’ responses.
Objective 2: To determine the proportion of pediatricians who refer children and adolescents with
major depressive disorder.
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The Phase I survey asked pediatricians to indicate all age groups they refer for the treatment of
major depressive disorder. The choices were “refer children (5-12 years old)”, “refer adolescents
(13-18 years old)”, or “do not refer”. Descriptive statistics were calculated for the responses. More
specifically the frequencies and proportions of pediatricians who refer children and/or adolescents
with major depressive disorder were calculated based on physicians’ responses.
Objective 3: To determine the health care provider to whom pediatricians refer a child or
adolescent with major depressive disorder.
Pediatricians were asked to indicate in an open ended format what type of health care provider they
would refer children and then adolescents, in the event they refer these patients. The frequencies of
the type of health care provider, to which pediatricians refer children and/or adolescents, were
calculated.
Objective 4: To determine geographic differences in pediatricians’ willingness to treat versus
referral of children and/or adolescents with major depressive disorder.
Null Hypothesis 4.0: There is no difference in the geographic locations of pediatricians who treat
versus refer children and/or adolescents for major depressive disorder.
Some physicians indicated they treated and referred, so that treating and referring patients was not a
mutually exclusive decision. Frequencies and proportions of pediatricians who treat children and/or
adolescents with major depressive disorder were calculated directly from the phase I survey
questions, as indicated above. The geographic location (state) was ascertained from the mailing
address for each pediatrician. The geographic regions were specified according to the U.S. Census
Bureau’s definitions. The U.S. Census Bureau divides the United States into five geographic regions
as follows: Northeast, South, Midwest, West, and Pacific. The states included in each of the
geographic regions are listed below in Table 3.2.
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Table 3.2: States Included in Each Geographic Region
Northeast
South
Midwest
West
Connecticut
Maine
Massachusetts
New Hampshire
New Jersey
Pennsylvania
Rhode Island
Vermont

Alabama
Arkansas
Delaware
District of Columbia
Florida
Georgia
Kentucky
Louisiana
Maryland
Mississippi
North Carolina
Oklahoma
South Carolina
Tennessee
Texas
Virginia
West Virginia

Illinois
Indiana
Iowa
Kansas
Michigan
Minnesota
Missouri
Nebraska
North Dakota
Ohio
South Dakota
Wisconsin

Arizona
California
Colorado
Idaho
Montana
Nevada
New Mexico
Oregon
Utah
Washington
Wyoming

Pacific
Alaska
Hawaii

Since both variables (treat, categorized as “yes” or “no” and geographic region, categorized as
“northeast”, “south”, “midwest”, “west”, and “pacific”) are categorical in nature the results of the χ2
statistic tested whether the proportion of pediatricians who treat children and adolescents by
geographic location are equal.
Phase II:
The overall goal of Phase II was to determine what physicians consider to be the most appropriate
treatment for children and/or adolescents with major depressive disorder, their recommended course
of treatment (i.e., length of treatment, pharmacotherapy monitoring), and the factors which impact
their decisions to treat major depressive disorder in children and adolescents with an antidepressant.
There were 20 specific objectives for this phase.
Objectives and Analysis for Children
Objectives 5 through 13 focused on the treatment, prescribing patterns, and factors which impact
the treatment of children (five through 12 years of age) with major depressive disorder.
Objective 5: To determine the demographic characteristics of physicians who treat newly diagnosed
children with major depressive disorder.
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This objective was determined from the pediatricians’ and child psychiatrists’ responses to the
survey questions in section eight of the Phase II survey. Descriptive statistics or frequency
distributions were estimated for these categorical variables (physicians’ gender, age, year of
graduation, practice site, geographic location, population of practice area, specialty, board
certifications, patient volume, and length of time treating children and adolescents).
Objective 6: To determine physicians’ first line of treatment for newly diagnosed children with
major depressive disorder by: a) type of treatment, b) drug category, and c) specific antidepressant
prescribed.
Descriptive statistics were calculated for the pediatricians’ and child psychiatrists’ responses to the
questions in section two of the Phase II survey. Frequency distributions were estimated for the
categorical variables type of treatment, drug category, and specific antidepressant prescribed.
Objective 7: To determine physicians’ second and third lines of treatment for newly diagnosed
children with major depressive disorder by: a) drug category, and b) specific antidepressant
prescribed.
These categorical variables are the responses to the survey questions in section three and section
four, of the Phase II survey. For both pediatricians and child psychiatrists, analysis consisted of
descriptive statistics, of the drug category and specific antidepressant variables.
Objective 8: To determine the difference in first, second, and third lines of antidepressant treatment
prescribed by physicians (pediatricians versus child psychiatrists) to newly diagnosed children with
major depressive disorder by a) the pharmacotherapy category and b) specific antidepressant
prescribed.
Null Hypothesis 8.a: There is no difference in the pharmacotherapy category prescribed by
physicians (pediatricians versus child psychiatrists) for first, second, and third lines of antidepressant
treatment for newly diagnosed children with major depressive disorder.
Sections two, three, and four of the Phase II survey gathered information from the physicians
regarding their first, second, and third lines of antidepressant treatment. The physicians were asked
to give their specific antidepressant choices. The variable, class of antidepressant, was created by
the researcher based on the specific answers from the physicians. Since both variables
(pharmacotherapy category and physician type) are categorical the χ2 statistic was utilized. The χ2
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statistic tested whether the proportion of Monoamine Oxidase Inhibitors (MAOIs), Tricyclic
Antidepressants (TCAs), Tetracyclic Antidepressants, Selective Serotonin Reuptake Inhibitors
(SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Norepinephrine and Dopamine
Reuptake Inhibitors (NDRIs), and Other Antidepressants for the first, second, and third lines of
treatment were equal for pediatricians versus child psychiatrists.
Null Hypothesis 8.b: There is no difference in the specific antidepressant prescribed by physicians
(pediatricians versus child psychiatrists) for first, second, and third lines of treatment for newly
diagnosed children with major depressive disorder.
Both variables are categorical (specific type of antidepressant and physician type) and the χ2 statistic
was utilized to test for an association between specific antidepressant (Celexa®, Cymbalta®,
Effexor®, etc.) and first, second, and third lines of treatment prescribed by pediatricians versus child
psychiatrists.
Objective 9: To predict which physician characteristics affect the treatment prescribed for children
with major depressive disorder.
The χ2 statistic is useful when the researcher wants to find the association between two categorical
variables. However, when there are more than one predictor variable regression is usually a more
useful statistical tool (Rosner, 2000; Vittinghoff, Glidden, Shiboski, & McCulloch, 2005). Logistic
regression is commonly utilized to investigate the association between binary outcomes and multiple
predictors (Rosner, 2000; Vittinghoff et al., 2005). This objective was met by using logistic
regression. Logistic regression was utilized to investigate the association between categorical
outcome variables (type of treatment, type of antidepressant treatment) and physician characteristics
(e.g. age, gender, year of graduation, specialty, board certifications, practice site, geographic
location, patient volume, and length of time treating children and adolescents).
Objective 10: To determine the average length of antidepressant treatment for newly diagnosed
children with major depressive disorder.
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Section two of the Phase II survey asked the physicians “how long they continue to prescribe the
antidepressant(s)” to the child, if the antidepressant is a successful treatment. The frequencies, as
these are categorical variables, related to how long physicians continue prescribing an antidepressant
assuming it is a successful treatment were calculated.
These categorical variables were transformed into continuous variables so that comparisons could be
made to the newly published American Academy of Child and Adolescent Psychiatry’s
recommended six months minimum length of treatment with antidepressant medication (AACAP,
2007).
Objective 11: To determine the types of pharmacotherapy monitoring in newly diagnosed children
with major depressive disorder.
Section six of the Phase II survey asked the physicians to indicate their primary mode of
pharmacotherapy monitoring, who conducts the monitoring, and the specific types of monitoring
conducted. Based on these responses the frequencies of the categorical variables (mode of
monitoring, who conducts the monitoring, type of monitoring, and frequency of monitoring) were
calculated.
Objective 12: To determine differences in antidepressant monitoring for newly diagnosed children
with major depressive disorder and the U.S. FDA recommendations for monitoring children treated
with antidepressants.
Null Hypothesis 12.0: There is no difference in pharmacotherapy monitoring for newly diagnosed
children with major depressive disorder and the U.S. FDA recommendations for monitoring children
treated with antidepressants.
Section six of the Phase II survey contained questions designed to determine how often physicians
monitor for the first, second, and third month of treatment. These categorical variables were
transformed into continuous variables so comparisons could be made to the U.S. FDA
recommendations. The average number of times the physicians monitor per month for month one,
two, and three of treatment were then compared to the U.S. FDA recommendations for months one,
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two, and three of treatment. A t-test was utilized to test for any significant differences between how
often physicians report they monitor and the U.S. FDA recommendations.
Objective 13: To determine whether there are differences, by physician type, in the average number
of times per month physicians monitor children with major depressive disorder.
Null Hypothesis 13.0: There is no difference, by physician type, in the average number of times per
month physicians monitor children with major depressive disorder.
The information gathered in section six of the Phase II survey was utilized to determine whether
there are differences in the average number of times per month physicians monitor children treated
with antidepressants by physician type. A comparison of the average number of times per month
child psychiatrists and pediatricians monitor was tested utilizing the t-test.
Objectives and Analysis for Adolescents
Next, Objectives 14 through 22 focused on the treatment, prescribing patterns, and factors which
impact the treatment of adolescents (13 through 18 years of age) with major depressive disorder.
Objective 14: To determine the demographic characteristics of physicians who treat newly
diagnosed adolescents with major depressive disorder.
This objective was determined from the pediatricians’ and child psychiatrists’ responses to the
survey questions in section eight of the Phase II survey. Descriptive statistics or frequency
distributions were estimated for these categorical variables
(physicians’ gender, age, year of graduation, practice site, geographic location, population of
practice area, specialty, board certifications, patient volume, and length of time treating children and
adolescents).
Objective 15: To determine physicians’ first line of treatment for newly diagnosed adolescents with
major depressive disorder by: a) type of treatment, b) drug category, and c) specific antidepressant
prescribed.
Descriptive statistics were calculated for the pediatricians’ and child psychiatrists’ responses to the
questions in section two of the Phase II survey. Frequency distributions were estimated for the
categorical variables type of treatment, drug category, and specific antidepressant prescribed.
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Objective 16: To determine physicians’ second and third lines of treatment for newly diagnosed
adolescents with major depressive disorder by: a) drug category, and b)specific antidepressant
prescribed.
These categorical variables are the responses to the survey questions in section three and section
four, of the Phase II survey. For both pediatricians and child psychiatrists, analysis consisted of
descriptive statistics of the drug category and specific antidepressant variables.
Objective 17: To determine the difference in first, second, and third lines of antidepressant
treatment prescribed by physicians (pediatricians versus child psychiatrists) to newly diagnosed
adolescents with major depressive disorder by a) the pharmacotherapy category and b) specific
antidepressant prescribed.
Null Hypothesis 17.a: There is no difference in the pharmacotherapy category prescribed by
physicians (pediatricians versus child psychiatrists) for first, second, and third lines of antidepressant
treatment for newly diagnosed adolescents with major depressive disorder.
Sections two, three, and four of the Phase II survey gathered information from the physicians
regarding their first, second, and third lines of antidepressant treatment. The physicians were asked
to give their specific antidepressant choices. The variable, class of antidepressant, was created by
the researcher based on the specific answers from the physicians. Since both variables
(pharmacotherapy category and physician type prescribed) are categorical the χ2 statistic was
utilized. The χ2 statistic tested whether the proportion of Monoamine Oxidase Inhibitors (MAOIs),
Tricyclic Antidepressants (TCAs), Tetracyclic Antidepressants, Selective Serotonin Reuptake
Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Norepinephrine and
Dopamine Reuptake Inhibitors (NDRIs), and Other Antidepressants for the first, second, and third
lines of treatment are equal for pediatricians versus child psychiatrists.
Null Hypothesis 17.b: There is no difference in the specific antidepressant prescribed by physicians
(pediatricians versus child psychiatrists) for first, second, and third lines of treatment for newly
diagnosed adolescents with major depressive disorder.
Both variables are categorical (specific type of antidepressant and physician type) and the χ2 statistic
was utilized to test for an association between specific antidepressant (Celexa®, Cymbalta®,
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Effexor®, etc.) and first, second, and third lines of treatment prescribed by pediatricians versus child
psychiatrists.
Objective 18: To predict which physician characteristics affect the treatment prescribed for
adolescents with major depressive disorder.
The χ2 statistic is useful when the researcher want to find the association between two categorical
variables. However, when there are multiple predictors regression is a more useful statistical tool
(Rosner, 2000; Vittinghoff et al., 2005). Specifically, logistic regression is commonly utilized to
investigate the association between binary outcomes and multiple predictors (Rosner, 2000;
Vittinghoff et al., 2005). This objective was met by using logistic regression. Logistic regression
was utilized to investigate the association between categorical outcome variables (type of treatment,
type of antidepressant treatment) and physician characteristics (e.g. age, gender, year of graduation,
specialty, board certifications, practice site, geographic location, patient volume, and length of time
treating children and adolescents).
Objective 19: To determine the average length of antidepressant treatment for newly diagnosed
adolescents with major depressive disorder.
Section two of the Phase II survey asked the physicians “how long they continue to prescribe the
antidepressant(s)” to the child, if the antidepressant is a successful treatment. The frequencies, as
these are categorical variables, related to how long physicians continue prescribing an
antidepressant, assuming it is a successful treatment, were calculated. These categorical variables
were transformed into continuous variables so that comparisons may be made to the newly published
American Academy of Child and Adolescents Psychiatry’s recommended six month minimum
length of treatment with antidepressant medication (AACAP, 2007).
Objective 20: To determine the types of pharmacotherapy monitoring in newly diagnosed
adolescents with major depressive disorder.
Section six of the Phase II survey asked the physicians to indicate their primary mode of
pharmacotherapy monitoring, who conducts the monitoring, and the specific types of monitoring
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conducted. Based on these responses the frequencies of the categorical variables (mode of
monitoring, who conducts the monitoring, type of monitoring, and frequency of monitoring) were
calculated.
Objective 21: To determine differences in antidepressant monitoring for newly diagnosed
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring
adolescents treated with antidepressants.
Null Hypothesis 21.0: There is no difference in pharmacotherapy monitoring for newly diagnosed
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring
children treated with antidepressants.
Section six of the Phase II survey contained questions designed to determine how often the
physicians monitor for the first, second, and third month of treatment. These categorical variables
were transformed into continuous variables so comparisons could be made to the U.S. FDA
recommendations. The average number of times the physicians monitor per month for month one,
two, and three of treatment were compared to the U.S. FDA recommendations for months one, two,
and three of treatment. A t-test was utilized to test for any significant differences between how often
physicians report they monitor and the U.S. FDA recommendations.
Objective 22: To determine whether there are differences, by physician type, in the average number
of times per month physicians monitor adolescents with major depressive disorder.
Null Hypothesis 22.0: There is no difference, by physician type, in the average number of times per
month physicians monitor adolescents with major depressive disorder.
The information gathered in section six of the Phase II survey was also utilized to determine whether
there are differences in the average number of times per month physicians monitor children treated
with antidepressants by physician type. A comparison of the average number of times per month
child psychiatrists and pediatricians monitor was tested utilizing the t-test.
Objectives for Factor Analysis
Objective 23: To determine the relative importance which physicians place on each factor prior to
prescribing antidepressants to newly diagnosed children and adolescents with major depressive
disorder.
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Objective 24: To determine the factors associated with physicians’ antidepressant prescribing
behavior for children and adolescents newly diagnosed with major depressive disorder.
Objectives 23 and 24 utilized the information collected in section seven of the Phase II survey. This
portion of the survey asked physicians to rate the extent to which 28 variables influences their
decision of whether or not to prescribe an antidepressant medication to a child or adolescent. The
physicians rated the influence of the 28 variables on a scale from 1-4, where 1= not influential, 2=
somewhat influential, 3= influential, and 4= extremely influential. Descriptive statistics including
measures of central tendency (mean) and dispersion (standard deviation) were calculated for the
physicians’ ratings of each of the variables. An exploratory factor analysis was utilized to identify
the hypothetical constructs that influence these 28 variables. The results of the analyses for both
phases of this study will be the focus of Chapter Four.

76

CHAPTER FOUR: RESULTS
This chapter contains the results for this study. The results of the Phase I survey of pediatricians
is presented first. As part of Phase II, a pilot study was conducted to evaluate the survey instrument.
These results are presented next in this chapter, followed by the results of the final survey to
pediatricians and child psychiatrists.
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Results for Phase I
A national random sample of 2,000 pediatricians was obtained from SK&A Informational
Services, Inc’s, American Medical Association member list. A cover letter, phase I survey, and
return postage-paid envelope was sent to 2,000 pediatricians. A second mailing was conducted
approximately five weeks later to those pediatricians who did not respond to the first mailing.
According to Salant & Dillman (1994) mailings of questionnaires should occur more closely
together than the five weeks allowed in this study. In this case, however, the second mailing would
have coincided with the Christmas holiday season. The decision was made to delay the second
mailing of the survey until after the holiday season in order to potentially increase the response rate
of the pediatricians.
Of the 2,000 pediatricians surveyed, a total of 424 responded and a total of 200 surveys were
retuned as bad addresses. Of the 424 pediatricians who responded 11 indicated they had retired or
were not in practice and another five surveys were not completed. Therefore, a total of 408 useable
surveys were received. This resulted in a usable response rate of 22.9% for phase I of the study.
Table 4.1: Response Rate for Phase I
__________________________________________N__________Percentage (%)_______________
Original sample size
Undeliverable surveys
Effective Sample Size
Number of Surveys Returned
Unusable Surveys
Usable Surveys
Usable Response Rate

2,000
200
1,800
424
16
408

100.0
23.6
22.9

The first three objectives intended to determine the proportion of pediatricians in the United
States who children and adolescents with major depressive disorder. In the case a pediatrician did
not treat major depressive disorder in this population the researcher sought to determine which type
of health care provider children and/or adolescents would likely be referred. The purpose for
determining this information was two-fold. This information is not in the current scientific literature
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and the researcher could identify pediatricians who would be willing to participate in Phase II of this
study. Each objective will be noted followed by the findings from the study.
Objective 1: To determine the proportion of pediatricians who treat children and adolescents with
major depressive disorder.
The frequency and proportion of pediatricians who treat children and/or adolescents with major
depressive disorder was calculated. The majority of pediatricians (60.0%) indicated they do not treat
either children or adolescents with major depressive disorder. Additionally, 28.2% of the
pediatricians surveyed indicated they treat both children and adolescents for major depressive
disorder. No pediatricians indicated they treat children only, while 11.8% indicated they treat
adolescents only. The results for Objective 1 are listed in Table 4.2.
Table 4.2: Pediatricians Treating Children and/or Adolescents with Major Depressive
Disorder
Frequency
Percentage
(N)
(%)
Treat Children Only
0
0.0
Treat Adolescents Only
48
11.8
Treat Both Children and Adolescents
115
28.2
Do Not Treat
245
60.0
Objective 2: To determine the proportion of pediatricians who refer children and adolescents with
major depressive disorder.
A minority of pediatricians (6.7%) indicated they do not refer either children or adolescents to
another type of health care provider for the treatment of major depressive disorder. Approximately
the same percentage of pediatricians indicated they refer children only (4.2%) or adolescents only
(4.5%) to another type of health care provider for the treatment of major depressive disorder. The
majority of the pediatricians (84.6%) indicated they referred both children and adolescents for the
treatment of major depressive disorder. These results are listed in Table 4.3.
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Table 4.3: Pediatricians Referring Children and/or Adolescents with Major Depressive
Disorder
Frequency
Percentage
(N)
(%)
Refer Children Only
17
4.2
Refer Adolescents Only
18
4.5
Refer Both Children and Adolescents
341
84.6
Do Not Refer
27
6.7
Objective 3: To determine the health care provider to whom pediatricians refer a child or
adolescent with major depressive disorder.
The results for pediatricians seeing children with major depressive disorder will be discussed first
followed by the results for adolescents. Pediatricians listed up to three different health care
providers to which they would refer children for treatment. This resulted in 358 total responses.
Pediatricians cited they most often refer children to some type of psychiatrist (67.6%), with 29.3% of
the responses indicating a child and adolescent psychiatrist and 38.3% indicating a psychiatrist. The
second most popular health care provider to refer children was a psychologist. A small percentage
of responses indicated they refer specifically to a child psychologist (1.4%), while some responses
(13.7%) indicated referral to a psychologist. A small percentage 5.9% of responses indicated
referral to a counselor, therapist, or Master’s in Social Work (MSW). These results are listed in
Table 4.4.
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Table 4.4: Health Care Provider to whom Pediatricians Refer Children and Adolescents with
Major Depressive Disorder
Total
PercentageTotal
PercentageFrequencychildren
Frequency- adolescents
Health Care Provider
children
(%)
adolescents
(%)
(N)
(N)
Psychiatrist
137
38.3
154
42.3
Child & Adolescent
Psychiatrist
Psychologist
Counselor, Therapist,
or MSW
Crisis Center, Mental
Health Clinic, Hospital
Other Physician
Unspecified Mental
Health Care Provider
Any Available Mental
Health Care Provider
Child Psychologist
Total

105

29.3

91

25.0

49

13.7

51

14.0

21

5.9

25

6.9

20

5.5

23

6.3

10

2.8

6

1.6

6

1.7

5

1.4

5

1.4

5

1.4

5

1.4

4

1.1

358

100.0

364

100.0

The responses for adolescents mirrored that of children. Pediatricians listed up to three different
health care providers to which they would refer adolescents for treatment. This resulted in 364 total
responses. Pediatricians cited they most often refer adolescents to some type of psychiatrist
(67.3%), with 25.0% of the responses indicating a child and adolescent psychiatrist and 42.3%
indicating a psychiatrist. The second most popular health care provider to refer adolescents was a
psychologist. A small percentage of responses indicated they refer specifically to a child
psychologist (1.1%), while some responses (14.0%) indicated referral to a psychologist. A small
percentage 6.9% of responses indicated referral to a counselor, therapist, or Master’s in Social Work
(MSW). These results are listed in Table 4.4.
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The next study objective sought to determine whether there were geographic differences in
pediatricians’ willingness to treat versus refer children and/or adolescents with major depressive
disorder. This objective and null hypothesis read as follows:
Objective 4: To determine geographic differences in pediatricians’ willingness to treat versus
referral of children and/or adolescents with major depressive disorder.
Null Hypothesis 4.0: There is no difference in the geographic locations of pediatricians who treat
versus refer children and/or adolescents for major depressive disorder.
.
Based on the responses, the results showed, that treating and referring patients was not a mutually
exclusive choice for pediatricians. Some physicians indicated they treated and referred. Some
pediatricians even indicated they would try one line of treatment and if that treatment did not
produce a response they would refer. Since treating and referring were not mutually exclusive
events it was decided to analyze the data by geographic region according to whether or not
pediatricians treated children. Next, the data was analyzed by geographic region according to
whether or not pediatricians treated adolescents. Since none of the pediatricians indicated they
“treated children only”, pediatricians were said to treat children if they indicated they “treat both
children and adolescents”. Likewise, pediatricians where said not to treat children if they indicated
they “treated adolescents only” or “did not treat”. Similarly, pediatricians were classified as treating
adolescents if they indicated they “treated adolescents only” or “treated both children and
adolescents”. Pediatricians were said not to treat adolescents if they indicated they “did not treat”.
Geographic regions were specified according to the U.S. Census Bureau’s definitions. The U.S.
Census Bureau divides the United States into five geographic regions as follows: Northeast, South,
Midwest, West, and Pacific. The states included in each geographic region are listed in Table 4.5.
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Table 4.5: States Included in Each Geographic Region
Northeast
South
Midwest
West
Connecticut
Maine
Massachusetts
New Hampshire
New Jersey
Pennsylvania
Rhode Island
Vermont

Alabama
Arkansas
Delaware
District of Columbia
Florida
Georgia
Kentucky
Louisiana
Maryland
Mississippi
North Carolina
Oklahoma
South Carolina
Tennessee
Texas
Virginia
West Virginia

Illinois
Indiana
Iowa
Kansas
Michigan
Minnesota
Missouri
Nebraska
North Dakota
Ohio
South Dakota
Wisconsin

Arizona
California
Colorado
Idaho
Montana
Nevada
New Mexico
Oregon
Utah
Washington
Wyoming

Pacific
Alaska
Hawaii

There were only four pediatricians classified as practicing in the Pacific geographic location.
Instead of dropping these physicians from the analysis it was decided to collapse or combine the
Pacific and West categories. This was conducted for the analysis of children and adolescents
(below). The results, for pediatricians treating children, are shown in Table 4.6 below and reflect the
combining of the Pacific and West categories.
Table 4.6: Treatment of Children Across Geographic Regions
Northeast
South
Midwest
Pacific and
Treatment
West
of Children
Yes
21
35
37
22
No
86
85
68
54
107
120
105
76
Total
Proportion
0.1963
0.2917
0.3524
0.2895

Total
115
293
408
--

The χ2 statistic was utilized to determine whether or not there were differences in whether or not
pediatricians treated children across the four geographic regions. The χ2 statistic was equal to 6.532,
df =3, and p= 0.088. This means that the proportion of pediatricians who treat children does not
significantly vary according to geographic region and we fail to reject the Null Hypothesis 4.0.
Since the p-value is close to 0.05, this result warranted a closer look because it is marginally
significant. Examining the results and the proportions of physicians who treat in each region
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revealed the following trend. Pediatricians in the Midwest are somewhat more likely to treat
children, while pediatricians in the Northeast are somewhat less likely to treat children for major
depressive disorder. Again this is not a significant difference, but a trend.
Next, the χ2 statistic was utilized to determine whether or not there were differences in whether or
not pediatricians treated adolescents across the four geographic regions. The results are shown in
Table 4.7 below.
Table 4.7: Treatment of Adolescents Across Geographic Regions
Northeast
South
Midwest
Pacific and
Treatment
West
of
Adolescents
Yes
37
44
47
35
No
70
76
58
41
107
120
105
76
Total

Total
163
245
408

The χ2 statistic was equal to 4.019, df = 3, and p=0.259. This result means the proportion of
pediatricians who treat adolescents does not significantly vary by geographic region and again we
fail to reject the Null Hypothesis 4.0.
One purpose of Phase I of this study was to identify study participants for Phase II of this study.
This was important since all pediatricians do not treat children and/or adolescents for major
depressive disorder and Phase II of the study was designed to determine the treatment and
prescribing practices of pediatricians and child psychiatrists. If a pediatrician indicated they treated
either children or adolescents, they were asked if they would be willing to participate in the Phase II
survey. The results indicate that 110 pediatricians were both eligible and willing to participate in
Phase II. These results are listed below in Table 4.8 and depicted in Figure 4.1. These 110
pediatricians were included in Phase II of this study.
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Table 4.8: Treating Pediatricians Willing to Participate in Phase II
Frequency
Percentage
(N)
(%)
Yes
106
26.4
Yes, depending on length of survey
4
1.0
No
46
11.5
Not Applicable
245
61.1

Figure 4.1: Breakdown of Pediatricians in Phase I
Refer
Children only= 17
Adolescents only=18
Both=341
Participants for
Phase I:
Pediatricians
N = 2,000

Treat
Adolescents = 48
Both= 115
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Willing to
Participate in
Phase II
Participants = 110

Not Willing to
Participate in
Phase II = 46

Results for the Pilot Study
A national random sample of 2,500 child psychiatrists was obtained from SK&A Informational
Services, Inc’s, American Medical Association member list. A cover letter, Phase II survey, and
return postage-paid envelope were sent to 10% or 250 of these 2,500 pediatricians. Due to resource
constraints only one mailing was performed for the pilot study. Of the 250 child psychiatrists
surveyed 22 returned a usable survey and six surveys were returned due to bad addresses. This
information is listed below in Table 4.9.
Table 4. 9: Response Rate for Pilot Study
__________________________________________N______________Percentage (%)___________
Original sample size
Undeliverable surveys
Effective Sample Size
Number of Surveys Returned
Unusable Surveys
Usable Responses
Usable Response Rate

250
6
244
22
0
22

100.00%
9.02%
9.02%

The demographics for the 22 child psychiatrists, who returned surveys for the pilot study are
listed in Table 4.10. The majority of the physicians were males (68.18%) and between 41 and 60
years of age (54.55%). The year of graduation from medical school varied: 36.36% indicated they
graduated in 1996- 2003, 22.73% indicated they graduated in 1976 -1985, 18.18% indicated they
graduated in 1966 – 1975, another 18.18% indicated they graduated in 1986 – 1995, and only 4.55%
graduated in 1965 or earlier. The majority (63.63%) of the physicians indicated their primary
practice site was private-based, as opposed to hospital-based. The geographic region of the
physicians’ primary practice site varied. No physicians practice in the Pacific region, while the
number practicing in the other regions ranged from 9.09% to 31.82%. The population of the primary
practice area varied as 47.62% practice in areas with 250,000 – 999,999 people, 33.33% have
primary practice sites in areas with 50,000 – 249,999 people, 19.05% practice in areas with a
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population of 1 million or more people, and none of the physicians practice in areas with 50,000
people or less. The majority (81.82%) of the physicians indicated specialties of both adult and child
psychiatry. The preponderance of the physicians are board certified as either both adult psychiatrists
and child psychiatrists (47.62%) or as adult psychiatrists (38.09%). The majority of physicians
(78.95%) indicated they treat 10 or less children per week. Additionally, the bulk (55.00%) of the
physicians indicated they treat 10 or less adolescents per week. The majority (54.55%) of the
physicians indicated they treated children and/or adolescents for greater than 10 years.
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Table 4.10: Demographics of Child Psychiatrists from Pilot Study
Variable
Type of Physician:
Child Psychiatrists
Gender:
Male
Female
Age:
40 years or younger
41 years – 60 years
61 years or older
Year Graduated from Medical School:
1965 or Before
1966 – 1975
1976 - 1985
1986 - 1995
1996 – 2003
Primary Practice Site:
Private Based Practice
Hospital Based Practice
Other (ex.hospital and private)
Geographic Location of Practice:
Northeast
South
Midwest
West
Pacific
Population of Practice Area:
Less than 50,000
50,000 – 249,999
250,000 – 999,999
1 million or more
Physician Specialty:
Adult Psychiatrist
Child Psychiatrist
Adult and Child Psychiatrist
Board Certification:
Adult Psychiatrist
Adult and Child Psychiatrist
Not Board Certified
Child Patient Volume Per Week:
10 or less
11 – 40
Adolescent Patient Volume Per Week:
10 or less
11 – 40
Number of Years Treating Children and/or
Adolescents:
Greater than 1 year to 5 years
Greater than 5 years to 10 years
Greater than 10 years

N (%)
22 (100.00%)
15 (68.18%)
7 (31.82%)
6 (27.27%)
12 (54.55%)
4 (18.18%)
1 (4.55%)
4 (18.18%)
5 (22.73%)
4 (18.18%)
8 (36.36%)
14 (63.63%)
3 (13.64%)
5 (22.73%)
2 (9.09%)
7 (31.82%)
6 (27.27%)
7 (31.82%)
0 (0.00%)
0 (0.00%)
7 (33.33%)
10 (47.62%)
4 (19.05%)
1 (4.54%)
3 (13.64%)
18 (81.82%)
8 (38.09%)
10 (47.62%)
3 (14.29%)
15 (78.95%)
4 (21.05%)
11 (55.00 %)
9 (45.00%)
2 (9.09%)
8 (36.36%)
12 (54.55%)

The purpose of the pilot study was to assess the survey instrument within the population prior to
mailing to the study population. All of the child psychiatrists who returned surveys for the pilot
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study indicated they treat both children and adolescents for major depressive disorder. The majority
(59.09%) of the child psychiatrists indicated they treat children with counseling/psychotherapy as a
first-line of treatment. Additionally, the majority (68.18%) of the child psychiatrists indicated they
treat adolescents with both antidepressants and counseling as a first-line of treatment. Physicians
were then asked to indicate, which antidepressant they would prescribe as their first-line of
treatment, in the event they utilized both antidepressants and counseling as the first-line of treatment.
The results of the pilot study showed that many of the physicians, who indicated they treat children
and adolescents with counseling only, as a first-line of treatment, also indicated an antidepressant for
this line of treatment. More specifically, 12 of the physicians who indicated they treat children with
counseling only as the first-line of treatment also indicated they utilize an antidepressant. Another
six of the physicians who indicated they treat adolescents with counseling only as the first-line of
treatment also indicated they utilize an antidepressant. Therefore, 54.55% of the physicians
answered the first-line of treatment for children incorrectly. Another, 27.27% of the physicians
answered the first-line of treatment for adolescents incorrectly. Based on these findings, it was
concluded the questions regarding treatment for children and adolescents were not clear and were
misunderstood and lacked clarity. Thus the questions regarding first, second, and third-line of
treatment were revised before the final survey was mailed to the larger sample of child psychiatrists.
The following changes were made to the survey instrument. First, the questions regarding
treatment were re-worded and headings denoting first, second, and third-lines of treatment were
added to the survey. Second, the directions, associated with these treatment questions were altered
by telling physicians if they indicated use of antidepressants for their first-line of treatment, then
they should answer the question regarding antidepressant treatment. More specifically, the
directions read as follows: “If your first-line of treatment (in Question #4) included antidepressants
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(either alone or in combination with counseling/psychotherapy), for EITHER children or adolescents
please answer Questions #5 - #8, otherwise skip to Section 3, Question #9”.
Based on the results from the final survey, the changes in the questions on the survey seemed to
help clarify the issue in the pilot study, somewhat. Only nine pediatricians (15.00%) indicated they
utilized counseling only as a first-line of treatment for children and/or adolescents and listed an
antidepressant also on the first-line of treatment. Only sixty-four child psychiatrists (20.25%)
indicated their preferred first line of treatment was counseling only for children and/or adolescents
and listed an antidepressant also on the first-line of treatment. The majority of the physicians went
on to list this same antidepressant as their answer for the second line of treatment. Since this was the
case, it was assumed, that counseling only was truly their first-line of treatment and the
antidepressant listed was actually part of their choice for the second-line of treatment.

Results for Phase II
Two groups of physicians were surveyed for Phase II of this study. The pediatricians (n=110)
who indicated in phase I they treated children and/or adolescents diagnosed with major depressive
disorder, and whom agreed to participate in phase II were included. Additionally, a random sample
of child psychiatrists (n=2,250) were surveyed in phase II. Pediatricians and child psychiatrists were
mailed a cover letter, eight-page survey, and return postage paid-envelope. Those who did not
respond to the first mailing were mailed a second copy of the cover letter, survey, and postage-paid
envelope approximately two and a half weeks later. Response rates are based on those surveys
received two months after the initial mailing, for both groups of physicians. Details of the number
of respondents are discussed next.
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Child Psychiatrists:
Of the 2,250 mailed surveys, 316 surveys were returned, and 268 were undeliverable, due to bad
addresses. Of the 316 returned surveys, 14 surveys were unusable as these physicians indicated they
were either retired or no longer in practice. Another three surveys were unusable because the
physicians failed to complete the survey. The usable number of surveys from the child psychiatrists
equaled 299.
Table 4.11: Response Rate for Child Psychiatrists - Phase II
__________________________________________N__________Percentage (%)_______________
Original sample size
Undeliverable surveys
Effective Sample Size
Number of Surveys Returned
Unusable Surveys
Usable Responses
Usable Response Rate

2,250
268
1,982
316
17
299

100.0%
15.9%
15.1%

Pediatricians:
One hundred ten pediatricians indicated they treated children and/or adolescents and were willing
to participate in the phase II survey. Of these 110 pediatricians surveyed, 60 returned surveys were
returned. Of the 60 returned surveys three were not useable, so these mailings resulted in 57 useable
surveys from pediatricians.
Table 4.12: Response Rate for Pediatricians - Phase II
__________________________________________N__________Percentage (%)_______________
Original sample size
Undeliverable surveys
Effective Sample Size
Number of Surveys Returned
Unusable Surveys
Usable Responses
Usable Response Rate

110
0
110
60
3
57

100.0

51.8%
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Results for Non-Response Analysis
Bias refers to any differences between an estimate from a survey and the actual value in the
population. Non-response is a type of bias and refers to the difference between respondents and
non-respondents of a survey. More specifically, non-response bias refers to the idea that people who
do not respond to surveys may answer questions differently than those people who do respond to
surveys. One method to assess non-response bias involves comparing “early responders” to “late
responders”. This method assumes late responders are similar to non-responders and thus late
responders serve as a proxy for non-responders. Utilizing this method revealed no statistical
differences among the demographic characteristics of early responders and non-responders, in this
study. Table 4.13 shows the statistical results of the comparisons of the demographic variables.
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Table 4.13: Comparison of Demographics of Early Responders and Non-Responders
Variable

Gender:
Male
Female
Primary Practice Site:
Hospital-Based
Private Practice
Population of Practice Area:
Less than 50,000
50,000-249,999
250,000-999,999
1 million or more
Geographic Location of Practice:
Northeast
South
Midwest
West
Pacific
Physician Specialty:
Child & Adolescent Psychiatry
Pediatrics
Adult/Child & Adolescent Psychiatry
Board Certification:
Adult Psychiatry
Child & Adolescent Psychiatry
Pediatrics
Not Board Certified
Adult/Child & Adolescent Psychiatry
Number of Years Treating Children
and/ or Adolescents:
1-5 years
5-10 years
Greater than 10 years

Early
Responders
(N)

NonResponders
(N)

Test
Statistic

Significance
(p)

80
42

66
51

χ2=2.110

0.146

20
76

25
65

χ2=1.221

0.269

18
42
24
34

18
32
35
33

χ2=3.417

0.332

37
29
31
19
1

24
44
23
23
1

χ2=7.402

0.116

10
17
87

15
18
82

χ2=1.172

0.557

17
0
20
10
65

22
1
20
5
66

χ2=3.298

0.509

7
17
96

8
21
87

χ2=0.863

0.650

Comparisons were also made to see if early responders and non-responders differed in the way
they answered treatment questions for children and adolescents. These comparisons are listed in
Table 4.14. No statistical differences were found between early responders and non-responders on
the age groups they treat, first-line of treatment for children, first-line of treatment for adolescents,
antidepressant treatment for children, antidepressant treatment for adolescents, and patient volume.
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Table 4.14: Comparisons of Treatment Variables of Early Responders and Non-Responders
Variable

Age Group Physician Treats:
Adolescents
Both Children and Adolescents
First-line of Treatment (Children):
Antidepressants or Antidepressants and
Counseling
Counseling Only
First-line of Treatment (Adolescents):
Antidepressants or Antidepressants and
Counseling
Counseling Only
First-line of Antidepressant Treatment
for Children:
Non-Prozac®
Prozac®
First-line of Antidepressant Treatment
for Adolescents:
Non-Prozac®
Prozac®
Child Patient Volume Per Week:
40 patients or less
Greater than 40 patients
Adolescent Patient Volume Per Week:
40 patients or less
Greater than 40 patients

Early
Responders
(N)

NonResponders
(N)

Test
Statistic

Significance
(p)

3
113

8
112

χ2=2.210

0.137

3
105

2
110

Fisher’s
Exact
Test

0.679

1
107

1
111

Fisher’s
Exact
Test

1.000

32
35

36
39

χ2=0.001

0.977

47
46

53
49

χ2=0.039

0.843

112
6

111
5

χ2=0.078

0.780

109
9

111
5

χ2=1.144

0.285

Based on the non-response analysis, it was found that there was no significant statistical
difference between early responders and non-responders.
Phase II: Results for Children with Major Depressive Disorder- Objectives 5-13
Objectives 5 through 13 focus on the treatment and prescribing patterns of children (five through
12 years of age) with major depressive disorder. Each objective will be stated followed by the
results pertaining to the objective.
Objective 5: To determine the demographic characteristics of physicians who treat newly diagnosed
children with major depressive disorder.
The demographics of physicians who treat children with major depressive disorder are listed in
Table 4.15 below. Of those physicians from phase II who indicated they treat children with major
depressive disorder, 42 (12.50%) were pediatricians and 294 (87.50%) were child psychiatrists. The
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majority of physicians who treat children with major depressive disorder are males (61.75%), and
are between 41 and 60 years of age (66.57%). The year of graduation from medical school varied:
33.66% indicated they graduated in 1986 -1995, 27.83% indicated they graduated in 1976 – 1985,
20.06% indicated they graduated in 1966 – 1975, 11.97% indicated they graduated in 1996 – 2003,
and only 6.47% graduated in 1965 or earlier. The majority (56.93%) of the physicians indicated
their primary practice site was private-based, as opposed to hospital-based. The geographic region
of the physicians’ primary practice site varied as only 0.63% practice in the Pacific. The number
practicing in the other four regions ranged between 19.75% and 29.15%. The population of the
primary practice area varied as 34.26% have primary practice sites in areas with 50,000 – 249,999
people, 25.93% practice in areas with a population of 1 million or more people, 24.38% practice in
areas with 250,000 – 999,999 people, and 15.43% practice in areas with 50,000 people or less. The
majority (73.57%) of the physicians indicated specialties of both adult and child psychiatry, and the
majority (57.14%) are board certified as both adult psychiatrists and child psychiatrists. The practice
volume also varied somewhat, however the majority of physicians indicated they treat both, 10 or
less children (70.68%) and 10 or less adolescents (56.17%) per week. The majority (74.77%) of the
physicians reported treating children for greater than 10 years.
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Table 4.15: Demographics of Physicians Who Treat Children for Major Depressive Disorder
Variable
Type of Physician:
Pediatricians
Child Psychiatrists
Gender:
Male
Female
Age:
40 years or younger
41 years – 60 years
61 years or older
Year Graduated from Medical School:
1965 or Before
1966 – 1975
1976 - 1985
1986 - 1995
1996 – 2003
Primary Practice Site:
Private Based Practice
Hospital Based Practice
Other (ex. hospital and private)
Geographic Location of Practice:
Northeast
South
Midwest
West
Pacific
Population of Practice Area:
Less than 50,000
50,000 – 249,999
250,000 – 999,999
1 million or more
Physician Specialty:
Child Psychiatrist
Pediatrics
Adult and Child Psychiatrist
Other (ex. adult and child psychiatry and general practice)
Board Certification:
Adult Psychiatrist
Child Psychiatrist
General Practitioner
Pediatrician
Adult and Child Psychiatrist
Other (ex. adult and child psychiatry and pediatrics)
Not Board Certified
Child Patient Volume Per Week:
10 or less
11 – 40
41 – 80
81 or greater
Adolescent Patient Volume Per Week:
10 or less
11 – 40
41 – 80
81 or greater
Number of Years Treating Children and/or Adolescents:
Greater than 1 year to 5 years
Greater than 5 years to 10 years
Greater than 10 years

N (%)
42 (12.50%)
294 (87.50%)
205 (61.75%)
127 (38.25%)
43 (12.95%)
221 (66.57%)
68 (20.48%)
20 (6.47%)
62 (20.06%)
86 (27.83%)
104 (33.66%)
37 (11.97%)
189 (56.93%)
66 (19.88%)
77 (23.19%)
73 (22.88%)
93 (29.15%)
88 (27.59%)
63 (19.75%)
2 (0.63%)
50 (15.43%)
111 (34.26%)
79 (24.38%)
84 (25.93%)
36 (10.81%)
37 (11.11%)
245 (73.57%)
15 (4.50%)
58 (17.63%)
1 (0.30%)
1 (0.30%)
41 (12.46%)
188 (57.14%)
18 (5.47%)
22 (6.69%)
229 (70.68%)
79 (24.38%)
13 (4.01%)
3 (0.93%)
182 (56.17%)
121 (37.35%)
16 (4.94%)
5 (1.54%)
24 (7.29%)
59 (17.93%)
246 (74.77%)
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Objective 6: To determine physicians’ first-line of treatment for newly diagnosed children with
major depressive disorder by: a) type of treatment, b) drug category, and c) specific antidepressant
prescribed.
A majority of physicians, both pediatricians (63.46%) and child psychiatrists (52.19%) indicated
their preferred first-line of treatment for children with major depressive disorder is a combination
treatment of antidepressants and counseling. Counseling only was the next most frequently
preferred choice as a first-line of treatment for both pediatricians (28.85%) and child psychiatrists
(40.07%). Few pediatricians (7.69%) and child psychiatrists (1.01%) indicated they use
antidepressants only as a first-line of treatment for children. The results for the first-line of
treatment for children with major depressive disorder are listed in Table 4.16.
Table 4.16 : First-Line of Treatment for Children with Major Depressive Disorder
Type of Treatment
All Physicians
Pediatricians
Child
N (%)
N (%)
Psychiatrists
N (%)
Antidepressants Only
7 (2.00%)
4 (7.69%)
3 (1.01%)
Counseling/Psychotherapy Only
134 (38.40%)
15 (28.85%)
119 (40.07%)
Both Antidepressants and Counseling
188 (53.87%)
33 (63.46%)
155 (52.19%)
Other Treatment
20 (5.73%)
0 (0.00%)
20 (6.73%)
In the event a physician utilized antidepressants as a first-line of treatment, all of the pediatricians
(100.00%) indicated their first-line of treatment would include an Selective Serotonin Reuptake
Inhibitors (SSRI) type antidepressant. The majority of the child psychiatrists (96.00%) also
indicated they utilize an SSRI type antidepressant. The results for the first-line of treatment by drug
class are listed in Table 4.17.
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Table 4.17: Therapeutic Category of Antidepressants Used as First-Line of Treatment for
Children
Drug Class
All Physicians
Pediatricians
Child
N (%)
N (%)
Psychiatrists
N (%)
Tricyclic Antidepressants (TCAs)
2 (0.95%)
0 (0.00%)
2 (1.14%)
Tetracyclic Antidepressants
1 (0.47%)
0 (0.00%)
1 (0.57%)
Selective Serotonin Reuptake
204 (96.68%)
36 (100.00%)
168 (96.00%)
Inhibitors (SSRIs)
Norepinephrine and Dopamine
4 (1.90%)
0 (0.00)%
4 (2.29%)
Reuptake Inhibitors (NDRIs)
The specific type of antidepressant varied somewhat for both pediatricians and child psychiatrists.
Still greater than half of the pediatricians (56.76%) and child psychiatrists (51.98%) indicated they
utilized Prozac® as their first-line of antidepressant treatment for children with major depressive
disorder. For first-line treatment, both pediatricians (24.33%) and child psychiatrists (27.12%)
indicated Zoloft® to be the second most commonly utilized antidepressant. Results for the first-line
of antidepressant treatment for children are listed in Table 4.18.
Table 4.18: Specific Antidepressant Used as First-Line Treatment for Children
Antidepressant
All Physicians Pediatricians
Child
N (%)
N (%)
Psychiatrists
N (%)
Prozac®
113 (52.80%)
21 (56.76%)
92 (51.98%)
Zoloft®
57 (26.64%)
9 (24.33%)
48 (27.12%)
Celexa®
21 (9.81%)
5 (13.51%)
16 (9.04%)
®
Lexapro
11 (5.14%)
0 (0.00%)
11 (6.21%)
Wellbutrin®
4 (1.87%)
0 (0.00%)
4 (2.26%)
®
Tofranil
2 (0.93%)
0 (0.00%)
2 (1.13%)
®
Paxil
1 (0.47%)
1 (2.70%)
0 (0.00%)
Remeron®
1 (0.47%)
0 (0.00%)
1 (0.57%)
Listed multiple antidepressants
4 (1.87%)
1 (2.70%)
3 (1.69%)
Objective 7: To determine physicians’ second and third-lines of treatment for newly diagnosed
children with major depressive disorder by: a) drug category, and b) specific antidepressant
prescribed.
In the event the first-line of treatment was not successful, pediatricians indicated they would
switch to a different antidepressant (48.00%), while another 26.00% indicated they would add
antidepressant treatment. The majority (53.85%) of child psychiatrists, reported switching to a
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different antidepressant, in the event the first-line of treatment was not successful. Many child
psychiatrists (39.86%) indicated they would add antidepressant treatment to the first-line of
treatment. The results for the second-line of treatment for children are listed in Table 4.19.
Table 4.19: Second-Line of Treatment for Children with Major Depressive Disorder
Type of Treatment
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Augment with Antidepressants
127 (37.80%)
13 (26.00%)
114 (39.86%)
Switch to a Different Antidepressant
178 (52.98%)
24 (48.00%)
154 (53.85%)
Augment with
11 (3.27%)
4 (8.00%)
7 (2.45%)
Counseling\Psychotherapy
Switch or Augment with
4 (1.19%)
1 (2.00%)
3 (1.04%)
Antidepressant
Other Treatment
16 (4.76%)
8 (16.00%)
8 (2.80%)
As was the case for the first-line of treatment, the majority of pediatricians (97.22%) and child
psychiatrists (85.43%) indicated they utilize SSRIs as the second-line of treatment for children with
major depressive disorder. The majority of pediatricians (Prozac® 36.85%, Zoloft® 28.95%) and
child psychiatrists (Prozac® 30.08%, Zoloft® 27.82%) reported either Prozac® or Zoloft® as their
principal choices of antidepressants for second-line of treatment. The antidepressant class and
specific antidepressant reported as second-line of treatment are listed in Table 4.20 and Table 4.21.
Table 4.20: Therapeutic Category of Antidepressant Used as Second-Line of Treatment for
Children
Drug Class
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Tricyclic Antidepressant (TCAs)
6 (2.07%)
1 (2.78%)
5 (1.97%)
Tetracyclic Antidepressants
2 (0.69%)
0 (0.00%)
2 (0.79%)
Selective Serotonin Reuptake Inhibitors
252 (86.90%)
35 (97.22%)
217 (85.43%)
(SSRIs)
Selective-Norepinephrine Reuptake
8 (2.76%)
0 (0.00%)
8 (3.15%)
Inhibtors (SNRIs)
Norepinephrine and Dopamine Reuptake
21 (7.24%)
0 (0.00%)
21 (8.27%)
Inhibitors (NDRIs)
Other Antidepressants
1 (0.34%)
0 (0.00%)
1 (0.39%)
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Table 4.21: Specific Antidepressant Used as Second-Line Treatment for Children
Antidepressant
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Prozac®
94 (30.92%)
14 (36.85%)
80 (30.08%)
Zoloft®
85 (27.96%)
11 (28.95%)
74 (27.82%)
Celexa®
29 (9.54%)
3 (7.89%)
26 (9.77%)
®
Lexapro
21 (6.91%)
3 (7.89%)
18 (6.77%)
Wellbutrin®
21 (6.91%)
0 (0.00%)
21 (7.90%)
®
Cymbalta
4 (1.31%)
0 (0.00%)
4 (1.50%)
®
Effexor
4 (1.31%)
0 (0.00%)
4 (1.50%)
Tofranil®
3 (0.99%)
0 (0.00%)
3 (1.13%)
Remeron
2 (0.66%)
0 (0.00%)
2 (0.75%)
Pamelor®
2 (0.66%)
0 (0.00%)
2 (0.75%)
®
Desyrel
1 (0.33%)
0 (0.00%)
1 (0.38%)
Elavil®
1 (0.33%)
1 (2.63%)
0 (0.00%)
®
Paxil
1 (0.33%)
1 (2.63%)
0 (0.00%)
Listed multiple
36 (11.84%)
5 (13.16%)
31 (11.65%)
antidepressants
In the event the second-line of treatment was not successful the majority (51.28%) of
pediatricians indicated they would try some “other” type of treatment for children with major
depressive disorder. In comparison, the majority of child psychiatrists (66.43%) reported they would
persist with antidepressant treatment by switching these children to another antidepressant treatment.
Table 4.22 shows the results for the third-line of treatment for children.
Table 4.22: Third-Line of Treatment for Children with Major Depressive Disorder
Type of Treatment
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Augment with Antidepressants
21 (6.58%)
1 (2.56%)
20 (7.15%)
Switch to a Different Antidepressant
191 (59.88%)
5 (12.82%)
186 (66.43%)
Augment with Counseling\Psychotherapy
24 (7.52%)
11 (28.21%)
13 (4.64%)
Switch or Augment with Antidepressant
4 (1.25%)
2 (5.13%)
2 (0.71%)
Switch or Other Treatment
3 (0.94%)
0 (0.00%)
3 (1.07%)
Other Treatment
76 (23.83%)
20 (51.28%)
56 (20.00%)
The majority of the pediatricians (95.00%), who indicated they would try some “other” type of
treatment for children, indicated they would refer these patients to psychiatry. The majority of the
child psychiatrists (71.44%) indicated they would try some other type of medication. The four
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medications reported to be utilized most often were antipsychotics, mood stabilizers,
anticonvulsants, or lithium. These “other treatment” choices are listed in Tables 4.23 and 4.24.
Table 4.23: Pediatricians’ “Other 3rd Line of Treatment” for Children
Type of Treatment
Pediatricians N (%)
Refer to Psychiatry
19 (95.00%)
Antipsychotic
1 (5.00%)
Table 4.24: Child Psychiatrists’ “Other 3rd Line Treatment” for Children
Type of Treatment
Child Psychiatrists N (%)
Antipsychotic
10 (17.86%)
Mood Stabilizer
10 (17.86%)
Anticonvulsants
5 (8.93%)
Lithium
5 (8.93%)
Combination of Antidepressants
3 (5.35%)
Antipsychotic or Anticonvulsant
2 (3.56%)
Thyroid
1 (1.79%)
Lithium or Thyroid
1 (1.79%)
Mood Stabilizer or Antipsychotic
1 (1.79%)
Lithium or Antipsychotic
1 (1.79%)
Thyroid or Antipsychotic
1 (1.79%)
Other: Re-evaluate environment,
16 (28.56%)
hospitalization, other counseling, etc
The third-line of treatment for children with major depressive disorder still included the use of an
SSRI antidepressant for the majority (52.94%) of the child psychiatrists. One-third, of the child
psychiatrists (33.16%) indicated they would utilize Norepinephrine and Dopamine Reuptake
Inhibitors (NDRIs) as their third-line of treatment in comparison a majority (55.56%) of
pediatricians indicated they would utilize an NDRI type antidepressant as their third-line of
treatment. In contrast, pediatricians (44.44%) indicated they utilize SSRIs in their third-line of
treatment. Findings for the therapeutic category associated with the third-line of treatment of
children with major depressive disorder are listed in Table 4.25.
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Table 4.25: Therapeutic Category of Antidepressant Used as Third-Line of Treatment for
Children
Drug Class
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Tricyclic Antidepressants (TCAs)
1 (0.51%)
0 (0.00%)
1 (0.53%)
Tetracyclic Antidepressants
2 (1.02%)
0 (0.00%)
2 (1.07%)
Selective Serotonin Reuptake Inhibitors
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(SSRIs)
(52.55%)
Selective-Norepinephrine Reuptake
22 (11.23%)
0 (0.00%)
22 (11.77%)
Inhibitors (SNRIs)
Norepinephrine and Dopamine Reuptake
67 (34.18%)
5 (55.56%)
62 (33.16%)
Inhibitors (NDRIs)
Other Antidepressants
1 (0.51%)
0 (0.00%)
1 (0.53%)
Results for the specific antidepressant associated with the third-line of treatment for children are
listed in Table 4.26. The majority of pediatricians indicated the use of either Wellbutrin® (55.56%)
or Zoloft® (33.33%) as their third-line of treatment for children with major depressive disorder.
Child psychiatrists’ choice of antidepressant for use as their third-line of treatment for children was
more varied than pediatricians’. Child psychiatrists indicated Wellbutrin® as their most frequently
(30.24%) utilized antidepressant for the third-line of treatment. As indicated above SSRIs were the
most frequently utilized class of antidepressants, however the specific type of SSRI medication
varied from Zoloft® 16.10%, Prozac® 11.22%, Celexa® 8.29%, Lexapro® 5.36%, and Paxil® 1.95%.
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Table 4.26: Specific Antidepressant Used as Third-Line Treatment for Children
Antidepressant
All Physicians
Pediatricians
Child
N (%)
N (%)
Psychiatrists
N (%)
Prozac®
24 (11.22%)
1 (11.11%)
23 (11.22%)
Zoloft®
36 (16.82%)
3 (33.33%)
33 (16.10%)
Celexa®
17 (7.94%)
0 (0.00%)
17 (8.29%)
®
Lexapro
11 (5.14%)
0 (0.00%)
11 (5.36%)
Wellbutrin®
67 (31.31%)
5 (55.56%)
62 (30.24%)
Cymbalta®
5 (2.33%)
0 (0.00%)
5 (2.44%)
®
Effexor
15 (7.01%)
0 (0.00%)
15 (7.32%)
Tofranil®
1 (0.47%)
0 (0.00%)
1 (0.49%)
®
Remeron
2 (0.93%)
0 (0.00%)
2 (0.98%)
Desyrel®
1 (0.47%)
0 (0.00%)
1 (0.49%)
®
Paxil
4 (1.87%)
0 (0.00%)
4 (1.95%)
Listed multiple antidepressants
31 (14.49%)
0 (0.00%)
31 (15.12%)
Objective 8: To determine the difference in first, second, and third-lines of antidepressant treatment
prescribed by physicians to newly diagnosed children with major depressive disorder by a) the
pharmacotherapy category and b) specific antidepressant prescribed.
Null Hypothesis 8.a: There is no difference in the pharmacotherapy category prescribed by
physicians (pediatricians versus child psychiatrists) for first, second, and third lines of
antidepressant treatment for newly diagnosed children with major depressive disorder.
Null Hypothesis 8.b: There is no difference in the specific antidepressant prescribed by physicians
(pediatricians versus child psychiatrists) for first, second, and third lines of treatment for newly
diagnosed children with major depressive disorder.
In order to determine whether there is an association between the first, second, and third lines of
antidepressant treatment and physician type several steps were needed in the statistical analysis. Chi
Square (χ2) tests were utilized to examined the association between two variables: physician type
(pediatrician versus child psychiatrist) and pharmacotherapy category or antidepressant (TCAs,
Tetracyclics, SSRIs, SNRIs, NDRIs, and Other Antidepressants). Separate χ2 tests examined the
association between the first-line of pharmacotherapy class and physician type, second-line of
pharmacotherapy class and physician type, and third-line of pharmacotherapy class and physician
type. Each of these three χ2 tests indicated no significance between the variables. Furthermore, over
20% of the cell counts for each of the tests were less than five. When this is the case the χ2 test is
103

probably not a valid statistical test. To manage small cell sizes cells can be collapsed or combined.
For this study, groups of antidepressant categories were collapsed or combined. Since the majority
of the scientific research has focused on utilizing SSRIs in treating children antidepressant
categories, were combined into SSRIs and Non-SSRIs. Therefore, the next set of analyses
determined whether there was a relationship between physician type (pediatrician versus child
psychiatrist) and SSRIs versus Non-SSRIs, for first, second, and third-lines of treatment. Even after
collapsing the antidepressant drugs into these two groups, χ2 tests still resulted in small expected
values. In this case, the Fisher’s exact test may be used to examine the associations between
physician type and antidepressant categories. The Fisher’s exact test may be utilized when a
researcher wants to make a comparison between two binomial variables and is especially useful for
small sample sizes because the assumption of normal approximation to the binomial distribution is
relaxed.
The association between physician type and antidepressant category prescribed for children is not
statistically significant at the p< 0.05 level. These results are listed in Table 4.27. Therefore, we fail
to reject the Null Hypothesis 8.a: There is no difference in the pharmacotherapy category
prescribed by physicians (pediatricians versus child psychiatrists) for first, second, and third lines of
antidepressant treatment for newly diagnosed children with major depressive disorder.
Table 4.27: Association Between Physician Type and Antidepressant Category
Association
Two-sided Probability
Children’s First-line of Antidepressant:
Physician Type * Antidepressant Type
0.6058
Children’s Second-line of Antidepressant:
Physician Type * Antidepressant Type

0.0616

Children’s Third-line of Antidepressant:
Physician Type * Antidepressant Type

0.7382
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For Objective 8, several steps were used to determined the association between the first, second,
and third lines of specific antidepressant treatment and physician type. First, three χ2 tests, one for
each line of treatment (first, second, and third-line) were conducted to examine the association
between two variables: physician type (pediatrician versus child psychiatrist) and specific
antidepressant prescribed. Results showed the specific type of antidepressant medication used by the
physicians varied across all three lines of treatment (first-line of treatment there were 11 different
antidepressants, for the second-line of treatment there were 29 different antidepressants, and for the
third-line there were 34 different antidepressants). Thus, it was necessary to collapse the
antidepressant categories into two groups. Since Prozac® is the only FDA approved antidepressant,
the researcher collapsed the specific antidepressants into, either a Prozac® or non- Prozac® group.
After the antidepressants were recoded into these groups, χ2 tests were utilized to determine the
association between physician type (pediatrician versus child psychiatrist) and specific
antidepressant (Prozac® versus non- Prozac®) for each line of treatment (first, second, and third).
Results of these analyses are below in Table 4.28.
Table 4.28: Association Between Physician Type and Prozac® versus Non-Prozac® Groups
Pediatrician
Child
Test Statistic
p-value
(N)
Psychiatrist
(N)
st
1 -Line of Antidepressant
Treatment:
Non-Prozac®
16
84
χ2=0.2468
0.6193
Prozac®
21
92
2nd-Line of Antidepressant
Treatment:
Non-Prozac®
24
186
χ2=0.7128
0.3985
Prozac®
14
80
3rd-Line of Antidepressant
Treatment:
Fisher’s
®
Non-Prozac
8
182
Exact Test
1.0000
Prozac®
1
23
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Based on the χ2 tests and the Fisher’s exact test it was concluded there is no statistically
significant association between physician type and the specific antidepressant (Prozac® versus NonProzac®) prescribed to children. On the basis of these tests the Null Hypothesis 8.b: There is no
difference in the specific antidepressant prescribed by physicians (pediatricians versus child
psychiatrists) for first, second, and third lines of treatment for newly diagnosed children with major
depressive disorder, is not rejected.
Objective 9: To predict which physician characteristics affect the treatment prescribed for children
with major depressive disorder.
Regression is a useful statistical tool to assess the possible association between an outcome
variable and one or more predictor variables. In this study, the association between the outcome
variable type of treatment prescribed for children and physician characteristics will be assessed. For
this analysis, the first line of treatment is the outcome or dependent variable. This line of treatment
may be categorized as treatment type (antidepressant treatment versus counseling). The outcome
variable is categorical in nature and necessitates a form of regression called logistic regression.
Logistic regression provides a method to model the dependency of a binary outcome variable on one
or more predictor or independent variables and was utilized to examine the association between firstline of treatment for major depressive disorder in children and physician characteristics. In this
study, the predictor or independent variables are physician characteristics such as: specialty of
physician, gender, age, physicians’ primary practice site, geographic location of practice, population
of community of physicians’ primary practice site, board certification, patient volume per week, and
the length of time the physician has treated the child and adolescent population. The logistic
regression equation predicts the probability an individual will be in one of the two levels of the
binary outcome. The logistic regression equation is as follows:
logit(p) = α + β1x1 +……….. + βk xk
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If x1,…….., xk are the independent variables of interest and y is a binomial outcome
variable with a probability of success = pi (Rosner, 2000).
Variable selection involves coming up with the best subset of independent variables for the
regression model. There are several variable selection methods which may be utilized including
forward, backward, and stepwise (Cody & Smith, 1997). Forward selection enters the most
significant, independent variable followed by the next most significant independent variable until a
specific criterion has been met. This criterion is usually based on statistical significance in the
model (Cody & Smith, 1997). Backward selection involves starting with all of the independent
variables in the model and then removing the least significant variable, then the next least significant
variable, and so on until the computer program finds the best subset of independent variables.
Stepwise selection begins like forward selection, however in stepwise selection variables may leave
the model as well as enter. After an independent variable is added to the regression model, the
model is tested for significance. If the addition of the variable still results in a significant model the
variable is retained, if not it is removed from the regression model. Stepwise selection provides an
effective method to screen a relatively large number of independent variables. This method is
especially useful if the outcome being studied is somewhat new and associations between the
outcome and independent variables are not understood (Hosmer & Lemeshow, 2000). The objective
in this study is to examine the relationship between physician treatment choices and physician
characteristics for a relatively large number of independent variables. Additionally, the relationships
between the outcome and independent variables have not been studied in the context of the treatment
of childhood or adolescent depression. Therefore, stepwise logistic regression will provide a means
to screen the various physician characteristics (independent variables) and examine whether or not
these associations exit.
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When utilizing stepwise logistic regression, the researcher selects the entry criterion or level of
statistical significance for which independent variables enter the model. Research has shown that
the choice of p = 0.05 is too stringent and often excludes important variables from the model
(Hosmer & Lemeshow, 2000). Hosmer & Lemeshow (2000) recommend choosing a p-value in
range of 0.15 – 0.20. A conservative approach was taken and the entry criterion was set at 0.15.
Stepwise methods were utilized to estimate the probability a physician would prescribe an
antidepressant versus prescribing counseling for children with major depressive disorder. The
explanatory variables utilized in this model were physician characteristics (physicians’ specialty,
gender, age, primary practice site, geographic location of physician, population of community of
physicians’ primary practice site, physicians’ board certification, patient volume per week, and the
length of time the physician has treated the child and adolescent population). Based on our prespecified criterion (p=0.15) four variables, type of physician, age of physician, geographic location
of primary practice site, and number of adolescents seen per week, were retained in the model.
Although, the four variables contribute significantly in statistical terms to the model there are
other considerations. Clinical considerations, biological considerations, and common sense are also
needed when deciding which variables to retain in a model (Hosmer & Lemeshow, 2000). It seems
unlikely that the number of adolescents a physician sees per week is associated with the type of
treatment the physician prescribes for a child. Therefore, this variable will be excluded from the
final model. It can be concluded from the logistic regression model that specialty of the physician,
age of physician, and southern, midwest, and pacific/west geographic locations of the primary
practice site are significantly associated with physicians prescribing antidepressants to children with
major depressive disorder. Variables were retained in the final model if the p-value was less than or
equal to 0.05 and the final regression model is as follows:

108

logit(p) = 0.3991 +(-0.9124 * Specialty of Physician) + (0.6197 * Age of Physician) + (0.9649 * Southern
Geographic Region) + (0.9911 * Midwest Geographic Region) + (0.8840 * Pacific/West Geographic Region)
Odds ratios were used to examine the magnitude of these associations and are listed in Table
4.29. After controlling for all other variables in the model, the odds in favor of a child psychiatrist
prescribing an antidepressant is only 0.402 times greater than pediatricians. The odds ratio of 1.85
indicates that the odds in favor of a physician prescribing an antidepressant medication is 1.85 times
greater for physicians who are more than 60 years of age, as compared to those who are less than 60
years of age. Finally, the odds in favor of physicians prescribing antidepressant medication for
physicians whose practice location is in the South, Midwest, or Pacific/West are 2.625, 2.694, and
2.421, respectively, times greater as compared to physicians located in the Northeast.
Next, the goodness of fit of the model was assessed. Assessing the goodness-of-fit of the model,
involves deciding whether the predicted values are an accurate representation of the observed values
(Hosmer & Lemeshow, 2000). In other words, the goodness-of-fit is a measure of how well the
model describes the dependent variable. The Hosmer-Lemeshow test is a goodness-of-fit test which
allows for any number of independent variables (Bewick, Cheek, & Ball, 2005). For this model, the
Hosmer-Lemeshow test is non-significant (p=0.8634). This indicates that the overall fit of the model
is good.

109

Table 4.29: Logistic Regression Analysis of Physicians’ Antidepressant Prescribing to
Children with Major Depressive Disorder
Variable
Intercept
Child Psychiatrist
Age of Physician
Greater than 60 years
Southern Geographic
Region
Midwest Geographic
Region
Pacific/West
Geographic Region

df

p-value

0.4537
0.4069
0.3230

Wald’s
χ2
0.7738
5.0280
3.6805

1
1
1

0.9649

0.3353

8.2788

0.9911

0.3496

0.8840

0.3697

Estimate
β
0.3991
-0.9124
0.6197

SE β

0.3790
0.0249*
0.0551*

Point
Estimate
NA
0.402
1.858

95% CI
NA
0.181 – 0.891
0.987 – 3.500

1

0.0040*

2.625

1.360 – 5.064

8.0375

1

0.0046*

2.694

1.358 – 5.346

5.7182

1

0.0168*

2.421

1.173 - 4.996

SE=Standard Error, df=degrees of freedom, CI=Confidence Interval, *Significance at p < 0.05

Multicollinearity occurs when there are strong linear dependencies among the independent
variables (Allison, 1999). Basically, the independent variables should not be highly correlated with
each other, as it is difficult to obtain good estimates of their association with the dependent variable.
Multicollinearity can be assessed by utilizing the diagnostics tolerance and variance inflation factor.
The tolerance can be computed by regressing each of the independent variables on all of the other
independent variables, calculating the R2 (the proportion of the variance of y that can be explained by
x) and subtracting from one (Rosner, 2000). The variance inflation factor (VIF) is the reciprocal of
the tolerance and tells how inflated the variance of the coefficient is compared to what it would be if
the variable were not correlated with other variables in the model (Allison, 1999). Tolerance ranges
between zero and one and VIF is one or greater, while tolerances below 0.40 may be an indication of
multicollinearity (Allison, 1999). Others have suggested that VIF values of less than 4.00 should be
considered acceptable (Allison, 1999). In conclusion, there is no strict rule for assessing
multicollinearity. In this model the tolerances ranged from 0.61166 to 0.98574 and VIF values
ranged from 1.01447 to 1.63488, and therefore multicollinearity is not an issue in this model.
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Objective 10: To determine the average length of antidepressant treatment for newly diagnosed
children with major depressive disorder.
Physicians were asked to indicate how long on average would they continue to prescribe an
antidepressant to a child, if the treatment was successful in terms of decreasing depressive
symptoms. The majority of the physicians, both pediatricians (51.35%) and child psychiatrists
(65.17%) indicated they would prescribe the antidepressant medication to the child for ten months or
longer. These frequencies are listed in Table 4.30.
Table 4.30: Frequencies of Average Length of Antidepressant Treatment for Children
Length of
All Physicians
Pediatricians
Child Psychiatrists
Antidepressant
N(%)
N(%)
N(%)
Treatment
3 (1.40)
1 (2.70)
2 (1.12)
1-3 months
34 (15.81)
10 (27.03)
24 (13.48)
4-6 months
43 (20.00)
7 (18.92)
36 (20.23)
7-9 months
84 (30.07)
8 (21.62)
76 (42.70)
10-12 months
51 (23.72)
11 (29.73)
40 (22.47)
Greater than 12
months
The American Academy of Child and Adolescent Psychiatry has recently recommended children
be treated for a minimum of six months (American Academy of Child and Adolescent Psychiatry,
2007). The categorical variable, length of treatment, was then transformed into a continuous
variable so comparisons could be made to the six month minimum. The categorical variable was
recoded by taking the average number of months the physician treats the children with an
antidepressant. The variable was re-coded as follows: 1-3 months was transformed into 2 months,
4-6 months was transformed into 5 months, 7-9 months was transformed into 8 months, 10-12
months was transformed into 11 months, and greater than 12 months was transformed into 12
months. The average length of time pediatricians and child psychiatrists prescribed antidepressant
treatment for children was then compared to the six month minimum length of time. It was found
that both pediatricians and child psychiatrists treated children significantly longer than the six month
minimum. These results are listed in Table 4.31.
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Table 4.31: Length of Antidepressant Treatment Compared to AACAP Recommendations
Physician
Length of
Minimum Length Test Statistic
Significance p
Type
Antidepressant of AACAP
Treatment
Recommendations
(Mean + SD)
(months)
8.865 + 3.102
6
t=5.618
0.000*
Pediatrician
9.708 + 2.485
6
t=19.909
0.000*
Child
Psychiatrist
*Significant at p<0.05, SD=Standard Deviation

Objective 11: To determine the types of pharmacotherapy monitoring in newly diagnosed children
with major depressive disorder.
Physicians were asked to indicate how they monitor antidepressants prescribed to children with
major depressive disorder. More specifically physicians were asked the mode of monitoring (e.g.,
how is the monitoring done), who conducts the monitoring, the type of monitoring they conduct, and
the frequency with which they monitor children. Physicians’ responses to the mode of monitoring,
who conducts the monitoring, and the type of monitoring conducted are listed in Table 4.32, Table
4.33, and Table 4.34, respectively. The majority of pediatricians (89.58%) and child psychiatrists
(96.04%) indicated they conduct monitoring by an individual office visit with the child. Both
pediatricians (95.83%) and child psychiatrists (96.04%) reported, almost exclusively, they would
conduct the monitoring themselves. The majority of pediatricians and child psychiatrists monitor for
adverse events, suicidality, and clinical symptoms. Some pediatricians (29.79%) and child
psychiatrists (72.95%) also require the patient to get some type of labwork. Some pediatricians
(4.26%) and child psychiatrists (24.91%) indicated they conduct some other type of monitoring for
children. Other types of monitoring physicians listed included monitoring ongoing psychotherapy
progress, monitoring school, social, family, or interpersonal functioning, and monitoring depressive
symptoms through the use of scales (ex. Beck’s Depression Inventory).
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Table 4.32: Mode of Antidepressant Monitoring for Children
Mode of
All Physicians
Pediatricians
Monitoring
N (%)
N (%)
Individual Office
310 (95.09)
43 (89.58)
Visit
Telephone
7 (2.15)
3 (6.25)
Other
9(2.76)
2 (4.17)

Child Psychiatrists
N(%)
267 (96.04)
4 (1.44)
7 (2.52)

Table 4.33: Healthcare Provider Conducting Antidepressant Monitoring for Children
Healthcare Provider
All Physicians
Pediatricians
Child Psychiatrists
N (%)
N (%)
N (%)
Physician
313 (95.09)
46 (95.83)
267 (96.04)
Nurse/Nurse Practitioner
4 (1.23)
0 ( 0.00)
4 (1.44)
Counselor/Psychotherapist
4 (1.23)
2 (4.17)
2 (0.72)
Other
5 (1.53)
0 (0.00)
5 (1.80)
Table 4.34: Type of Antidepressant Monitoring for Children
Type of
All Physicians
Pediatricians
Monitoring
(N=328)
(N=47)
Adverse Events
326 (99.39)
47 (100.00)
Suicidality
323 (98.48)
45 (95.74)
Conduct Labwork
219 (66.77)
14 (29.79)
Clinical Symptoms
324 (98.78)
47 (100.00)
Other
72 (21.95)
2 (4.26)

Child Psychiatrists
(N=281)
279 (98.93)
278 (98.93)
205 (72.95)
277 (98.58)
70 (24.91)

Physicians were asked to indicate how frequently they monitor children treated with
antidepressants during the first three months of treatment. During the first month of treatment the
majority of pediatricians (54.35%) indicated they monitor children every two weeks, with another
39.13% of pediatricians monitoring once a week. The majority of child psychiatrists reported
monitoring children either once a week (41.43%) or every two weeks (30.71%) during the first
month of antidepressant treatment. Results for the frequency of antidepressant monitoring during
the first month of treatment are shown in Table 4.35.
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Table 4.35: Frequency of Antidepressant Monitoring: Month One
All Physicians
Pediatricians
Child Psychiatrists
(N)
(N)
(N)
Frequency of Monitoring:
Two Times per Week
3 (0.92%)
0 (0.00%)
3 (1.07%)
Once a Week
134 (41.11%)
18 (39.13%)
116 (41.43%)
Every Two Weeks
111 (34.05%)
25 (54.35%)
86 (30.71%)
Every Three Weeks
12 (3.68%)
0 (0.00%)
12 (4.29%)
Once a Month
36 (11.04%)
2 (4.35%)
34 (12.14%)
Greater than Once a Month
0 (0.00%)
0 (0.00%)
0 (0.00%)
Other
30 (9.20%)
1 (2.17%)
29 (10.36%)
Physicians were asked to indicate how frequently they monitor children treated with
antidepressants during the second month of treatment. During this time period the majority of
pediatricians (65.23%) reported monitoring children once a month compared to 42.65% of the child
psychiatrists. Another 21.74% of the pediatricians indicated they monitor children every two weeks,
while 34.06% of the child psychiatrists monitor children every two weeks. Table 4.36 shows the
results for the frequency of monitoring during the second month of treatment.
Table 4.36: Frequency of Antidepressant Monitoring: Month Two
All Physicians
Pediatricians
Child Psychiatrists
(N)
(N)
(N)
Frequency of Monitoring:
Two Times per Week
3 (0.92%)
1 (2.17%)
2 (0.72%)
Once a Week
14 (4.31%)
0 (0.00%)
14 (5.02%)
Every Two Weeks
105 (32.31%)
10 (21.74%)
95 (34.05%)
Every Three Weeks
27 (8.31%)
1 (2.17%)
26 (9.32%)
Once a Month
149 (45.84%)
30 (65.23%)
119 (42.65%)
Greater than Once a Month
13 (4.00%)
3 (6.52%)
10 (3.58%)
Other
14 (4.31%)
1 (2.17%)
13 (4.66%)
During month three, the majority of pediatricians (52.18%) reported monitoring children on
antidepressants at some time interval greater than one month, while another 39.13% indicated they
monitor children once a month. The majority of child psychiatrists (62.72%) monitor children
taking an antidepressant once a month with another 20.43% indicating they monitor children at some
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interval greater than once a month. Results for the frequency of monitoring children during the third
month of antidepressant treatment are listed in Table 4.37.
Table 4.37: Frequency of Antidepressant Monitoring: Month Three
All Physicians
Pediatricians
Child Psychiatrists
(N)
(N)
(N)
Frequency of Monitoring:
Two Times per Week
2 (0.62%)
0 (0.00%)
2 (0.72%)
Once a Week
7 (2.15%)
0 (0.00%)
7 (2.51%)
Every Two Weeks
12 (3.69%)
1 (2.17%)
11 (3.94%)
Every Three Weeks
15 (4.62%)
2 (4.35%)
13 (4.66%)
Once a Month
193 (59.38%)
18 (39.13%)
175 (62.72%)
Greater than Once a Month
81 (24.92%)
24 (52.18%)
57 (20.43%)
Other
15 (4.62%)
1 (2.17%)
14 (5.02%)
Objective 12: To determine differences in antidepressant monitoring for newly diagnosed children
with major depressive disorder and the United States Food and Drug Administration (U.S. FDA)
recommendations for monitoring children treated with antidepressants.
Null Hypothesis 12.0: There is no difference in pharmacotherapy monitoring for newly diagnosed
children with major depressive disorder and the U.S. FDA recommendations for monitoring children
treated with antidepressants.
The frequencies associated with physician monitoring of children treated with antidepressant
medication was provided in Objective #11. This information was gained from the Phase II survey as
physicians were asked to indicate how often they monitored children on antidepressant therapy
during the first, second, and third-months of treatment. Physicians could answer this question as
follows: “two times per week”, “once a week”, “every two weeks’, “every three weeks”, “once a
month”, greater than once a month”, or “other”. These variables are categorical in nature. So that
comparisons could be made to the U.S. FDA recommendations, these categorical variables needed to
be transformed into continuous variables. Therefore, to compute an average number of times per
month, the physicians’ answers were transformed into a number corresponding to the number of
times per month physicians monitored children. This was done as follows: “two times per week”
was transformed into eight times per month, “once a week” was transformed into four times a
month, “every two weeks” was transformed into two times per month, “every three weeks” was
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transformed into 1.4 times per month, “once a month” was transformed into 1 time per month, and
“greater than once a month” was transformed into .5 times per month. In this case the “other”
category was eliminated from the analysis. Frequencies of the transformed variables are provided
below in Tables 4.38, 4.39, and 4.40.
Table 4.38: Recoded Frequency of Antidepressant Monitoring: Month One
Frequency of Monitoring
All Physicians
Pediatricians
Child Psychiatrists
(Number of Times per
(N)
(N)
(N)
Month) :
0
0
0
0.5
36
2
34
1
12
0
12
1.4
111
25
86
2
134
18
116
4
3
0
3
8
Table 4.39: Recoded Frequency of Antidepressant Monitoring: Month Two
Frequency of Monitoring
All Physicians
Pediatricians
Child Psychiatrists
(Number of Times per
(N)
(N)
(N)
Month):
13
3
10
0.5
149
30
119
1
27
1
26
1.4
105
10
95
2
14
0
14
4
3
1
2
8
Table 4.40: Recoded Frequency of Antidepressant Monitoring: Month Three
Frequency of Monitoring
All Physicians
Pediatricians
Child Psychiatrists
(Number of Times per
(N)
(N)
(N)
Month):
81
24
57
0.5
193
18
175
1
15
2
13
1.4
12
1
11
2
7
0
7
4
2
0
2
8
The U.S. FDA made recommendations that a child receiving antidepressant treatment should be
seen by a physician once per week for the first four weeks of treatment (U.S. FD, 2005). During the
second month of treatment the patient should be seen biweekly and at week 12 during the third
month (U.S. FDA, 2005). Comparisons were made between the U.S.FDA recommendations and the
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number of times per month the physicians reported monitoring children, during the first three
months of antidepressant treatment. Pediatricians (t=-7.967, p=0.000) and child psychiatrists (t=14.004, p=0.000) monitor significantly less than the U.S. FDA recommended four times, during the
first month of treatment. During the second month of treatment again, both pediatricians (t=-3.905,
p=0.000) and child psychiatrists (t=-7.156, p=0.000) monitor significantly less than the U.S. FDA
recommended two times per month. The findings show that pediatricians (t=-4.507, p=0.000) still
monitor significantly less than the U.S. FDA recommendations, during the third month of treatment.
However, child psychiatrists’ (t=1.660, p=0.098) monitoring does not differ significantly from the
U.S. FDA recommendations of one time during month three. These comparisons are listed in Table
4.41.
Table 4.41: Comparisons of Physician Monitoring to U. S. FDA Recommendations
Mean + SD
Test Statistic
Significance (p)
Month One:
All Physicians
2.820 + 1.282
t=-15.827
0.000*
Pediatricians
2.756 + 1.048
t=-7.967
0.000*
Child Psychiatrists
2.832 + 1.322
t=-14.004
0.000*
Month Two:
All Physicians
1.554 + 0.967
t=-8.130
0.000*
Pediatricians
1.272 + 1.111
t=-3.905
0.000*
Child Psychiatrists
1.588 + 0.939
t=-7.156
0.000*
Month Three:
All Physicians
1.040 + 0.795
t=0.893
0.372
Pediatricians
0.773 + 0.337
t=-4.507
0.000*
Child Psychiatrists
1.086 + 0.840
t=1.660
0.098

*Significant at p<0.05, SD=Standard Deviation , U.S. FDA= United States Food and Drug Administration

Objective 13: To determine whether there are differences, by physician type, in the average number
of times per month physicians monitor children with major depressive disorder.
Null Hypothesis 13.0: There is no difference, by physician type, in the average number of times per
month physicians monitor children with major depressive disorder.
The hypothesis that there is no difference by physician type (pediatricians versus child
psychiatrists) in the average number of times per month physicians monitor children was tested. The
survey for Phase II asked physicians to indicate how often they monitored children on antidepressant
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therapy during the first, second, and third-months of treatment. Physicians could answer this
question as follows: “two times per week”, “once a week”, “every two weeks’, “every three weeks”,
“once a month”, greater than once a month”, or “other”. To compute an average number of times
per month that physicians monitor children on antidepressant therapy, the categorical variables
above, were converted to the number of times per month physicians monitored children. This was
accomplished by transforming the variables as follows: “two times per week” was transformed into
eight times per month, “once a week” was transformed into four times a month, “every two weeks”
was transformed into two times per month, “every three weeks” was transformed into 1.4 times per
month, “once a month” was transformed into 1 time per month, and “greater than once a month” was
transformed into .5 times per month. After recoding, the average number of times per month that
physicians monitor children, were computed for each group of physicians. The results are provided
above in Tables 4.38. 4.39, and 4.40.
Next, comparisons for months one, two, and three, of the average number of times per month
pediatricians monitor children could be made with the average number of times child psychiatrists
monitor children. The Levene’s test for equality of variances was first conducted on each of the
comparisons. If the Levene’s test for equality was significant then equal variances could not be
assumed. If the Levene’s test for equality was not significant then equal variances were assumed.
Next, the appropriate two sample t-test, either for the assumption of equal variances or unequal
variances was conducted. The results are listed below in Table 4.42.
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Table 4.42: Comparison of Pediatricians and Child Psychiatrists Monitoring of Children
Mean + SD
Test Statistic
p-value
Month One:
t = -0.431
0.668
2.76 + 1.05
Pediatricians
2.83
+
1.32
Child Psychiatrists
Month Two:
Pediatricians
Child Psychiatrists
Month Three:
Pediatricians
Child Psychiatrists

1.35 + 1.11
1.59 + 0.94

t = -1.508

0.133

0.77 + 0.34
1.09 + 0.84

t = -2.457

0.015*

* Significant at p< 0.05

The average number of times physicians (pediatricians versus child psychiatrists) monitored
children did not significantly differ during the first (p=0.668) and second months (p=0.133) of
antidepressant treatment. However, during the third month of treatment there was a significant
difference in the average number of times, pediatricians versus child psychiatrists, monitored
children on antidepressant therapy. Child psychiatrists monitored significantly (p=0.015) more than
pediatricians during the third month of treatment. Therefore, Null Hypothesis 13.0: There is no
difference, by physician type, in the average number of times per month physicians monitor children
with major depressive disorder, will fail to be rejected for months one and two, and will be rejected
for month three of treatment.

Phase II: Results for Adolescents with Major Depressive Disorder- Objectives 14-22
Objectives 14 through 22 are identical to Objectives 1 through 13 for children with major
depressive disorder except the population studied were adolescents (13 through 18 years of age) with
major depressive disorder.
Objective 14: To determine the demographic characteristics of physicians who treat newly
diagnosed adolescents with major depressive disorder.
Of those physicians from phase II who indicated they treat adolescents with major depressive
disorder 57 (16.06%) were pediatricians and 298 (83.94%) were child psychiatrists. The majority of
physicians who treat adolescents with major depressive disorder are males (61.25%). Additionally,
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the majority (66.10%) of the respondents who treat adolescents indicated they are between 41 and 60
years of age. The year of graduation from medical school varied: 33.03% indicated they graduated
in 1986 -1995, 27.83% indicated they graduated in 1976 – 1985, 20.18% indicated they graduated in
1966 – 1975, 11.93% indicated they graduated in 1996 – 2003, and only 7.03% graduated in 1965 or
earlier. Approximately sixty percent, (57.55%) of the physicians indicated their primary practice site
was private-based, as opposed to hospital-based. The geographic region of the physicians’ primary
practice site varied: 29.29% practice in the South, 26.63% practice in the Midwest, 23.08% practice
in the Northeast, 20.41% practice in the West, and only 0.59% practice in the Pacific. The
population of the primary practice area varied as 34.40% have primary practice sites in areas with
50,000 – 249,999 people, 25.36% practice in areas with a population of 1 million or more people,
24.78% practice in areas with 250,000 – 999,999 people, and 15.45% practice in areas with 50,000
people or less. The majority (70.74%) of the physicians indicated specialties of both adult and child
psychiatry, and the majority (54.89%) are board certified as both adult psychiatrists and child
psychiatrists. The practice volume also varied somewhat, however the majority of physicians
indicated they treat both, 10 or less children (72.01%) and 10 or less adolescents (56.85%) per week.
Approximately three-fourths, (75.57%) of physicians, indicated they have treated adolescents for
greater than 10 years. The demographics of physicians who treat adolescents with major depressive
disorder are shown below in Table 4.43.
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Table 4.43: Demographics of Physicians Who Treat Adolescents for Major Depressive
Disorder
Variable
Type of Physician:
Pediatricians
Child Psychiatrists
Gender:
Male
Female
Age:
40 years or younger
41 years – 60 years
61 years or older
Year Graduated from Medical School:
1965 or Before
1966 – 1975
1976 - 1985
1986 - 1995
1996 – 2003
Primary Practice Site:
Private Based Practice
Hospital Based Practice
Other (ex. hospital and private)
Geographic Location of Practice:
Northeast
South
Midwest
West
Pacific
Population of Practice Area:
Less than 50,000
50,000 – 249,999
250,000 – 999,999
1 million or more
Physician Specialty:
Child Psychiatrist
Pediatrics
Adult and Child Psychiatrist
Other (ex. adult and child psychiatry and general practice)
Board Certification:
Adult Psychiatrist
Child Psychiatrist
General Practitioner
Pediatrician
Adult and Child Psychiatrist
Other (ex. adult and child psychiatry and pediatrics)
Not Board Certified
Child Patient Volume Per Week:
10 or less
11 – 40
41 – 80
81 or greater
Adolescent Patient Volume Per Week:
10 or less
11 – 40
41 – 80
81 greater
Number of Years Treating Children and/or Adolescents:
Greater than 1 to 5 years
Greater than 5 to 10 years
Greater than 10 years

N (%)
57 (16.06%)
298 (83.94%)
215 (61.25%)
136 (38.75%)
45 (12.82%)
232 (66.10%)
74 (21.08%)
23 (7.03%)
66 (20.18%)
91 (27.83%)
108 (33.03%)
39 (11.93%)
202 (57.55%)
67 (19.09%)
82 (23.36%)
78 (23.08%)
99 (29.29%)
90 (26.63%)
69 (20.41%)
2 (0.59%)
53 (15.45%)
118 (34.40%)
85 (24.78%)
87(25.35%)
36 (10.23%)
52 (14.77%)
249 (70.74%)
15 (4.26%)
59 (16.95%)
1 (0.29%)
1 (0.29%)
56 (16.09%)
191(54.89%)
18 (5.17%)
22 (6.32%)
247(72.01%)
79 (23.03%)
14 (4.08%)
3 (0.87%)
195 (56.85%)
126 (36.73%)
16 (4.66%)
6 (1.75%)
25 (7.18%)
60(17.24%)
263(75.57%)
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Objective 15: To determine physicians’ first line of treatment for newly diagnosed adolescents with
major depressive disorder by: a) type of treatment, b) drug category, and c) specific antidepressant
prescribed.
A majority of physicians, both pediatricians (87.72%) and child psychiatrists (76.95%) indicated
their preferred first-line of treatment for adolescents with major depressive disorder is a combination
treatment of antidepressants and counseling. Counseling only was the next most frequently
preferred choice as a first-line of treatment of both pediatricians (8.77%) and child psychiatrists
(15.93%). Few pediatricians (3.51%) and child psychiatrists (0.68%) indicated they use
antidepressants only as a first-line of treatment for adolescents. These results are shown in Table
4.44.
Table 4.44: First-Line of Treatment for Adolescents with Major Depressive Disorder
Type of Treatment
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Antidepressants Only
4 (1.14%)
2 (3.51%)
2 (0.68%)
Counseling/Psychotherapy Only
52 (14.77%)
5 (8.77%)
47 (15.93%)
Both Antidepressants and Counseling
277
50 (87.72%)
227
(78.69%)
(76.95%)
Other Treatment
19 (5.40%)
0 (0.00%)
19 (6.44%)
In the event the physicians utilized antidepressants as a first-line of treatment, all pediatricians
(100.00%) indicated their first-line of treatment would include an SSRI type antidepressant. Over
ninety percent (94.67%) of the child psychiatrists also indicated they would utilize an SSRI type
antidepressant. The results per antidepressant class, associated with the first-line treatment, for
adolescents are displayed in Table 4.45.
The specific type of antidepressant varied somewhat for both pediatricians and child psychiatrists.
Similar to the findings in the child population, the majority of pediatricians and child psychiatrists
indicated they would utilize either Prozac® or Zoloft® in their first-line of treatment for adolescents
with major depressive disorder. For first-line treatment, 44.23% of pediatricians indicated they
would utilize Prozac® and 50.21% indicated they would utilize Zoloft®. For first-line treatment
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38.46% of the child psychiatrists indicated they would utilize Prozac® and 19.84% indicated they
would utilize Zoloft® as part of their first-line of treatment for adolescents with major depressive
disorder. The specific antidepressants utilized by physicians as a first-line of treatment for
adolescents can be found in Table 4.46.
Table 4.45: Therapeutic Category of Antidepressant Used as First-Line of Treatment for
Adolescents
Drug Class
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Tricyclic Antidepressants (TCAs)
1 (0.34%)
0 (0.00%)
1 (0.41%)
Tetracyclic Antidepressants
1 (0.34%)
0 (0.00%)
1 (0.41%)
Selective Serotonin Reuptake Inhibitors 281 (95.58%) 50 (100.00%) 231 (94.67%)
(SSRIs)
Selective-norepinephrine Reuptake
1 (0.34%)
0 (0.00%)
1 (0.41%)
Inhibitors (SNRIs)
Norepinephrine and Dopamine
10 (3.40%)
0 (0.00%)
10 (4.10%)
Reuptake Inhibitors (NDRIs)
Table 4.46: Specific Antidepressant Used as First-Line of Treatment for Adolescents
Antidepressant
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
®
Prozac
147 (49.16%)
23 (44.23%)
124 (50.21%)
Zoloft®
69 (23.08%)
20 (38.46%)
49 (19.84%)
®
Celexa
31 (10.37%)
5 (9.61%)
26 (10.53%)
®
Lexapro
33 (11.04%)
2 (3.85%)
31 (12.55%)
Wellbutrin®
10 (3.35%)
0 (0.00%)
10 (4.05%)
®
Tofranil
1 (0.33%)
0 (0.00%)
1 (0.40%)
Cymbalta®
1 (0.33%)
0 (0.00%)
1 (0.40%)
®
Remeron
1 (0.33%)
0 (0.00%)
1 (0.40%)
Listed multiple
6 (2.01%)
2 (3.85%)
4 (1.62%)
antidepressants
Objective 16: To determine physicians’ second and third lines of treatment for newly diagnosed
adolescents with major depressive disorder by: a) drug category, and b) specific antidepressant
prescribed.
In the event the first-line of treatment is not successful, the majority of pediatricians, 68.43%,
indicated they would switch an adolescent patient to a different antidepressant. Also, approximately
seventy percent (72.73%) of child psychiatrists reported switching an adolescent patient to a
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different antidepressant. The results for physicians’ second-line of treatment for adolescents are
shown in Table 4.47.
Table 4.47: Second-Line of Treatment for Adolescents with Major Depressive Disorder
Type of Treatment
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Augment with Antidepressants
63 (17.80%)
5 (8.77%)
58 (19.53%)
Switch to a Different Antidepressant
255
39 (68.43%)
216
(72.03%)
(72.73%)
Augment with Counseling\Psychotherapy
15 (4.24%)
7 (12.28%)
8 (2.69%)
Switch or Augment with Antidepressant
4 (1.13%)
1 (1.75%)
3 (1.01%)
Other Treatment
17 (4.80%)
5 (8.77%)
12 (4.04%)
As was the case for the first-line of treatment, the majority of pediatricians (86.37%) and child
psychiatrists (74.00%) indicated they utilize SSRIs a part of the second-line of treatment for
adolescents with major depressive disorder. The SSRIs most often utilized as part of the second-line
of treatment by pediatricians are Prozac® (30.43%), Zoloft® (19.57%), and Celexa® (15.22%).
Whereas, the SSRIs most often utilized as part of the second-line of treatment by child psychiatrists
are Prozac® (18.73%), Zoloft® (23.97%), and Celexa® (8.99%). The antidepressant drug categories
and specific antidepressants utilized by physicians as part of their second-line of treatment for
adolescents with major depressive disorder are listed in Tables 4.48 and 4.49.
Table 4.48: Therapeutic Category of Antidepressant used as Second-Line of Treatment for
Adolescents
Drug Class
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Tricyclic Antidepressants
2 (0.68%)
0 (0.00%)
2 (0.80%)
(TCAs)
Tetracyclic Antidepressants
1 (0.34%)
0 (0.00%)
1 (0.40%)
Selective Serotonin Reuptake
223 (75.85%)
38 (86.37%)
185 (74.00%)
Inhibitors (SSRIs)
Selective-norepinephrine
27 (9.18%)
1 (2.27%)
26 (10.40%)
Reuptake Inhibitors (SNRIs)
Norepinephrine and
41 (13.95%)
5 (11.36%)
36 (14.40%)
Dopamine Reuptake
Inhibitors (NDRIs)
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Table 4.49: Specific Antidepressant Used as Second-Line of Treatment for Adolescents
Antidepressant
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Prozac®
64 (20.45%)
14 (30.43%)
50 (18.73%)
Zoloft®
73 (23.32%)
9 (19.57%)
64 (23.97%)
Celexa®
31 (9.90%)
7 (15.22%)
24 (8.99%)
®
Lexapro
28 (8.95%)
4 (8.70%)
24 (8.99%)
Wellbutrin®
41 (13.10%)
5 (10.87%)
36 (13.48%)
Cymbalta®
13 (4.15%)
0 (0.00%)
13 (4.87%)
®
Effexor
13 (4.15%)
1 (2.17%)
12 (4.50%)
Remeron®
1 (0.32%)
0 (0.00%)
1 (0.37%)
®
Pamelor
2 (0.64%)
0 (0.00%)
2 (0.75%)
Paxil®
3 (0.96%)
2 (4.34%)
1 (0.37%)
Listed multiple
44 (14.06%)
4 (8.70%)
40 (14.98%)
antidepressants
In the event the second-line of treatment for major depressive disorder in adolescents is not
successful, pediatricians (52.00%) indicated using some “other’ type of treatment for adolescents. In
contrast, the majority (66.43%) of child psychiatrists indicated they would switch another type of
antidepressant and 20.00% of the child psychiatrists reported they would try some “other” type of
treatment. Table 4.50 shows the results for physicians’ third-line of treatment for adolescents with
major depressive disorder.
Table 4.50: Third-Line of Treatment for Adolescents with Major Depressive Disorder
Type of Treatment
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
Augment with Antidepressants
28 (8.26%)
1 (2.00%)
27 (9.34%)
Switch to a Different Antidepressant
172
8 (16.00%)
164
(50.74%)
(56.75%)
Augment with Counseling\Psychotherapy
32 (9.44%)
11 (22.00%)
21 (7.27%)
Switch or Augment with Antidepressant
5 (1.47%)
2 (4.00%)
3 (1.04%)
Switch or Refer Patient
2 (0.59%)
2 (4.00%)
0 (0.00%)
Switch or Other Treatment
4 (1.18%)
0 (0.00%)
4 (1.38%)
Other Treatment
96 (28.32%) 26 (52.00%) 70 (24.22%)
The majority of the pediatricians (96.15%), who indicated they would use some “other” treatment
as the third-line for adolescents, specified they would refer these patients to psychiatry. In
comparison, the majority of the child psychiatrists (84.29%) who indicated they would utilize some
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“other” treatment reported the use of some other type of medication. These child psychiatrists
indicated they would use antipsychotics, mood stabilizers, anticonvulsants, thyroid medications, or a
combination of these medications. The results for the “other” treatment may be found in Tables 4.51
and 4.52.
Table 4.51: Pediatricians’ “Other 3rd Line of Treatment” for Adolescents
Type of Treatment
Pediatricians N (%)
Refer to Psychiatry
25 (96.15%)
Antipsychotic
1 (3.85%)
Table 4.52: Child Psychiatrists’ “Other 3rd Line Treatment” for Adolescents
Type of Treatment
Child Psychiatrists N (%)
Antipsychotic
14 (20.00%)
Mood Stabilizer
13 (18.57%)
Anticonvulsant
10 (14.29%)
Lithium
11 (15.71%)
Combination of Antidepressants
5 (7.14%)
Lithium or Thyroid
2 (2.86%)
Antipsychotic or Anticonvulsant
1 (1.43%)
Mood Stabilizer or Antipsychotic
1 (1.43%)
Thyroid or Anticonvulsant
1 (1.43%)
Benzodiazepine
1 (1.43%)
Other: Re-evaluate environment,
11 (15.71%)
hospitalization, other counseling, etc
Of those reporting, the third-line of treatment for adolescents included the use of either an SSRI
or NDRI for the majority of pediatricians and child psychiatrists. Pediatricians utilized either SSRIs
(46.15%) or NDRIs (38.46%). In contrast, child psychiatrists reported using NDRIs (41.81%) more
often than SSRIs (33.33%). Results for physicians’ third-line of treatment for adolescents with
major depressive disorder by drug category can found in Table 4.54.
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Table 4.53: Therapeutic Category of Antidepressant Used as Third-Line of Treatment for
Adolescents
Drug Class
All
Pediatricians
Child
Physicians N
N (%)
Psychiatrists
(%)
N (%)
Tricyclic Antidepressants
1 (0.53%)
0 (0.00%)
1 (0.56%)
(TCAs)
Tetracyclic Antidepressants
1 (0.53%)
0 (0.00%)
1 (0.56%)
Selective Serotonin Reuptake
65 (34.21%)
6 (46.15%)
59 (33.33%)
Inhibitors (SSRIs)
Selective-norepinephrine
43 (22.63%)
2 (15.39%)
41 (23.16%)
Reuptake Inhibitors (SNRIs)
Norepinephrine and
79 (41.57%)
5 (38.46%)
74 (41.81%)
Dopamine Reuptake
Inhibitors (NDRIs)
Other Antidepressants
1 (0.53%)
0 (0.00%)
1 (0.56%)
Of those reporting, approximately one-third of pediatricians (31.25%) and child psychiatrists
(37.76%) indicated they would utilize Wellbutrin®, as part of their third-line treatment for
adolescents. Although many physicians indicated the use of SSRIs the choice of the specific SSRI
was varied. The most preferred antidepressant for third-line treatment by both pediatricians
(18.75%) and child psychiatrists (37.76%) is Lexapro®. The next most preferred antidepressant by
child psychiatrists (10.20%) was Zoloft®. All other antidepressants were preferred by less than ten
percent of both pediatricians and child psychiatrists. The results of the physicians’ choice of
antidepressant for the third-line of treatment for adolescents with major depressive disorder are listed
in Table 4.54.
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Table 4.54: Specific Antidepressant Used as Third-Line Treatment for Adolescents
Antidepressant
All
Pediatricians
Child
Physicians
N (%)
Psychiatrists
N (%)
N (%)
®
Prozac
8 (3.77%)
1 (6.25%)
7 (3.57%)
Zoloft®
21 (9.91%)
1 (6.25%)
20 (10.20%)
Celexa®
11 (5.19%)
0 (0.00%)
11 (5.61%)
Lexapro®
11 (5.19%)
3 (18.75%)
8 (4.08%)
®
Wellbutrin
79 (37.26%)
5 (31.25%)
74 (37.76%)
Cymbalta®
10 (4.72%)
0 (0.00%)
10 (5.10%)
®
Effexor
29 (13.68%)
2 (12.50%)
27 (13.78%)
®
Tofranil
1 (0.47%)
0 (0.00%)
1 (0.51%)
Remeron®
1 (0.47%)
0 (0.00%)
1 (0.51%)
®
Desyrel
1 (0.47%)
0 (0.00%)
1 (0.51%)
Paxil®
5 (2.36%)
1 (6.25%)
4 (2.04%)
®
Luvox
1 (0.47%)
0 (0.00%)
1 (0.51%)
Listed multiple
34 (16.04%)
3 (18.75%)
31 (15.82%)
antidepressants
Objective 17: To determine the difference in first, second, and third lines of antidepressant treatment
prescribed by physicians to newly diagnosed adolescents with major depressive disorder by a) the
pharmacotherapy category and b) specific antidepressant prescribed.
Null Hypothesis 17.a: There is no difference in the pharmacotherapy category prescribed by
physicians for first, second, and third lines of antidepressant treatment for newly diagnosed
adolescents with major depressive disorder.
Null Hypothesis 17.b: There is no difference in the specific antidepressant prescribed by physicians
for first, second, and third lines of treatment for newly diagnosed adolescents with major depressive
disorder.
In order to determine whether there is an association between the first, second, and third lines of
antidepressant treatment and physician type several steps were required for the statistical analysis.
First, a series of χ2 tests, examined the association between two sets of variables: physician type
(pediatrician versus child psychiatrist) and pharmacotherapy category (TCAs, Tetracyclics, SSRIs,
SNRIs, NDRIs, and Other Antidepressants). Separate χ2 tests examined the association between the
first-line of pharmacotherapy class and physician type, second-line of pharmacotherapy class and
physician type, and third-line of pharmacotherapy class and physician type. Each of these three χ2
tests indicated no significance between the variables. Furthermore, over 20% of the cell counts for
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each of the tests were less than five. When this is the case the χ2 test is probably not a valid
statistical test. Researchers can manage small expected values by collapsing or combining cells. In
this study, groups of antidepressant categories were collapsed or combined. Since the majority of
the scientific research has focused on utilizing SSRIs in treating adoelscents, it was decided to
combine antidepressant categories into SSRIs and Non-SSRIs. After recoding the data into these
two groups, χ2 tests were run to determine whether there was a relationship between physician type
(pediatrician versus child psychiatrist) and the new antidepressant categories (SSRIs versus NonSSRIs) for first, second, and third-lines of treatment. Even after collapsing the antidepressant drugs
by drug category the χ2 tests still resulted in small expected values. If this occurs, however, another
statistic may be used to examine the associations between physician type and antidepressant
categories. This statistic is the Fisher’s exact test. The Fisher’s exact test may be utilized when a
researcher wants to make a comparison between two binomial variables. This test is especially
useful when small sample sizes because the assumption of normal approximation to the binomial
distribution is relaxed.
Table 4.55 shows no statistically significant (p=0.871 to p=0.3733) association between physician
type and the antidepressant category prescribed for first, second, or third-lines of treatment for
adolescents with major depressive disorder. On the basis of these tests, the Null Hypothesis 17.a:
There is no difference in the pharmacotherapy category prescribed by physicians (pediatricians
versus child psychiatrists) for first, second, and third lines of antidepressant treatment for newly
diagnosed adolescents with major depressive disorder is not rejected.
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Table 4.55: Association of Physician Type and Antidepressant Category
Association
Two-sided Probability
Adolescent’s First-line of Antidepressant:
Physician Type * Antidepressant Type
0.1349
Adolescent’s Second-line of
Antidepressant:
Physician Type * Antidepressant Type

0.0871

Adolescent’s Third-line of Antidepressant:
Physician Type * Antidepressant Type

0.3733

As was the case with the first part of Objective 17 several steps were necessary to determined
whether there is an association between the first, second, and third lines of specific antidepressant
treatment and physician type. Three χ2 tests, one for each line of treatment (first, second, and thirdline) were conducted and examined the association between two variables: physician type
(pediatrician versus child psychiatrist) and specific antidepressant prescribed. However, the specific
type of antidepressant medication varied so that for the first-line of treatment there were 12 different
groups of antidepressants, for the second-line of treatment there were 30 different groups of
antidepressants, and for the third-line there were 34 different antidepressant groups. Since the
number of groups were so large, it was necessary to collapse the antidepressant categories. Prozac®
is the only antidepressant, U.S. FDA approved to treat major depressive disorder in adolescents,
therefore, it was decided to collapse the antidepressants into two categories, either Prozac® or nonProzac® type antidepressants. Therefore, for each line of treatment (first, second, and third) the χ2
statistic tested whether or not there is an association between physician type (pediatrician versus
child psychiatrist) and specific antidepressant (Prozac® versus non- Prozac®). The results of these
analyses are in Table 4.56 below.
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Table 4.56: Association of Physician Type and Specific Antidepressant
Pediatrician
Child
Test Statistic
(N)
Psychiatrist
(N)
1st-Line of Antidepressant
Treatment:
Non-Prozac®
34
170
χ2=0.5338
®
Prozac
23
124
2nd-Line of Antidepressant
Treatment:
Non-Prozac®
42
232
χ2=3.2576
®
Prozac
14
50
rd
3 -Line of Antidepressant
Treatment:
Fisher’s
®
Non-Prozac
53
279
Exact Test
Prozac®
1
7

p-value

0.4650

0.0711

0.4721

Based on the χ2 tests and the fisher’s exact test there is not statistically significant association
between physician type and the specific antidepressant prescribed to adolescents. Hence, we must
fail to reject the Null Hypothesis 17.b: There is no difference in the specific antidepressant
prescribed by physicians (pediatricians versus child psychiatrists) for first, second, and third lines of
treatment for newly diagnosed adolescents with major depressive disorder.

Objective 18: To predict which physician characteristics affect the treatment prescribed for
adolescents with major depressive disorder.
Logistic regression was utilized to estimate the probability that a physician would prescribe
antidepressant medication versus counseling to adolescents with major depressive disorder. The
explanatory or independent variables utilized in this model were physician characteristics (specialty
of physician, gender of physician, age of physician, physicians’ primary practice site, geographic
location of physician, population of community of physicians’ primary practice site, physicians’
board certification, patient volume per week, and length of time physician has treated the child and
adolescent population). The pre-specified criterion of p = 0.15 was utilized and a stepwise logistic
regression model was estimated using SAS®, just as was conducted for the child population.
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However, in this model convergence was not achieved. Estimation of the logistic model is an
iterative process involving many approximations. This process ceases when the change in the
coefficients become very small, at this point the model is said to have converged (Allison, 1999).
Two reasons convergence may not be achieved. These two reasons are complete separation and
quasi-complete separation of the data. Complete separation occurs when the dependent variable is
perfectly predicted by some linear combination of the independent variables (Allison, 1999). The
other reason, quasi-complete separation, is what occurred in the data for this model. Quasi-complete
separation is similar to complete separation except for there being a value for the predictor (or
independent variable) for which both values of the dependent variable occur (Allison, 1999). Quasicomplete separation can occur when all of the cases at one level of the independent variable fall into
one of the two levels of the dependent variable. This can be seen if cross-tabs of the independent
and dependents variables are examined. Examination of the cross-tabs for the data in this model
reveals the independent variable, number of adolescents treated per week, has this property. This is
shown below in Table 4.57. One way to manage quasi-complete separation is to recode and collapse
categories of the independent variable (Allison, 1999). In the current data set, the independent
variable has only two levels already. Therefore, collapsing these variables is not possible. Another
method and most common method to manage quasi-separation is to delete the cases(s) causing the
problem (Allison, 1999). In this case, the cases were deleted and the stepwise logistic procedure recalculated.
Table 4.57: Crosstabs of Treatment by Number of Adolescents Seen Per Week
40 Patients or Less
41 Patients or Greater
Treatment:
Antidepressants
248
21
Counseling
51
0
Based on our pre-specified criterion, two variables, type of physician and age of physician were
retained in the stepwise model. The final logistic regression model resulted in no independent
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variables being retained, based on a p < 0.05 criterion. However, it should be noted that age of the
physician approached statistical significance (χ2=3.2178, p=0.0728). These results are listed in
Table 4.58. Therefore, it can be concluded from this model that none of our independent variables
are significantly associated with the probability of a physician prescribing antidepressant treatment
for an adolescent patient.
Table 4.58: Logistic Regression Analysis of Physicians’ Antidepressant Prescribing to
Adolescents with Major Depressive Disorder
Variable

SE β

Wald’s
χ2
22.5219
2.6632

df

p-value

1
1

<0.0001
0.1027

Point
Estimate
NA
0.444

Age of Physician
0.8238
0.4592
3.2178
1
Greater than 60 years
SE=Standard Error, df=degrees of freedom, CI=Confidence Interval

0.0728

2.279

Intercept
Child Psychiatrist

Estimate
β
2.2345
-0.8114

0.4708
0.4972

95% CI
NA
0.168 –
1.177
0.927 –
5.606

Objective 19: To determine the average length of antidepressant treatment for newly diagnosed
adolescents with major depressive disorder.
Physicians were asked to indicate how long on average an antidepressant be prescribed to an
adolescent, if the treatment was successful in terms of decreasing depressive symptoms. The
majority of the physicians, both pediatricians (25.00+38.46=63.46%) and child psychiatrists
(46.59+24.90=71.49%) indicated they would prescribe the antidepressant medication to an
adolescent for at least ten months. These frequencies are listed in Table 4.59.
Table 4.59: Frequencies of Average Length of Antidepressant Treatment for Adolescents
Length of
All Physicians
Pediatricians
Child Psychiatrists
Antidepressant
N (%)
N (%)
N (%)
Treatment
1(0.33)
0(0.00)
1(0.40)
1-3 months
36(11.96)
10(19.23)
26(10.44)
4-6 months
53(17.61)
9(17.31)
44(17.67)
7-9 months
129(42.86)
13(25.00)
116(46.59)
10-12 months
82(27.24)
20(38.46)
62(24.90)
Greater than 12
months
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The American Academy of Child and Adolescent Psychiatry has recently recommended
adolescents be treated for a minimum of six months (American Academy of Child and Adolescent
Psychiatry, 2007). The categorical variable, length of treatment, was then transformed into a
continuous variable so comparisons could be made to the six month minimum. The categorical
variable was re-coded by computing the average number of months the physician treats the
adolescent with an antidepressant. The variable was re-coded as follows: 1-3 months was
transformed into 2 months, 4-6 months was transformed into 5 months, 7-9 months was transformed
into 8 months, 10-12 months was transformed into 11 months, and greater than 12 months was
transformed into 12 months. The average length of time pediatricians and child psychiatrists
prescribed antidepressant treatment for adolescents was then compared to the minimum length of
time. It was found that both pediatricians and child psychiatrists treat adolescents significantly
longer than the six month minimum. These results are listed in Table 4.60.
Table 4.60: Length of Antidepressant Treatment Compared to the AACAP Recommendations
Physician
Length of
Minimum Length Test Statistic
Significance p
Type
Antidepressant of AACAP
Treatment
Recommendations
(Mean + SD)
(months)
9.712 + 2.710
6
t=9.874
0.000*
Pediatrician
10.056 + 2.248
6
t=28.473
0.000*
Child
Psychiatrist
*Significant at p<0.05, SD=Standard Deviation

Objective 20: To determine the types of pharmacotherapy monitoring in newly diagnosed
adolescents with major depressive disorder.
Physicians were asked several questions related to the monitoring they conduct, in the event they
utilize antidepressant treatment for adolescents with major depressive disorder. More specifically
physicians were asked the mode of monitoring (e.g., how is the monitoring done), who conducts the
monitoring, the type of monitoring they conduct, and the frequency with which they monitor. The
physicians’ responses to the mode of monitoring, who conducts the monitoring, and the type of
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monitoring conducted are listed in Table 4.61, Table 4.62, and Table 4.63, respectively. The
majority of pediatricians (89.10%) and child psychiatrists (96.48%) indicated they would conduct
monitoring through an individual office visit with the adolescent. Both pediatricians (96.36%) and
child psychiatrists (95.41%) indicated, almost exclusively, they would conduct the monitoring
themselves. Greater than ninety-five percent of pediatricians and child psychiatrists reported they
monitor for adverse events, suicidality, and monitor clinical symptoms. Some pediatricians
(27.78%) and three-fourths of the child psychiatrists (74.65 %) indicated they would conduct some
type of labwork to monitor medication therapy.
Some pediatricians (%) and child psychiatrists (%) indicated they conduct some other type of
monitoring for adolescents. Other types of monitoring physicians listed included monitoring
ongoing psychotherapy progress, monitoring school, social, family, or interpersonal functioning, and
monitoring depressive symptoms through the use of scales (ex. Beck’s Depression Inventory).

Table 4.61: Mode of Antidepressant Monitoring for Adolescents
Mode of
All Physicians
Pediatricians
Child Psychiatrists
Monitoring
N(%)
N(%)
N(%)
Individual Office
323 (95.28)
49 (89.10)
274 (96.48)
Visit
Telephone
6 (1.77)
3 (5.45)
3 (1.06)
Other
10 (2.95)
3 (5.45)
7 (2.46)

Table 4.62: Healthcare Provider Conducting Antidepressant Monitoring for Adolescents
Healthcare Provider
All Physicians
Pediatricians N(%) Child Psychiatrists
N(%)
N(%)
Physician
323 (95.56)
53 (96.36)
270 (95.41)
Nurse/Nurse Practitioner
5 (1.48)
1 (1.82)
5 (1.77)
Counselor/Psychotherapist
4 (1.18)
1 (1.82)
3 (1.06)
Other
6 (1.78)
0 (0.00)
5 (1.77)
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Table 4.63: Type of Antidepressant Monitoring for Adolescents
Type of
All Physicians
Pediatricians
Child Psychiatrists
Monitoring
(N=340)
(N=54)
(N=284)
Adverse Events
337 (99.12)
54 (100.00)
283 (99.65)
Suicidality
335 (98.53)
52 (96.30)
283 (99.65)
Conduct Labwork
227 (66.76)
15 (27.78)
212 (74.65)
Clinical Symptoms
334 (98.24)
53 (98.15)
281 (98.94)
Other
78 (22.94)
4 (7.41)
74 (26.06)
Physicians were also asked to indicate how frequently they monitor adolescents treated with
antidepressants during the first three months of treatment. During the first month of treatment over
half of the pediatricians (53.70%) indicated they monitor children every two weeks, with another
38.89% pediatricians reported monitoring once a week. In comparison, approximately the same
percentage of child psychiatrists reported, monitoring adolescents either once a week (38.95%) or
every two weeks (32.98%) during the first month of antidepressant treatment. The findings for
monitoring frequency during the first month of treatment are listed in Table 4.64.
Table 4.64: Frequency of Antidepressant Monitoring: Month One
All Physicians
Pediatricians
Child Psychiatrists
(N)
(N)
(N)
Frequency of Monitoring:
Two Times per Week
2(0.59%)
0(0.00%)
2(0.70%)
Once a Week
132(38.94%)
21(38.89%)
111(38.95%)
Every Two Weeks
123(36.28%)
29(53.70%)
94(32.98%)
Every Three Weeks
14(4.13%)
0(0.00%)
14(4.91%)
Once a Month
40(11.80%)
3(5.56%)
37(12.98%)
Greater than Once a Month
0(0.00%)
0(0.00%)
0(0.00%)
Other
28(8.26%)
1(1.85%)
27(9.47%)
For the second month of antidepressant treatment about two-thirds of pediatricians (62.97%)
monitor adolescents once a month, while another one-fourth (24.07%) monitor adolescents every
two weeks. The majority of child psychiatrists indicated they monitor adolescents either once a
month (45.77%) or every two weeks (30.28%). Results for the frequency of monitoring, by these
physicians, during the second month of treatment are listed in Table 4.65.
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Table 4.65: Frequency of Antidepressant Monitoring: Month Two
All Physicians
Pediatricians
Child Psychiatrists
(N)
(N)
(N)
Frequency of Monitoring:
Two Times per Week
2(0.59%)
0(0.00%)
2(0.70%)
Once a Week
15(4.44%)
1(1.85%)
14(4.93%)
Every Two Weeks
99(29.29%)
13(24.07%)
86(30.28%)
Every Three Weeks
29(8.58%)
1(1.85%)
28(9.86%)
Once a Month
164(48.52%)
34(62.97%)
130(45.77%)
Greater than Once a Month
16(4.73%)
4(7.41%)
12(4.23%)
Other
13(3.85%)
1(1.85%)
12(4.23%)
During month three, over ninety percent of the pediatricians reported they monitor adolescents
either once a month (42.60%) or at some time interval greater than one month (50.00%). The
majority of child psychiatrists (62.68%) indicated they monitor adolescents once a month. Another
21.48% of the child psychiatrists reported they monitor adolescents at some interval greater than
once a month. Table 4.66 shows the results of the frequency of monitoring by physicians during the
third month of treatment.
Table 4.66: Frequency of Antidepressant Monitoring: Month Three
All Physicians
Pediatricians
Child Psychiatrists
(N)
(N)
(N)
Frequency of Monitoring:
Two Times per Week
2(0.59%)
0(0.00%)
2(0.70%)
Once a Week
9(2.66%)
0(0.00%)
9(3.17%)
Every Two Weeks
10(2.96%)
1(1.85%)
9(3.17%)
Every Three Weeks
12(3.55%)
2(3.70%)
10(3.52%)
Once a Month
201(59.47%)
23(42.60%)
178(62.68%)
Greater than Once a Month
88(26.04%)
27(50.00%)
61(21.48%)
Other
16(4.73%)
1(1.85%)
15(5.28%)
Objective 21: To determine differences in antidepressant monitoring for newly diagnosed
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring
adolescents treated with antidepressants.
Null Hypothesis 21.0: There is no difference in pharmacotherapy monitoring for newly diagnosed
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring
adolescents treated with antidepressants.
The frequencies associated with physician monitoring of adolescents treated with antidepressant
medication was provided in the above objective, and listed in Tables 4.64 4.65, and 4.66. Physicians
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answered the monitoring frequency question by selecting one of the following categories: “two times
per week”, “once a week”, “every two weeks’, “every three weeks”, “once a month”, greater than
once a month”, or “other”. These variables are categorical in nature. Therefore, to compute an
average number of times per month a physician monitors adolescents on antidepressants these
categories were re-coded. This was accomplished as follows: “two times per week” was
transformed into eight times per month, “once a week” was transformed into four times a month,
“every two weeks” was transformed into two times per month, “every three weeks” was transformed
into 1.4 times per month, “once a month” was transformed into 1 time per month, and “greater than
once a month” was transformed into .5 times per month. For this analysis the “other” category was
eliminated. The frequencies of the recoded variables are provided below in Tables 4.67, 4.68, and
4.69.
Table 4.67: Recoded Frequency of Antidepressant Monitoring: Month One
Frequency of Monitoring
All Physicians
Pediatricians
Child Psychiatrists
(Number of Times per
(N)
(N)
(N)
Month) :
0
0
0
0.5
40
3
37
1
14
0
14
1.4
123
29
94
2
132
21
111
4
2
0
2
8
Table 4.68: Recoded Frequency of Antidepressant Monitoring: Month Two
Frequency of Monitoring
All Physicians
Pediatricians
Child Psychiatrists
(Number of Times per
(N)
(N)
(N)
Month):
16
4
12
0.5
164
34
130
1
29
1
28
1.4
99
13
86
2
15
1
14
4
2
0
2
8
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Table 4.69: Recoded Frequency of Antidepressant Monitoring: Month Three
Frequency of Monitoring
All Physicians
Pediatricians
Child Psychiatrists
(Number of Times per
(N)
(N)
(N)
Month):
88
27
61
0.5
201
23
178
1
12
2
10
1.4
10
1
9
2
9
0
9
4
2
0
2
8
The U.S. FDA recommendation, for physician monitoring of antidepressant treatment is one time
per week for the first four weeks of treatment (U.S.FDA, 2005). During the second month of
treatment the patient should be seen biweekly, and at week 12, during the third month (U.S.FDA,
2005). These recommendations were compared to the number of times per month the physicians
reported they monitor adolescents, during the first three months of antidepressant treatment. For the
first month of treatment pediatricians (t=-7.967, p=0.000) and child psychiatrists (t=-15.941,
p=0.000) monitor adolescents significantly less than the U.S. FDA recommended four times. During
the second month of treatment, both pediatricians (t=-8.715, p=0.000) and child psychiatrists (t=8.078, p=0.000) monitor significantly less than the U.S. FDA recommended two times per month.
During the third month of treatment pediatricians (t=-4.947, p=0.000) still monitor significantly less
than the U.S. FDA recommendations. However, child psychiatrists’ (t=1.847, p=0.101) monitoring
does not differ significantly from the U.S. FDA recommendations of one time during month three.
These comparisons are listed in Table 4.70.
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Table 4.70: Comparisons of Physician Monitoring to U.S. FDA Recommendations
Mean + SD
Test Statistic
Significance
Month One:
All Physicians
2.732 + 1.242
t=-18.001
0.000*
Pediatricians
2.736 + 1.059
t=-7.967
0.000*
Child Psychiatrists
2.731 + 1.277
t=-15.941
0.000*
Month Two:
All Physicians
1.497 + 0.896
t=-8.130
0.000*
Pediatricians
1.272 + 0.608
t=-8.715
0.000*
Child Psychiatrists
1.541 + 0.937
t=-8.078
0.000*
Month Three:
All Physicians
1.037 + 0.814
t=0.893
0.372
Pediatricians
0.779 + 0.325
t=-4.947
0.000*
Child Psychiatrists
1.087 + 0.870
t=1.847
0.101

*Significant at p<0.05, SD=Standard Deviation, U.S. FDA=United States Food and Drug Administration

Objective 22: To determine whether there are differences, by physician type, in the average number
of times per month physicians monitor adolescents with major depressive disorder.
Null Hypothesis 22.0: There is no difference, by physician type, in the average number of times per
month physicians monitor adolescents with major depressive disorder.
The hypothesis that there is no difference by physician type (pediatricians versus child
psychiatrists) in the average number of times per month physicians monitor adolescents was tested.
The recoded data from Objective #21 was utilized to analyze this objective. This data was used to
compare the average number of times per month pediatricians monitor adolescents to the average
number of times child psychiatrists monitor adolescents on antidepressant therapy. The Levene’s
test for equality of variances was first conducted on each of the comparisons. If the Levene’s test for
equality was significant then equal variances could not be assumed. If the Levene’s test for equality
was not significant then equal variances were assumed. Next, the appropriate two sample t-test,
either for the assumption of equal variances or unequal variances was conducted. The results are
listed below in Table 4.71.
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Table 4.71: Comparison of Pediatricians and Child Psychiatrists Monitoring
of Adolescents
Mean + SD
Test Statistic
p-value
Month One:
Pediatricians
2.74 + 1.06
t = 0.029
0.977
Child Psychiatrists
2.73 + 1.28
Month Two:
Pediatricians
Child Psychiatrists
Month Three:
Pediatricians
Child Psychiatrists

* Significant at p <0.05

1.27 + 0.61
1.54 + 0.94

t = -2.667

0.009*

0.78 + 0.32
1.09 + 0.87

t = -2.541

0.012*

The average number of times physicians (pediatricians versus child psychiatrists) monitored
adolescents did not significantly differ during the first (p=0.977) month of antidepressant treatment.
Child psychiatrists monitored significantly more than pediatricians during the second (p=0.009) and
third (p=0.012) months of treatment. Therefore, Null Hypothesis 13.0: There is no difference, by
physician type, in the average number of times per month physicians monitor adolescents with major
depressive disorder, will fail to be rejected for month one and will be rejected for months two and
three of treatment.
Phase II Results for Exploratory Factor Analysis
Objective 23: To determine the relative importance which physicians place on each factor prior to
prescribing antidepressants to newly diagnosed children and adolescents with major depressive
disorder.
Objective 24: To determine the factors associated with physicians’ antidepressant prescribing
behavior for children and adolescents newly diagnosed with major depressive disorder.
Section seven of the phase II survey asked physicians to rate the extent to which 28 variables
influenced their decisions to prescribe or not to prescribe an antidepressant to a newly diagnosed
child or adolescent with major depressive disorder. The physicians rated the influence of these 28
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variables on a scale of 1-4, where 1= not influential, 2= somewhat influential, 3= influential, and 4=
extremely influential.
The physicians’ ratings of these 28 variables are listed in Table 4.68. Both pediatricians and
child psychiatrists on average rated clinical experience with prescribing antidepressants, co-existing
conditions of patient (e.g. obsessive compulsive disorder), comfort in managing MDD in youth, drug
safety, drug efficacy, familiarity with an antidepressant being prescribed, severity of MDD
symptoms, and suicidal thinking as being “influential” or “extremely influential”.
Pediatricians and child psychiatrists rated advertisements to physicians via journals and/or mail,
availability of patient education materials, direct-to-consumer advertising, face-to-face detailing by
medical sciences liaison and/or pharmaceutical representatives, FDA approved, formulary inclusion,
frequency of dosing, generic form of drug available, manufacturer provides free drugs to indigent
patients, medication cost, monitoring requirements, parents’ education level, parental use of
antidepressants, patient's ability to perform daily activities, patient's age, patient's family income,
patient's gender, patient's insurance, and sample drugs available as being either “not influential” or
only “somewhat influential”.
Pediatricians rated potential adverse effects as being “not influential” or only “somewhat
influential”, while child psychiatrists rated potential adverse effects as being either “influential” or
“extremely influential”.
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Table 4.72: Means and Standard Deviations of Variables/Factors Which Influence
Antidepressant Prescribing Decisions for Child Psychiatrists and Pediatricians
Factor
Advertisements to physicians via
journals and/or mail
Availability of patient education
materials

Child Psychiatrists
(Mean ± S.D.)

Pediatricians
(Mean ± S.D.)

t-test

Significance
(p)

1.2 ±0.5

1.1 ±0.4

-2.009

0.048

1.4 ±0.7

1.3 ±0.5

-1.881

0.063

3.8 ±0.4

3.5 ±0.6

-3.535

0.001*

3.7 ±0.6

3.5 ±0.6

-2.583

0.012*

3.5 ±0.8

3.3 ±0.6

-1.226

0.221

1.3 ±0.5

1.0 ±0.2

-5.309

0.000*

3.8 ±0.4

3.5 ±0.6

-4.017

0.000*

3.8 ±0.4

3.7 ±0.5

-1.520

0.133

1.5 ±0.6

1.3 ±0.5

-2.188

0.032*

3.7 ±0.5

3.6 ±0.5

-1.864

0.063

2.5 ±1.0

2.9 ±1.0

2.783

0.006*

2.4 ±0.9

2.6 ±0.9

1.883

0.061

2.8 ±0.8

2.6 ±0.8

-1.029

0.304

2.4 ±0.9

2.5 ±0.8

0.850

0.396

2.0 ±0.9

1.5 ±0.7

-4.366

0.000*

2.5 ±0.8

2.5 ±0.6

0.018

0.985

2.4 ±0.9

2.3 ±0.8

-0.582

0.561

1.9 ±0.9

1.9 ±0.8

0.071

0.943

Clinical experience with prescribing
antidepressants
Co-existing conditions of patient (e.g.
obsessive compulsive disorder)
Comfort in managing MDD in youth
Direct-to-consumer advertising
Drug efficacy
Drug safety
Face-to-face detailing by medical
sciences liaison and/or pharmaceutical
representatives
Familiarity with an antidepressant being
prescribed
FDA approved
Formulary inclusion
Frequency of dosing
Generic form of drug available
Manufacturer provides free drugs to
indigent patients
Medication cost
Monitoring requirements
Parents’ education level
Parental use of antidepressants

2.6 ±0.9

2.1 ±0.9

-3.683

0.000*

Patient's ability to perform daily
activities

2.9 ±0.9

2.8 ±0.9

-0.638

0.524

Patient's age

2.9 ±0.8

2.8 ±0.7

-0.384

0.701

1.5 ±0.8

1.4 ±0.6

-1.748

0.084

1.3 ±0.6

1.2 ±0.4

-1.487

0.140

1.7 ±0.9

1.7 ±0.8

0.109

0.913

3.3 ±0.7

3.0 ±0.7

-3.139

0.002*

1.8 ±0.8

1.4 ±0.7

-2.854

0.005*

3.7 ±0.6

3.3 ±0.9

-3.301

0.002*

3.6 ±0.7

3.5 ±0.8

-1.451

0.148

Patient's family income
Patient's gender
Patient's insurance
Potential adverse effects
Sample drugs available
Severity of MDD symptoms
Suicidal thinking
* Significant at p < 0.05, S.D. =Standard Deviation
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Comparisons of the pediatricians’ ratings of the factors and child psychiatrists’ ratings of the
factors were made. The Levene’s test for equality of variances was first conducted on each of the 28
comparisons. If this test was significant then equal variances were not assumed, if the Levene’s test
was not significant then equal variances could be assumed. Next, the appropriate two-sample t-test,
either for equal variances or unequal variances was conducted. The results are listed in the Table
4.72. Mean ratings were significantly different for pediatricians and child psychiatrists for the
following factors: clinical experience with prescribing antidepressants, co-existing conditions of
patient (e.g. obsessive compulsive disorder), direct-to-consumer advertising, drug efficacy, face-toface detailing by medical sciences liaison and/or pharmaceutical representatives, FDA approved,
manufacturer provides free drugs to indigent patients, parental use of antidepressants, potential
adverse effects, sample drugs available, and severity of MDD symptoms.
Next, an exploratory factor analysis was conducted on the physicians’ responses to the 28
variables. Exploratory factor analysis is appropriate when the researcher has obtained measures on a
number of variables (in this study the variables are the 28 factors or variables association with the
decision to prescribe or not prescribe an antidepressant) and wants to identify the factor structure or
underlying factors or constructs in the set of data (Hatcher, 1994). A factor “is an unobserved
variable (or latent variable)” or a “hypothetical construct” that you believe exists and influences
certain “manifest or observed variables” (Hatcher, 1994). Some variables will correlate strongly/are
intercorrelated with each other because these variables are all “caused by the same latent factor” or
construct (Hatcher, 1994).
There are guidelines to choose the sample size that is adequate for a factor analysis (Hatcher,
1994). The minimal number of subjects should be at least 100 or five times the number of variables
being analyzed (Hatcher, 1994). In the current study physicians were asked to rate how influential
28 variables are when deciding whether or not to prescribe an antidepressant medication to children
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or adolescent patients. Therefore, 28*5 or a minimum of 140 subjects are required to conduct a
factor analysis in the current study. A factor analysis was not conducted for the pediatrician group
because only 57 useable surveys were obtained from pediatricians. For the child psychiatrist group
there were 299 returned and usable surveys. If a subject fails to answer even one item they will not
provide usable data for a factor analysis and SAS will drop these subjects from the final sample
(Hatcher, 1994). The final sample consisted of 259 subjects. This number is more than the 140
subjects minimally required for a factor analysis.
There are three decisions points or steps in conducting an exploratory factor analysis. The
researcher must decide which extraction method to utilize, the number of factors to be retained in the
analysis for rotation, and choose a rotation method.
There are several extraction methods that can be utilized when conducting a factor analysis.
However, information regarding the strengths and weaknesses of these methods is limited (Osborne
& Costello, 2005). The most common methods utilized are principal components analysis and
principal axis factoring (Hatcher, 1994; Osborne & Costello, 2005; Thompson, 2004). There is
much debate regarding whether or not principal components analysis should be utilized in as an
extraction method in exploratory factor analysis (Osborne & Costello, 2005; Thompson, 2004).
Additionally, principal axis factoring is more robust and does not even assume that data is normally
distributed. For these reasons the researcher took a conservative approach and utilized the principal
axis method for this study.
The researcher also needs to determine the number of factors to retain (Hatcher, 1994; Osborne &
Costello, 2005). In other words the researcher must decide how many factors are meaningful factors
and should be retained for rotation and interpretation. Usually it can be expected that the first few
factors in the model account for the large majority of the common variance and are therefore more
meaningful (Hatcher, 1994). There are several guidelines to follow in order to determine the number
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of factors to retain for interpretation (Hatcher, 1994). Since these are guidelines and are rather
subjective, it has been recommended that these guidelines be used in combination, in order for the
researcher maximize his/her chances of identifying the correct factor structure for the data (Hatcher,
1994). The four guidelines utilized to determine the number of factors to be retained are as follows:
1) Kaiser Criterion, 2) Scree Test, 3) Proportion of Variance , and 4) Interpretability Criterion
(Hatcher, 1994).
The Kaiser Criterion calls for factors to be retained if they have an eigenvalue equal to 1.0 or
greater (Hatcher, 1994). In this study, the first four factors (4.66, 2.04, 1.30, and 1.00 respectively)
produced rounded eigenvalues equal to or greater than 1.0. Therefore, based on this criterion four
factors should be retained.
The scree test plots the eigenvalues for each factor against the number of each factor. The
researcher looks for “breaks” in the scree plot to determine how many factors should be retained
(Cattell, 1966; Hatcher, 1994). In this study, the scree plot showed four breaks after factor 1, factor
2, factor 3, and factor 4.

Therefore, based on this criterion four factors should be retained.

The proportion of variance criteria can also be utilized to determine the number of factors to
retain for rotation. According to this criterion, a factor is retained if it accounts for a certain
percentage of the variance in a set of data (Hatcher, 1994). This method has been criticized for
being subjective (Hatcher, 1994). If applied to this study the proportion of variance criteria yields
the slightly different results as the other methods. For example, if any factor that accounts for at
least 10% of the common variance is retained, as suggested by Hatcher (1994) only three factors
would be retained. The fourth factor having a proportion of variance equal to 0.0922, would not be
retained. Although subjective this criterion can serve as a check for the other criterion, especially if
the results are in agreement.
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The last guideline is the interpretability criterion. This guideline is not empirical in nature, but
involves the researcher examining the variables that load on any given factor and determining
whether or not they seem to share some common conceptual meaning (Hatcher, 1994). Table 4.73
lists the variables which loaded on each of the three factors.
Table 4.73: Initial Factor Pattern
Variable

Factor

Face-to-face detailing by medical sciences liaison and/or
pharmaceutical representatives
Formulary inclusion
Frequency of dosing
Generic form of drug available
Manufacturer provides free drugs to indigent patients
Medication cost
Monitoring requirements
Parents’ education level
Parental use of antidepressants
Patient's ability to perform daily activities
Patient's age
Patient's family income
Patient's insurance
Potential adverse effects
Sample drugs available
Patient's ability to perform daily activities
Severity of MDD symptoms
Suicidal thinking
Drug efficacy
Drug safety
Formulary inclusion

Factor 1

Factor 2
Factor 3
Factor 4

According to the interpretable criterion the variables which load on each of the three factors
should have something in common or seem to group together. On the first factor the variables faceto-face detailing by medical sciences liaison and/or pharmaceutical representatives, formulary
inclusion, frequency of dosing, generic form of drug available, manufacturer provides free drugs to
indigent patients, medication cost, monitoring requirements, parents’ education level, parental use of
antidepressants, patient's ability to perform daily activities, patient's age, patient's family income,
patient's insurance, potential adverse effects, and sample drugs available load. These variables seem
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to relate to the concepts of “drug cost and socio-economic status of the patient”. Patient’s ability to
perform daily activities, severity of major depressive disorder symptoms, and suicidal thinking all
seem to correspond to the idea of “disease presentation or severity of disease”. The drug efficacy
and drug safety variables which load on factor 3 could both be related to the concept of “drug
profile”. In this initial factor pattern matrix, the variable formulary inclusion loads by itself on factor
4. If this factor continued to load only one variable, it should probably be dropped from the analysis,
as it would be considered a weak or unstable factor. However, this is not the case as seen in the
remaining analysis.
The next step in factor analysis is rotation of the data. There are two main types of rotation that
may be utilized. These rotation methods are orthogonal rotation or oblique rotation (Hatcher, 1994;
Osborne & Costello, 2005). Orthogonal rotation seems to be easier to interpret. However oblique
rotation seems to provide better results for many types of variables, as it allows factors to correlate
with one another. If the factors are correlated and orthogonal rotation is used this information is lost.
Oblique rotation is more appropriate in social sciences because behavior is rarely placed in neat
packages and variables tend to correlate (Hatcher, 1994; Osborne & Costello, 2005). Therefore, this
study utilized oblique rotation.
The goal of rotation is to simplify the structure of the data. Simple structure of the data is said to
be achieved when the variables have “relatively high factor loadings” on one factor and low factor
loadings (near zero) on the other factors (Hatcher, 1994). In other words, maximize high factor
loadings while minimizing low factor loadings.
Factor loadings are the coefficients that result in the factor pattern matrix or factor structure matrix
in the results of the factor analysis or the coefficients of the variable on each of the factors (Hatcher,
1994).
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For analysis utilizing oblique rotation the researcher must interpret at least two matrices in order
to understand the results. These are the “Rotated Factor Pattern” and the Factor Structure Matrix”
(Hatcher, 1994). In order to understand the results the researcher reviewed the “Rotated Factor
Pattern” first. The variables which have meaningful loadings on the factors are identified. For the
social sciences factor loadings/ communalities are considered meaningful if they are greater than
0.40 (Osborne & Costello, 2005; Stevens, 1986). Second if variables have meaningful loadings on
two or more factors they are said to crossload and researchers tend to drop these variables, as they do
not represent a “pure” measure of any one factor or construct (Hatcher, 1994). The other matrix that
should be examined is the “Factor Structure Matrix”. This matrix is less likely to demonstrate
simple structure, and for this reason it is recommended that researchers rely more on the
interpretation gained from the rotated factor pattern (Hatcher, 1994). The results for these matrices
are listed below in Table 4.74.
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Table 4.74: Results of Rotated Factor Pattern and Factor Structure Matrix
Factor Loadings
Factor 1:
Rotated Factor Pattern
Factor Structure Matrix
1. Direct-to-consumer
0.47
0.46
advertising
2. Face-to-fact detailing by
0.46
0.48
medical sciences liaison
and/or pharmaceutical
representative
3. Monitoring requirements
0.42
CL
4. Parents’ education level
0.55
0.58
5. Parental use of
0.48
0.50
antidepressants
6. Patient’s family income
0.67
0.67
7. Patient’s gender
0.59
0.51
8. Availability of patient
DNL
0.43
education materials
9. Patient’s age
DNL
CL
Factor 2:
1. Patient’s ability to perform
0.59
0.63
daily activities
2. Severity of MDD
0.77
0.73
symptoms
3. Suicidal thinking
0.80
0.76
4. Patient’s age
DNL
CL
Factor 3:
1. Formulary inclusion
0.66
0.60
2. Frequency of dosing
0.43
0.50
3. Generic form of drug
0.69
0.66
available
4. Manufacturer provides free
0.51
0.56
drugs to indigent patients
5. Medication cost
0.62
CL
6. Monitoring requirements
DNL
CL
7. Patient’s insurance
DNL
0.42
8. Sample drugs to patients
DNL
CL
Factor 4:
1. Drug efficacy
0.68
0.67
2. Drug safety
0.64
0.65
3. Co-existing conditions of
DNL
0.41
patient
4. Potential adverse effects
DNL
0.44
DNL= variable did not achieve a factor loading greater than 0.40 on the matrix
CL=variable had a meaningful factor loading on two factors under the matrix structure

The next step is to determine whether or not the variables which load on each factor in the rotated
factor matrix have anything in common or seem to measure a similar construct. In reviewing the
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variables which loaded on Factor 1 (Direct-to-consumer advertising, Face-to-face detailing by
medical sciences liaison and/or pharmaceutical representatives, Monitoring requirements, Parents’
education level, Parental use of antidepressants, Patient's family income, and Patient's gender) these
variables have a theme of drug marketing or patient socio-economics. The variables which loaded
on Factor 2 (Patient’s ability to perform daily activities, Severity of major depressive disorder
symptoms, and Suicidal thinking) all seem to measure the construct of disease severity. The
variables (Formulary inclusion, Frequency of dosing, Generic form of dug available, Manufacturer
provides free drugs to indigent patients, and Medication cost) that loaded on Factor 3 all measure
treatment or antidepressant cost to the patient. The variables (Drug efficacy and Drug safety) loaded
on Factor 4 and both measure antidepressant drug profile.
The “Reference Structure Matrix” can be reviewed in the case where variables do not
demonstrate simple structure in the “Rotated Factor Pattern”. This can result if the factors are
correlated with one another. The analysis indicated that Factor 1 and Factor 3 have an inter-factor
correlation coefficient of 0.50. This is not a strong correlation, but does show that these two factors
are correlated. Conceptually, this does make sense as the variables which load on Factor 1 are
related to the patient’s socio-economic status and the variable which load on Factor 3 are related to
the cost of the medication. Socio-economic status and the ability to pay for the medication are
related concepts or constructs. Since some of the variables have meaningful loadings on one of the
four factors identified above, but do not have zero or near-zero loadings on the other factors, the
“Reference Structure Matrix”, will be reviewed. Factor loadings on the “Reference Structure
Matrix” are listed below in Table 4.75.
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Table 4.75: Factor Loadings on the Reference Structure Matrix
Factor Loading
Factor 1: Socio-economic Status of
Patient
1. Parents’ education level
0.47
2. Parental use of antidepressants
0.41
3. Patient’s family income
0.57
4. Patient’s gender
0.50
Factor 2: Disease Severity
1. Patient’s ability to perform daily
0.57
activities
2. Severity of MDD symptoms
0.75
3. Suicidal thinking
0.77
Factor 3: Medication Cost
1. Formulary inclusion
0.57
2. Generic form of drug available
0.59
3. Manufacturer provides free drugs to
0.44
indigent patients
4. Medication cost
0.53
Factor 4: Drug Profile
1. Drug efficacy
0.66
2. Drug safety
0.62
Conceptually, the evaluation of this matrix provides a cleaner split of the variables. The variables
that load on Factor 1 all measure patients’ socio-economic status, the variables on Factor 2 measure
disease severity, the variables on Factor 3 measure drug cost to the patient, and the variables on
Factor 4 measure drug profile. No variables crossloaded on two factors on this matrix and simple
structure was achieved for most variables. The drawback to the interpretation of this matrix is that
only two variable loaded on factor 4. The number of variables, however, was not increased in the
rotated factor pattern in this study. This analysis shows this matrix is most useful for our in
interpretation of the four factors underlying our variables. Therefore, it can be concluded that four
factors labeled socio-economic status of the patient, disease severity, medication cost, and drug
profile influence child psychiatrists’ decision to prescribe or not to prescribe antidepressant
medication to a child or adolescent who has been newly diagnosed with major depressive disorder.
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CHAPTER FIVE: DISSCUSION & CONCLUSIONS
This chapter contains the discussion and the conclusions of this study. The results are discussed
in the context of their significance and relation to the current published literature. This discussion is
followed by study limitations, conclusions, and directions for future research.
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Discussion and Conclusions for Phase I
The purpose of Phase I of this study was to determine whether pediatricians treat children and/or
adolescents with major depressive disorder. It has been documented in the literature that children
and adolescents receive antidepressant treatment from primary care physicians (Olfson, 2008;
Rushton et al., 2000). Due to resource limitations, the present study surveyed only one group of
primary care providers, pediatricians. The current study found 60% of the pediatricians surveyed did
not treat children or adolescents for major depressive disorder. None of the pediatricians surveyed
treated children only, while 11.80% treated only adolescents. Additionally, 28.20% of the
pediatricians reported treating both children and adolescents for major depressive disorder. A study
conducted after the 2004 United States (U.S.) FDA black box warning on antidepressants, reported a
shift away from primary health care providers to specialists treating children and adolescents with
depression (Nemeroff et al., 2007). Nemeroff et al. (2007) found before the warning, psychiatrists
accounted for 44% of the patient care for these depressed children and adolescents, however after the
warning psychiatrists cared for 63% of the depressed children and adolescents (Nemeroff et al.,
2007). If the current study had been conducted before the 2004 “black box” warning the results may
have indicated more pediatricians willing to treat children and adolescents with major depressive
disorder, however, this is not known to be a fact.
Even before the 2004 U.S. FDA warning, many pediatricians referred children and adolescents to
other mental health care professionals for treatment. One such study conducted by Olfson (2008)
found that pediatricians referred 78-79% of cases to other professionals. This was consistent with
the findings of the current study which showed that over 80 % of the pediatricians reported they
refer children and adolescents to some other type of health care provider. Results also showed that
pediatricians’ decision to refer or treat was not necessarily a mutually exclusive decision.
Psychiatrists were the primary health care provider to whom pediatricians most often refer children
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(67.60%) and adolescents (67.30%). The second most commonly cited health care professional was
a psychologist for both children (13.70%) and adolescents (14.00%). Although the previously
conducted studies did not focus specifically on major depressive disorder in children and
adolescents, as did the current study, the results represent a consistent trend and hesitation of
pediatricians to treat any form of depression in children and adolescents, including major depressive
disorder.
The reason for pediatricians’ hesitation to treat these patients may be due to their lack of
confidence in their ability and training regarding the diagnosis and management of this disorder. A
2001 study found that 90% of pediatricians feel a responsibility to recognize depression in children
and adolescents, but only 26-27% feels responsible for treating these patients (Olfson, 2008). Few
pediatricians (10-14%) felt confident in treating children and adolescents with depression, however,
35% of these physicians indicated they felt motivated to enhance skills to recognize and manage
these patients (Olfson, 2008). This implies a readiness for education and training in the assessment
and treatment of children and adolescents with major depressive disorder. This also implies a need
for the creation of educational resources for pediatricians related to the management and treatment of
childhood and adolescent major depressive disorder.
From Phase I, it can be concluded that the proportion of pediatricians who treat children (χ2 =
6.532, p = 0.088) and adolescents (χ2 = 4.019, p = 0.259) across the U.S. does not significantly vary
according to geographic region. However, pediatricians in the Midwest are somewhat more likely to
treat children, while pediatricians in the Northeast are somewhat less likely to treat children for
major depressive disorder. Geographic variation in physician prescribing has been documented in
other studies, so the trend toward statistical significance is not surprising (Cox, Motheral,
Henderson, & Mager, 2003; Hull, Aquino, & Cotter, 2005). The current study like the previous
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ones, however, did not reveal the reasons behind the geographic variation (Cox et al., 2003; Hull et
al., 2005).
The other purpose of Phase I was to identify pediatricians who treat children and/or adolescents
for major depressive disorder and who were willing to participate in the larger Phase II survey,
regarding specific treatment practices. Only 39.95% of the pediatricians who returned surveys
indicated they treat children and/or adolescents. Of those 163 pediatricians who treat children and/or
adolescents, only 67.48% (n=110) were willing to participate in the Phase II survey. This
information is useful by providing a basis for calculating future sample sizes when surveying
pediatricians who treat children and/or adolescents with major depressive disorder.
Discussion and Conclusions for Phase II
Choice of Treatment for Children and Adolescents
The American Academy of Child and Adolescent Psychiatry (AACAP) recently published
Practice Parameters for the treatment of depression in children and adolescents (AACAP, 2007).
According to the Practice Parameters, children and adolescents with mild depression may benefit
from education, supportive counseling, and case management (AACAP, 2007). More severe cases
of depression, such as the population investigated in the current study, generally require treatment
with antidepressants (AACAP, 2007). According to the AACAP the child or adolescent may be
treated with antidepressants, either alone or in combination with counseling/psychotherapy
(AACAP, 2007). It should be noted the Practice Parameters outline treatments shown to be effective
in the treatment of depression but do not specify how physicians should treat children and
adolescents with any type of depression, including major depressive disorder. The treatment of
depression remains an individualized physician’s decision.
One purpose of the Phase II study was to determine physicians’ first, second, and third-lines of
treatment for children and adolescents with major depressive disorder. The preponderance of child
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psychiatrists indicated they would first attempt to use a combination of antidepressants and
counseling to treat children (52.19%) and adolescents (76.95%) with major depressive disorder. The
same finding was reported by the majority of the pediatricians that they utilize a combination of
antidepressants and counseling to treat children (63.46 %) and adolescents (87.72 %) with major
depressive disorder. However, many other physicians indicated they would first attempt to treat the
child or adolescent with counseling only. Child psychiatrists and pediatricians reported they use this
approach more for children (40.07%; 28.85%) than adolescents (15.93%; 8.77%).
In the event the first-line of treatment is not successful the majority of child psychiatrists
(93.71%) and pediatricians (74.00%) would switch the child to a different antidepressant medication
or augment the counseling therapy, as the second-line of treatment. For adolescents, the majority of
child psychiatrists (72.73%) and pediatricians (68.43%) reported switching the patient to a different
antidepressant medication.
In the event the second-line of treatment was not successful, two-thirds of the child psychiatrists
(66.43%) reported switching the child to another antidepressant medication. While another 20% of
the child psychiatrists indicated they would use some “other” type of treatment. For the child
psychiatrists this “other” treatment consisted of treating the child with some other type of
medication. These medications included antipsychotics (17.86%), mood stabilizers (17.86%),
anticonvulsants (8.93%), or lithium (8.93%). The majority of pediatricians (51.28%) reported
attempting some “other treatment” for children. This “other treatment” consisted of pediatricians
referring these children for psychiatric care. In the event the second-line of treatment was not
successful for adolescents most of the child psychiatrists (56.75%) reported switching these patients
to another type of antidepressant medication. Over one-half of the pediatricians (52.00%) reported
they would attempt some “other” treatment. That treatment consists of referring the adolescent to a
psychiatrist. Twenty four (24.22%) percent of the child psychiatrists also indicated attempting some
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“other” treatment for these adolescents. For the child psychiatrists this “other” treatment consisted
of treating the adolescent with some other type of medication. These medications included
antipsychotics (20.00%), mood stabilizers (18.57%), anticonvulsants (14.29%), or lithium (15.71%).
The findings of this study indicate the preponderance of child psychiatrists and pediatricians
utilize a combination of antidepressant treatment and counseling/psychotherapy for children and
adolescents with major depressive disorder. This treatment is consistent with the American
Academy of Child and Adolescent Psychiatry’s recommendations for the treatment of children and
adolescents with major depressive disorder (AACAP, 2007). The current study also found that many
child psychiatrists and pediatricians try counseling/psychotherapy only as a first-line treatment for
children. This seemingly more conservative approach should not be interpreted as an inadequate
treatment, as this therapy is also supported by the AACAP for the treatment of depression. This
approach may be related back to the pediatricians’ lack of confidence in diagnosing and managing
this disorder (Olfson, 2008). The child psychiatrists’ desire to treat children with counseling only
could be a function of their training, education, and expertise in counseling and psychotherapeutic
techniques (AACAP, 2004). More investigation is necessary to draw valid conclusions on the
reason for these treatment choices. Additionally, more examination is necessary to explore the
timelines associated with switching treatments. Presently there are no guidelines on switching
treatment in children and adolescents. Based on the adult literature, however, it is understood that
treatment response to antidepressants is not immediate and requires several weeks (AACAP, 2004).
The purpose of this study did not include investigating how long physicians wait for a treatment
response until they switch to a new treatment for a child or adolescent with major depressive
disorder. This could be investigated in future research.
In the event physicians utilize an antidepressant medication for the first-line of treatment for
children or adolescents, they indicated they most commonly prescribe either Prozac® or Zoloft®.
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This result was found for both child psychiatrists and pediatricians. For the first-line of treatment,
the majority of child psychiatrists (51.98%) and pediatricians (56.76%) indicated they utilize
Prozac® to treat children. Other child psychiatrists (27.12%) and pediatricians (24.33%) indicated
the use of Zoloft® to treat children. The findings were similar for physicians treating adolescents.
For the first-line of treatment the majority of the child psychiatrists indicated they would utilize
either Prozac® (50.21%) or Zoloft® (19.84%) to treat adolescents. This was also true for most of the
pediatricians who indicated they would utilize either Prozac® (44.23%) or Zoloft® (38.46%).
For the second-line of treatment the majority of the physicians still reported utilizing Prozac® or
Zoloft® to treat children. The choice of antidepressant for the treatment of adolescents, however,
varied somewhat for both child psychiatrists and pediatricians. The second-line of treatment choice
was varied for the child psychiatrists. They utilized Zoloft® (23.97%), Prozac®, (18.73%),
Wellbutrin (13.48%), and Celexa® (8.99%) and Lexapro® (8.99%). In comparison to pediatricians
who reported utilizing Prozac® (36.85%), Zoloft® (28.95%), or Celexa® (15.22%).
For the third-line of treatment physicians’ choice of antidepressant treatment for children and
adolescents was more varied than for the first and second-lines of treatment. Child psychiatrists
primarily reported utilizing one of the SSRI type antidepressants, but thirty percent (30.24%) noted a
preference for Wellbutrin® as a third-line of treatment for children. In comparison, the majority
(55.56%) of the pediatricians indicated they would try the child on Wellbutrin®. Another one-third,
of the pediatricians (33.33%) indicated the use of Zoloft® as a third-line of treatment.
When treating adolescents, the choice of antidepressants was even more varied. Approximately
40% of child psychiatrists reported using Wellbutrin®. However, many indicated they would utilize
some type of SSRI (most frequently Zoloft®) or Effexor® (SNRI). In contrast, pediatricians
(31.25%) utilized Wellbutrin® or some type of SSRI. Of those reporting, Lexapro® was the most
frequent SSRI chosen. The specific antidepressant most commonly used as first-line treatment for
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both children and adolescents by child psychiatrists and pediatricians was Prozac®. The second most
commonly used antidepressant by both specialties is Zoloft®. As a second line of antidepressant
treatment child psychiatrists and pediatricians and still utilized Prozac® and Zoloft® more commonly
than other antidepressants for both children and adolescents.
The reasons for the popularity of these antidepressants may be related to the fact Prozac® is the
only U.S. FDA approved antidepressant treatment for children and adolescents with major
depressive disorder (U.S. FDA, 2004). The 2004 U. S. FDA warning highlighted a possible increase
in suicidality in child and adolescents who are treated with antidepressants. Because of this risk,
physicians may view Prozac® as a safer or more conservative treatment option and be hesitant to
prescribe off-label antidepressants to children and adolescents. Although Zoloft® is not approved for
the treatment of depression in children and adolescents; it is indicated for the treatment of obsessivecompulsive disorder in the pediatric population (U.S.FDA, 2007). Since this medication is indicated
for the treatment of another disorder in this population, physicians may feel more comfortable
prescribing it to this age group. The current study, however, did not investigate the specific rationale
for prescribing one antidepressant over another.
Association of Physician Type and Antidepressant Category
The relationship between physician type and antidepressant category was assessed for the first,
second, and third-lines of treatment for children and then for adolescents treated for major
depressive disorder. It was concluded there was no significant difference in the antidepressant
category prescribed by physicians (child psychiatrists versus pediatricians) for children or
adolescents for either the first, second, or third-line of treatment. This result may have been due to
the fact there was a small sample size of pediatricians and there was not enough power to detect a
statistical difference between the two physician groups. These comparisons have not been reported
in the literature to date.
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Association of Physician Type and Specific Antidepressant
The relationship between physician type and the specific antidepressant prescribed was also
assessed for the first, second, and third-lines of treatment for children and then for adolescents
treated for major depressive disorder. It was concluded there was no significant difference in the
specific antidepressant prescribed by physicians (child psychiatrists versus pediatricians) for children
or adolescents for the first, second, and third-lines of treatment. This result may have been due to
the fact there was a small sample size of pediatricians and there was not enough power to detect a
statistical difference between the two physician groups. Again, these comparisons have not been
reported in the literature.
Association of Physician Characteristics and Type of Treatment Prescribed for Children and
Adolescents with Major Depressive Disorder
The association between physician characteristics and type of treatment (antidepressant treatment
versus counseling) prescribed for children, was assessed by the use of logistic regression. It was
found that the type of physician, age of the physician, and geographic region in which the physician
practiced was associated with prescribing antidepressant medication for a child with major
depressive disorder.
The odds in favor of a physician prescribing an antidepressant is 0.402 times greater for a child
psychiatrist as compared to a pediatrician. At first this finding may seem counterintuitive; however,
this study found that many child psychiatrists use counseling only as a first-line approach to treat
children and adolescents. This association of physician type and probability of prescribing an
antidepressant medication for treatment may be related, at least in part, to the fact that child
psychiatrists receive more training in conducting counseling/psychotherapy and are more confident
in their abilities to treat the child or adolescent with counseling/psychotherapy (AACAP, 2004).
The odds in favor of a physician prescribing an antidepressant medication is greater for
physicians older than 60 years of age. This finding may be related to the idea that many physicians
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rely on their own clinical experience to guide treatment choices. The current study found that a
majority of the physicians surveyed utilize their own clinical experience or that of their colleagues to
help guide their treatment choices. Perhaps even with the U.S. FDA “black box” warning many of
these physicians have successfully utilized antidepressants in children and adolescents for many
years in their own practices.
The odds in favor of physicians prescribing antidepressant medication whose practices are
located in the South, Midwest, or Pacific/West are respectively, 2.625, 2.694, and 2.421, times
greater as compared to physicians who practice in the Northeast. Geographic variation in
prescribing psychotropic medications has been documented (Cox et al., 2003; Hull et al., 2005;
Webster, Cifuentes, Verma, & Pransky, 2008). This variation has been related to the demographics
of the physicians. For example, Hull et al. (2005) reported, Asian-trained physicians were less likely
to prescribe antidepressants to adults patients. Another study attributed geographic variation to
differential training of physicians (Cox et al., 2003). The current study found that specialty of
physician (p=0.0249), physician age (p=0.0551), and geographic location (p=0.0040 to p=0.0168)
were significantly associated with physicians prescribing antidepressants as treatment. The findings
of the current study suggest an association between these variables and not causation. Therefore, to
better understand the relationships between geographic variation, physician characteristics, and the
treatment prescribed for children and adolescents with major depressive disorder, further study of
these associations is warranted.
Average Length of Treatment for Children and Adolescents
The current study found approximately two-thirds (65.15%) of child psychiatrists and one-half
(51.35%) of pediatricians continue to prescribe antidepressant medication to both children and
adolescents for a period of at least ten months.

Additionally, it was found the majority of child

psychiatrists (71.49%) and pediatrician (63.46%) prescribe antidepressant medication for
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adolescents for at least ten months. The average length of time the physicians treat children and
adolescents with antidepressant therapy was compared to the recent recommendations published by
the AACAP. These recommendations are to continue treatment for depression for at least six
months. This time frame has been associated with a lower rate of relapse of depressive symptoms.
A randomized controlled trial compared children and adolescents with major depressive disorder on
Prozac® to patients on placebo. The objective of this trial was to determine whether treatment for six
months could prevent relapse. It was concluded that the mean time to relapse was significantly
longer (p=0.046) in the patients taking Prozac® than those given placebo treatment (Emslie et al.,
2004). Therefore, based on the findings of the current study, both child psychiatrists and
pediatricians are prescribing antidepressant medications to children and adolescents in accordance
with the recently published recommendations of the AACAP (AACAP, 2207). The significance of
this finding is that both children and adolescents, who are treated by pediatricians and child
psychiatrists are receiving antidepressant medication for a sufficient length of time in order to
prevent disease relapse.
Pharmacotherapy Monitoring for Children and Adolescents
Both child psychiatrists and pediatricians reported they conduct monitoring as part of an office
visit with the child or adolescent. Furthermore, child psychiatrists and pediatricians indicated they
would conduct the monitoring themselves. Over 90% of the pediatricians and child psychiatrists
reported monitoring for adverse events, suicidality, and clinical symptoms. Some child psychiatrists
and pediatricians also indicated they conduct some type of labwork for children and adolescents
treated with an antidepressant.
Physicians were asked to indicate how frequently they monitored child and adolescent
patients during the first three months of antidepressant treatment. For the first month of treatment,
the majority of child psychiatrists monitor either once a week (41.43%) or every two weeks
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(30.71%) while pediatricians (54.35%) reported monitoring children every two weeks. During the
second month, the majority of child psychiatrists indicated they monitor either once a month
(42.65%) or every two weeks (34.05%) compared to most pediatricians (65.23%), who indicated
they monitor once a month. Throughout the third month, the preponderance of child psychiatrists
(62.72%) monitor children once a month, whereas most of pediatricians (52.18%) monitor children
at some interval greater than once a month. For adolescents, during the first month, child
psychiatrists monitor either once a week (38.95%) or every two weeks (32.98%) in comparison to
most of the pediatricians (53.70%) who monitor adolescents every two weeks. During the second
month of treatment, child psychiatrists continue to monitor once (45.77%) or twice a month
(30.28%), whereas pediatricians (62.97%) reported that they did more frequent monitoring during
the second month of treatment (once a month) than in the first month. During the third month of
treatment, child psychiatrists (62.68%) continue to monitor adolescents on antidepressant therapy
once a month. In contrast, pediatricians monitor adolescents either once a month (42.60%) or
interval greater than once a month (50.00%). The fact that physicians monitor more frequently early
in treatment may be related to the idea that antidepressants can trigger agitation in some patients, and
this agitation has been linked to an increase in suicidality (NIMH, 2009).
The frequency with, which physicians monitor children and adolescents, while they are on
antidepressant treatment, was compared to the U.S. FDA recommendations. It was concluded that
child psychiatrists and pediatricians monitor, both children and adolescents significantly less than
the U.S. FDA recommendations during the first and second month of antidepressant therapy. During
month three pediatricians still monitor children and adolescents significantly less than the U.S. FDA
recommendations. However, the frequency with which child psychiatrists monitor children and
adolescents, who are on antidepressant treatment, during the third month of treatment, does not
differ significantly from the U.S. FDA recommendations.
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A recent study compared the frequency of physician monitoring before and after the U.S. FDA
black box warning and found that less than 5% of all patients met the U.S. FDA monitoring
recommendations before or after the 2004 warning (Morrato et al., 2008). Another recent study
found that only 7.5% of “prescribing physicians” met the U.S. FDA recommendations for
monitoring frequency (Bhatia et al., 2008). The results of the current study seem to be in agreement
with other, similar studies in that physicians are not monitoring as frequently as the U.S. FDA
recommended in 2004. The rationale for the monitoring frequency, however, was not explored in
the current study.
The U.S. FDA recommends children and adolescents on antidepressant medication be monitored
as follows: one time per week for the first month of treatment, biweekly during the second month of
treatment, and at week twelve (U.S. FDA, 2004). Therefore, if child psychiatrists and pediatricians
wish to monitor according to the U.S. FDA recommendations, they need to increase the frequency of
monitoring during the first and second months of treatment. Pediatricians also need to increase
monitoring frequency for children and adolescents during the third month of antidepressant
treatment.
Variables Influencing Physicians’ Decision to Prescribe Antidepressants
Physicians were asked to rate the extent to which 28 variables influenced their decisions of
whether or not to prescribe an antidepressant to a child or adolescent with major depressive disorder.
Both child psychiatrists and pediatricians on average rated clinical experience with prescribing
antidepressants, co-existing conditions of patient (e.g. obsessive compulsive disorder), comfort in
managing major depressive disorder in youth, drug safety, drug efficacy, familiarity with an
antidepressant being prescribed, severity of major depressive disorder symptoms, and suicidal
thinking as being “influential” or “extremely influential”. Child psychiatrists also, rated potential
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adverse effects as being either “influential” or “extremely influential”, while pediatricians rated
potential adverse effects as being “not influential” or only “somewhat influential”.
Exploratory factor analysis revealed four underlying factors socio-economic status of patient,
disease severity, medication cost, and drug profile. Based on this analysis it was concluded that
these four factors influence child psychiatrists’ decision of whether or not to prescribe antidepressant
medication to a child or adolescent who had been newly diagnosed with major depressive disorder.
This was the first study to examine these relationships for children and adolescents with major
depressive disorder. However, other studies have examined the relationships between variables and
physician prescribing behavior. Patient characteristics have been found to be related to physicians
prescribing of antidepressants and medication for the treatment of panic disorder (Freeman et al.,
1993; Sleath & Shih, 2003). Disease severity and physical impairment have been shown to be
related to physicians prescribing of antidepressants and antipsychotics to adults (Benson, 1983;
Sleath & Shih, 2003). Medication cost has been found to be related to physicians prescribing
antidepressants to adults (Cates, 2001). Drug safety and efficacy have been found to influence
physicians prescribing of antidepressants and medications to treat panic disorder in adults (Cates,
2001; Freeman et al., 1993). The results of this study also show associations similar to those in the
aforementioned studies conducted for various disorders in the adult population.
Study Limitations
The limitations to the current study are related to the survey methodology employed.
Surveys can be prone to sampling error, non-response bias, measurement error, and self-report.
Steps were taken in this study to help mitigate the impact of these factors. The sample utilized in
this survey was a national random sample of pediatricians and child psychiatrists. This was done in
order to increase the generalizability of the results of the survey. The degree to which the returned
surveys were geographically representative to the original sample was not assessed in this study.
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The reason for this was that the researcher did not have access to an electronic database of the
original sample of pediatricians and child psychiatrists and data analysis was not feasible. Also, two
mailings of each survey were completed in order to increase the response rate. The length of the
survey, at eight pages was long and may have impacted the response rates to some extent.
Physicians are busy people especially, child psychiatrists, in light of the current shortage of child
psychiatrists in the United States (AACAP, 2004). Incentives have been shown to increase response
rates, however due to limited resources, offering an incentive was not feasible for this study
(Kellerman, 2001).
Non-response bias can be a problem with survey research if the respondents differ from the nonresponders. A non-response analysis was conducted, which compared early responders of the Phase
II survey to late responders (who served as a proxy for non-responders). The non-response analysis
found no statistical significant difference between early responders and non-responders. Based on
this analysis, it appears that non-response bias was not a factor in this survey.
Measurement error occurs when respondents do not understand the survey questions or surveys
instructions, and will impact the accuracy of the inferences drawn from the survey responses. A
pilot study was done in order to assess the survey instrument for Phase II. Based on the findings
from the pilot study it was concluded some of the questions and instructions regarding treatment
choices (first, second, and third-line of treatment) for children and adolescents were unclear and
were misunderstood. These questions were revised and the instructions were re-written. The
changes to the survey seemed to help clarify these issues somewhat when the final survey was sent
to the larger sample of child psychiatrists and pediatricians. Some of the child psychiatrists
(20.25%) still indicated their first-line of treatment was “counseling only”, but also listed the use of
an antidepressant for the first-line of treatment. Since the majority of these physicians also listed the
same antidepressant in the second-line of treatment, the researchers made the assumption that
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“counseling only” was truly their first-line of treatment and the antidepressant chosen was their
second-line of treatment. This is a reasonable assumption; however, if a similar survey is conducted
in the future the wording of these questions should be re-examined and pilot tested to further ensure
clarity.
This study surveyed a national sample of both pediatricians and child psychiatrists. Thus, the
results from the study should be generalizable. A response rate of 22.9% was obtained for Phase I of
the study and a response rate of 15.1% was obtained for the surveyed child psychiatrists (Phase II).
However, only 57 pediatricians’ surveys were usable out of the 110 mailed in Phase II. This was a
function of the finding that 60% of the pediatricians in Phase I do not treat children or adolescents
for major depressive disorder. Unfortunately, this impacted some of the planned analyses for this
population. For instance, factor analysis requires at a very minimum five subjects for every variable
(Hatcher, 1994). In this study, there were 28 variables and a minimum of 140 subjects needed to
conduct factor analysis. The 57 pediatricians did not meet these minimum standards. The small
sample size of pediatricians in Phase II is also a cause for concern in comparisons between
pediatricians and child psychiatrists. Post hoc power analyses failed to demonstrate adequate power
to conduct many of these comparisons. The associations between physician type and class of
antidepressant (SSRIs versus Non-SSRIs) and then specific type of antidepressant (Prozac® versus
Non-Prozac®) were tested. None of these comparisons resulted in statistically significant
associations. For these comparisons, the actual sample sizes for the pediatricians ranged from 9 to
57, and for the child psychiatrists ranged from 175 to 294. The significance level was α =0.05 and
the post hoc power for these comparisons resulted in 0.51 or less power for all comparisons (Cohen,
1988). For other objectives the t-test statistic was utilized to test for differences between the average
number of times pediatricians and child psychiatrists monitor patients during months one, two, and
three of antidepressant treatment. The sample sizes for the pediatricians ranged from 45-53, and
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ranged from 251-272 for child psychiatrists. The observed power for these comparisons ranged
from 0.05 – 0.88 power. The sample size of 53 pediatricians and 269 child psychiatrists, achieved
0.88 power to detect an effect size of d=0.47 (d=0.50 represents a “medium” effect size) using a ttest with a significance level of α =0.05 (Cohen, 1988). Power analyses were conducted using the
computer programs PASS® or G*Power 3 (Erdfelder, 1996). In summary, the number of
pediatricians was not adequate to conduct all of the comparisons, with adequate power, between
pediatricians and child psychiatrists for this study. Additionally, because of the limited number of
pediatricians in Phase II, caution should be exercised when extrapolating the findings from this
survey to the entire population of pediatricians in the U.S.
Overall Conclusions
In the absence of empirical research to guide the selection of antidepressant treatment, research
was necessary to examine: what physicians consider to be the most appropriate antidepressant
treatment, physicians’ recommended course of treatment (i.e., length of treatment, monitoring), and
the factors which impact physicians’ decisions to treat major depressive disorder in children and
adolescents with antidepressants.
In achieving these goals some preliminary information needed to be collected on pediatricians, in
Phase I. The findings from this phase provide a basis for calculating a sample size for future surveys
of pediatricians who treat children and/or adolescents with major depressive disorder and allowed
for the identification of pediatricians eligible for Phase II of this study.
The treatment of depression is an individualized choice and therefore strict guidelines for
treatment choices do not exist. The AACAP has published Practice Parameters to outline the
treatments that have been shown, through randomized clinical trials, to be effective in the treatment
of major depressive disorder in children and adolescents. These parameters are meant to help direct
physicians in treating children and adolescents with major depressive disorder, but in no way dictate
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proper treatment of these patients. The current study gathered information on pediatricians’ and
child psychiatrists’ preferred treatment choices for children and adolescents with major depressive
disorder and these preferences are in line with the current AACAP Practice Parameters.
The current study gathered information on the frequency with which physicians monitor children
and adolescents who are prescribed antidepressant medication. These findings indicate pediatricians
and child psychiatrists are not monitoring as frequently as the U.S. FDA recommends. The reasons
for this are not known.
Exploratory factor analysis did reveal four underlying factors (socio-economic status of patient,
disease severity, medication cost, and drug profile) related to the physicians’ decision of whether or
not to prescribe antidepressant treatment. The associations between physician characteristics
(specialty of physician, geographic location of practice, and physician age) and the treatment
prescribed were also found in this study and concur with similar studies in other patient populations.
Future Research
Four areas of future research were identified. First, the study gathered preliminary information
regarding pediatricians’ treatment of children and adolescents with major depressive disorder.
Since this information is now available, it will be possible to conduct a larger, more representative
study regarding pediatricians’ treatment choices for treating children and adolescents with major
depressive disorder. Additionally, a larger study of pediatricians can investigate in more detail areas
why pediatricians lack training and skills to diagnose and treat major depressive disorder.
Second, the study collected information on pediatricians’ and child psychiatrists’ treatment
choices for children and adolescents with major depressive disorder. However, it did not investigate
the rationale behind these choices. For example, although the majority of physicians treat patients
with a combination of antidepressants and counseling, some physicians opt to treat with counseling
only as a fist-line of therapy. Additionally, as a third-line of treatment, many physicians treat with
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other type of medications such as, antipsychotics or mood stabilizers. Also, the most popular
choices for antidepressant treatment were Prozac® and Zoloft®. Future studies should also explore
why these were the choices of the physicians surveyed.
Third, according to the findings of this study and other recent studies (Bhatia et al., 2008;
Morrato et al., 2008), pediatricians and child psychiatrists do not monitor as frequently as the U.S.
FDA recommendations. The reasons for this could not be determined from this study and should be
an area for further research.
Fourth, the researcher found that the socio-economic status of the patient, disease severity,
medication cost, and drug profile are related to the physicians’ decision of whether or not to
prescribe antidepressant treatment. Also, associations between physician characteristics (specialty,
age, and geographic location) and the treatment prescribed were found in this study. In order to
better understand these relationships, these associations warrant further investigation.
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APPENDIX A
Identification of Physicians Treating Children and Adolescents with Major Depressive
Disorder (MDD)

Instructions: This survey is designed to identify physicians who treat children and adolescents
with MDD and who are willing to participate in a larger study related to MDD in children and
adolescents.

1. Please check all age group(s) whom you treat in an outpatient setting for MDD.
 Children (5 – 12 years old)
 Adolescents (13 – 18 years old)
 Do not treat
2. Please check all age group(s) whom you refer for the treatment of MDD and
indicate the type of health care provider to whom you refer these patients.
 Refer children (5 - 12 years) to ___________________________________.
 Refer adolescents (13 - 18 years) to _______________________________.
 Do not refer
3. If you treat children and/or adolescents with MDD, are you willing to participate
in a more in-depth questionnaire designed to gain information about physicians’
prescribing habits in treating those patients?
 Yes
 No

Comments: Please use this space to provide additional comments.

THANK YOU FOR YOUR TIME AND ASSISTANCE!
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APPENDIX B
Physician Prescribing Behavior and Factors Related to Antidepressant Prescribing to
Children and Adolescents with Major Depressive Disorder (MDD)
Instructions: This survey is designed to determine 1) your first, second, and third-lines of
outpatient treatment for children and/or adolescents who have been diagnosed with MDD, 2) the
type and length of pharmacotherapy monitoring you conduct, and 3) the factors that influence your
decision to prescribe an antidepressant. The survey is divided into eight sections.
For this survey, the definition of major depressive disorder is a condition that is “manifested by
a combination of symptoms that interfere with the ability to work, study, sleep, eat, and enjoy once
pleasurable activities“(NIMH, 2007). MDD can be diagnosed using the criteria set forth by the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). In the scientific literature,
children are typically defined as being 5 through 12 years of age while adolescents are 13 through
18 years old. This survey will utilize these definitions of age for both children and adolescents.
Reference: National Institute of Mental Health. (2007). Retrieved October 15, 2007, from
http://www.nimh.nih.gov/health/publications/depression/what-is-a-depressive-disorder.shtml.

Section 1: Outpatient Treatment versus Referral of Children and Adolescents
with Major Depressive Disorder (MDD)
1. Please check all age group(s) whom you treat for MDD.
 Children (5 – 12 years old)
 Adolescents (13 – 18 years old)
 Do not treat (please skip to Section 8, Question #23)
2. Please check the age group(s) of patients you refer for the treatment of MDD and indicate the type of
health care provider to whom you refer these patients.
 Refer children (5 - 12 years) to ___________________________________.
 Refer adolescents (13 - 18 years) to _______________________________.
 Do not refer
3. Please indicate the youngest patient (under 13 years of age) with MDD to whom you would consider
prescribing an antidepressant medication.
 1 – 4 years
 5 – 7 years
 8 – 10 years
 11 – 12 years
 Do not prescribe for children less than 13 years

Section 2: Preferred First-Line Outpatient Treatment
4. Check your first-line of outpatient treatment, for children and/or adolescents who have been newly
diagnosed with MDD.
Children (5-12 years)

Adolescents (13-18 years)

 Antidepressants only

 Antidepressants only

 Counseling/psychotherapy only

 Counseling/psychotherapy only

 Both antidepressant and
counseling/psychotherapy

 Both antidepressant and
counseling/psychotherapy

 Other, please specify

 Other, please specify
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If your first-line of treatment (in Question #4) included antidepressants (either alone or
in combination with counseling/psychotherapy), for EITHER children or adolescents
please answer Questions #5 - #8, otherwise skip to Section 3, Question #9.
5. As indicated in Question #4, check the ONE antidepressant (either alone or in combination with
counseling/psychotherapy) you would most commonly select as a typical first-line treatment for that
child (5-12 years old) and/or adolescent (13-18 years old) newly diagnosed with MDD.





















Child (5-12 years)
®
Celexa (citalopram HBr)
®
Cymbalta (duloxetine HCl)
®
Effexor (venlafaxine HCl)
®
Elavil (amitriptyline HCl)
®
Desyrel (trazodone HCl)
®
Lexapro (escitalopram oxalate)
®
Luvox (fluvoxamine maleate)
®
Nardil (phenelzine sulfate)
®
Norpramin (desipramine HCl)
®
Pamelor (nortriptyline HCl)
®
Paxil (paroxetine HCl)
®
Parnate (tranlcypromine sulfate)
®
Prozac (fluoxetine HCl)
®
Remeron (mirtazpine)
®
Serzone (nefazodone HCl)
®
Tofranil (imipramine HCl)
®
Wellbutrin (buproprion HCl)
®
Zoloft (sertraline HCl)
Other, please specify





















Adolescent (13-18 years)
®
Celexa (citalopram HBr)
®
Cymbalta (duloxetine HCl) 
®
Effexor (venlafaxine HCl) 
®
Elavil (amitriptyline HCl) 
®
Desyrel (trazodone HCl)

®
Lexapro (escitalopram oxalate)
®
Luvox (fluvoxamine maleate) 
®
Nardil (phenelzine sulfate) 
®
Norpramin (desipramine HCl) 
®
Pamelor (nortriptyline HCl)

®
Paxil (paroxetine HCl)

®
Parnate (tranlcypromine sulfate) 
®
Prozac (fluoxetine HCl)

®
Remeron (mirtazpine)

®
Serzone (nefazodone HCl)

®
Tofranil (imipramine HCl)

®
Wellbutrin (buproprion HCl)

®
Zoloft (sertraline HCl)

Other, please specify

6. For the first-line antidepressant(s) selected above, please indicate the standard total daily starting dosage
and the standard maximum total daily dosage you use for an outpatient child and/or adolescent with MDD.
Drug Dosage
Starting dosage
(mg/day)
Maximum dosage
(mg/day)

Child (5-12 years)

Adolescent (13-18 years)

_______________mg

_______________mg

_______________mg

_______________mg

7. If antidepressant therapy is successful, how long do you continue prescribing the antidepressant(s)
to the newly diagnosed outpatient child and/or adolescent? (Check one)
Child (5-12 years)
 1-3 months
 4-6 months
 7-9 months
10-12 months
 > 12 months

Adolescent (13-18 years)
 1-3 months
 4-6 months
 7-9 months
10-12 months
 > 12 months
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8. If there is no improvement in the depressive symptoms of the child and/or adolescent, after reaching the
antidepressant’s tolerated maximum prescribed dosage (assuming no adverse events), how long do you
continue to prescribe the drug before considering another treatment approach? (Check one)
Child (5-12 years)
 < 2 weeks
2 – 4 weeks
5 – 6 weeks
7 – 8 weeks
9 –10 weeks
> 10 weeks

Adolescent (13-18 years)
 < 2 weeks
2 – 4 weeks
5 – 6 weeks
7 – 8 weeks
9 –10 weeks
> 10 weeks

Section 3: Preferred Second-Line Outpatient Treatment
9. Assuming you have re-evaluated and confirmed the diagnosis of MDD, if there are no improvements in
depressive symptoms with the first-line treatment, what would you typically recommend as your next step
in outpatient treatment for this child and/or adolescent? (Check one)
Child (5-12 years)
Augment with antidepressant therapy
Switch to a different antidepressant
Augment with counseling/psychotherapy

Adolescent (13-18 years)
Augment with antidepressant therapy
Switch to a different antidepressant
Augment with counseling/psychotherapy

Other treatment, please specify


Other treatment, please specify


10. If you indicated above (Question # 9) you would augment with antidepressant therapy or switch to a
different antidepressant, what would you typically prescribe as your second-line of treatment for this
child and/or adolescent (otherwise please skip to Question #11)?
Child (5-12 years)
Antidepressant

Adolescent (13-18 years)

_______________

_______________

Section 4: Preferred Third-Line Outpatient Treatment
11. If there are no improvements in depressive symptoms with the second-line treatment, what would you
typically recommend as your next step in outpatient treatment for this child and/or adolescent?
(Check one)
Child (5-12 years)
Augment with antidepressant therapy
Switch to a different antidepressant
Augment with counseling/psychotherapy

Adolescent (13-18 years)
Augment with antidepressant therapy
Switch to a different antidepressant
Augment with counseling/psychotherapy

Other treatment, please specify


Other treatment, please specify


12. If you indicated above (Question # 11) you would augment with antidepressant therapy or switch to a
different antidepressant, what would you typically prescribe as your third-line of treatment for this
child and/or adolescent (otherwise please skip to Question #13)?
Child (5-12 years)
Antidepressant

_______________
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Adolescent (13-18 years)
_______________

Section 5: Counseling/Psychotherapy
13. If you believe the child and/or adolescent should have counseling/psychotherapy, would you refer to a
counselor or psychotherapist or conduct the counseling/psychotherapy yourself? (Check one)
 Refer the child and/or adolescent to ________________________________
 Conduct my own therapy (please skip to Question # 15)
 Do not utilize counseling/psychotherapy (please skip to Section #6, Question #16)
14. If you refer a child and/or adolescent with MDD for counseling/psychotherapy treatment, please
indicate how far, in approximate miles, the patient would have to travel, from their residence, to visit a
counselor/psychotherapist. ____________________ Miles (please skip to Section 6, Question #16)
15. If you conduct your own counseling/psychotherapy, please rank the following types of
counseling/psychotherapy based on how likely you would be to utilize them when treating a child and/or
adolescent, newly diagnosed with MDD. Rank the following types from 1 – 7, where 1 = the type you
would most likely recommend or utilize and 7 = the type you would least likely recommend or
utilize.
Rank

Children (5-12 years)
Cognitive behavioral therapy
Family therapy
Interpersonal therapy
Patient education
Play therapy
Psychodynamic therapy
Supportive counseling

Rank

Adolescents (13-18 years)
Cognitive behavioral therapy
Family therapy
Interpersonal therapy
Patient education
Play therapy
Psychodynamic therapy
Supportive counseling

Section 6: Pharmacotherapy Monitoring of Outpatient Children and Adolescents
If you do not utilize pharmacotherapy, please skip to Section 7, Question #22
16. Check the primary mode of monitoring outpatient children and/or adolescents who are receiving an
antidepressant for MDD? (Check one)
Children (5-12 years)
Individual patient office visit
Telephone contact
Patient medication group
Other, please specify


Adolescents (13-18 years)
Individual patient office visit
Telephone contact
Patient medication group
Other, please specify


17. Check the primary type of health care provider who conducts the monitoring? (Check one)
Children (5-12 years)
Physician
Nurse/Nurse Practitioner
Counselor/Psychotherapist
Pharmacist
Physician Assistant
Other, please specify

Adolescents (13-18 years)
Physician
Nurse/Nurse Practitioner
Counselor/Psychotherapist
Pharmacist
Physician Assistant
Other, please specify
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18. Check all types of monitoring conducted for outpatient children and/or adolescents taking an
antidepressant for MDD?
Children (5-12 years)
Monitor for adverse events
Monitor for suicidality
Conduct labwork related to treatment 
Monitor clinical symptoms (e.g. sleep,
appetite, energy, activities) 
Other, please specify

Adolescents (13-18 years)
Monitor for adverse events
Monitor for suicidality
Conduct labwork related to treatment 
Monitor clinical symptoms (e.g. sleep,
appetite, energy, activities) 
Other, please specify

19. During the first month of treatment, check the most appropriate timeline you use, on average, to
monitor outpatient children and/or adolescents taking an antidepressant for MDD?
Children (5-12 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


Adolescents (13-18 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


20. During the second month of treatment, check the most appropriate timeline you use, on average, to
monitor outpatient children and/or adolescents taking an antidepressant for MDD?
Children (5-12 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


Adolescents (13-18 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


21. During the third month of treatment, check the most appropriate timeline you use, on average, to
monitor outpatient children and/or adolescents taking an antidepressant for MDD?
Children (5-12 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


Adolescents (13-18 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify
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Section 7: Factors Influencing Whether or Not to Prescribe an Antidepressant
22. Please circle the number that best represents the extent to which the following factors influence your
decision of whether or not to prescribe an antidepressant to a newly diagnosed child or adolescent with
MDD, in an outpatient setting (e.g. selecting an antidepressant versus some other type of treatment).
Not
Somewhat
Extremely
Factor
Influential
Influential
Influential
Influential
Advertisements to physicians via journals
and/or mail
1
2
3
4
Availability of patient education materials

1

2

3

4

Clinical experience with prescribing
antidepressants

1

2

3

4

Co-existing conditions of patient (e.g.
obsessive compulsive disorder)

1

2

3

4

Comfort in managing MDD in youth

1

2

3

4

Direct-to-consumer advertising

1

2

3

4

Drug efficacy

1

2

3

4

Drug safety

1

2

3

4

Face-to-face detailing by medical
sciences liaison and/or pharmaceutical
representatives
Familiarity with an antidepressant being
prescribed

1

2

3

4

1

2

3

4

FDA approved

1

2

3

4

Formulary inclusion

1

2

3

4

Frequency of dosing

1

2

3

4

Generic form of drug available

1

2

3

4

Manufacturer provides free drugs to
indigent patients

1

2

3

4

Medication cost

1

2

3

4

Monitoring requirements

1

2

3

4

Parents’ education level

1

2

3

4

Parental use of antidepressants

1

2

3

4

Patient's ability to perform daily activities

1

2

3

4

Patient's age

1

2

3

4

Patient's family income

1

2

3

4

Patient's gender

1

2

3

4

Patient's insurance

1

2

3

4

Potential adverse effects

1

2

3

4

Sample drugs available

1

2

3

4

Severity of MDD symptoms

1

2

3

4

Suicidal thinking

1

2

3

4
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Section 8: Demographic Information
23. Please indicate your gender:
 Male
 Female
24. Please indicate your age-group:
30 years or younger
31 to 40 years
41 to 50 years
51 to 60 years
61 years and older
25. Year of graduation from medical school: __________
26. Your primary practice site:
Hospital based: non-university-affiliated
Hospital based: university-affiliated
Private practice: solo, office-based
Private practice: group, office-based
Other, please specify _______________
27. In which state is your primary practice site located?

__________

28. Check the population of the community where your primary practice site is located?
 Less than 10,000
 10,000 - 24,999
 25,000 - 49,999
 50,000 -. 99,999
 100,000 - 249,999
 250,000 - 499,999
 500,000 - 999,999
 1 million or more
29. Please check all of your practice specialties:
 Adult psychiatry
 Child & adolescent psychiatry
 Family practice
 General practice
 Pediatrics
 Other, please specify _____________
30. Please check all of your board certifications:
 Adult psychiatry
 Child & adolescent psychiatry
 Family practice
 General practice
 Pediatrics
 Not board certified
 Other, please specify _____________
31. Average number of children (5 – 12 years) with MDD seen in your office. _________ per week
32. Average number of adolescents (13 – 18 years) with MDD seen in your office. ______ per week
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33. How long have you treated children and/or adolescents?
 One year or less
 Greater than one year to five years
 Greater than five years to 10 years
 Greater than 10 years
34. Check all reasons that influence your choice of treatment for children and/or adolescents with MDD.
Results of randomized clinical trials
Results of pilot studies, chart reviews, case studies, letters to the editor
Own clinical experience
Clinical experience of colleagues
Other, please specify ____________________
35. Are you aware of the U.S. FDA black box warning for antidepressant medication for children and/or
adolescents?
 Yes
 No
36. Has the U.S. FDA black box warning had any impact on your decision-making about treatment of
children and/or adolescents with MDD?
 Yes (Go to Question 37)
 No
37. Please describe any major changes you have made in
the treatment of MDD in children and/or adolescents as a
result of the FDA black box warning.
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________

Comments : Please use this space to provide additional comments.

THANK YOU FOR YOUR TIME AND ASSISTANCE!
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APPENDIX C
Physician Prescribing Behavior and Factors Related to Antidepressant Prescribing to
Children and Adolescents with Major Depressive Disorder (MDD)
Instructions: This survey is designed to determine 1) your first, second, and third-lines of
treatment for outpatient children and/or adolescents who have been diagnosed with MDD, 2) the
type and length of pharmacotherapy monitoring you conduct, and 3) the factors that influence your
decision to prescribe an antidepressant. The survey is divided into six sections.
For this survey, the definition of major depressive disorder is a condition that is “manifested by
a combination of symptoms that interfere with the ability to work, study, sleep, eat, and enjoy once
pleasurable activities“(NIMH, 2007). MDD can be diagnosed using the criteria set forth by the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). In the scientific literature,
children are typically defined as being 5 through 12 years of age while adolescents are 13 through
18 years old. This survey will utilize these definitions of age for both children and adolescents.
Reference: National Institute of Mental Health. (2007). Retrieved October 15, 2007, from
http://www.nimh.nih.gov/health/publications/depression/what-is-a-depressive-disorder.shtml.

Section 1: Treatment versus Referral of Outpatient Children and Adolescents
with Major Depressive Disorder (MDD)

1. Please check all age group(s) whom you treat for MDD.
 Children (5 – 12 years old)
 Adolescents (13 – 18 years old)
 Do not treat
2. Please check the age group(s) of patients you refer for the treatment of MDD and indicate the type of
health care provider to whom you refer these patients.
 Refer children (5 - 12 years) to ___________________________________.
 Refer adolescents (13 - 18 years) to _______________________________.
 Do not refer
3. Please indicate the youngest patient (under 13 years of age) with MDD to whom you would consider
prescribing an antidepressant medication.
 1 – 4 years
 5 – 7 years
 8 – 10 years
 11 – 12 years
 Do not prescribe for children less than 13 years

Section 2: Preferred Outpatient Treatment
4. Check your first-line of outpatient treatment, for children and/or adolescents who have been newly
diagnosed with MDD.
Children (5-12 years)
Adolescents (13-18 years)
 Do not treat
 Do not treat
 Antidepressants
 Antidepressants
 Counseling/psychotherapy
 Counseling/psychotherapy
 Both antidepressant and
 Both antidepressant and
Counseling/psychotherapy
counseling/psychotherapy
 Other, please specify
 Other, please specify
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5. Check ALL reasons, why this would be your first choice for treatment
 Results of randomized clinical trials
 Results of pilot studies, chart reviews, case studies, letters to the editor
 Own clinical experience
 Clinical experience of colleagues
 Other, please specify ____________________
6. Check the ONE antidepressant (either alone or in combination with counseling/psychotherapy) you would
most commonly select as a typical first-line outpatient antidepressant treatment for a child (5-12 years old)
and/or adolescent (13-18 years old) newly diagnosed with MDD?





















Child (5-12 years)
Celexa (citalopram HBr)
®
Cymbalta (duloxetine HCl)
®
Effexor (venlafaxine HCl)
®
Elavil (amitriptyline HCl)
®
Desyrel (trazodone HCl)
®
Lexapro (escitalopram oxalate)
®
Luvox (fluvoxamine maleate)
®
Nardil (phenelzine sulfate)
®
Norpramin (desipramine HCl)
®
Pamelor (nortriptyline HCl)
®
Paxil (paroxetine HCl)
®
Parnate (tranlcypromine sulfate)
®
Prozac (fluoxetine HCl)
®
Remeron (mirtazpine)
®
Serzone (nefazodone HCl)
®
Tofranil (imipramine HCl)
®
Wellbutrin (buproprion HCl)
®
Zoloft (sertraline HCl)
Other, please specify
®





















Adolescent (13-18 years)
Celexa (citalopram HBr)
®
Cymbalta (duloxetine HCl) 
®
Effexor (venlafaxine HCl) 
®
Elavil (amitriptyline HCl) 
®
Desyrel (trazodone HCl)

®
Lexapro (escitalopram oxalate)
®
Luvox (fluvoxamine maleate) 
®
Nardil (phenelzine sulfate) 
®
Norpramin (desipramine HCl) 
®
Pamelor (nortriptyline HCl)

®
Paxil (paroxetine HCl)

®
Parnate (tranlcypromine sulfate) 
®
Prozac (fluoxetine HCl)

®
Remeron (mirtazpine)

®
Serzone (nefazodone HCl)

®
Tofranil (imipramine HCl)

®
Wellbutrin (buproprion HCl)

®
Zoloft (sertraline HCl)

Other, please specify
®

7. For the first-line antidepressant(s) selected above, please indicate the standard total daily starting dosage
and the standard maximum total daily dosage you use for an outpatient child and/or adolescent with MDD.
Drug Dosage
Starting dosage
(mg/day)
Maximum dosage
(mg/day)

Child (5-12 years)

Adolescent (13-18 years)

_______________mg

_______________mg

_______________mg

_______________mg

8. If antidepressant therapy is successful, how long do you continue prescribing the antidepressant(s)
to the newly diagnosed outpatient child and/or adolescent? (Check one)
Child (5-12 years)
Adolescent (13-18 years)

1-3 months

1-3 months

4-6 months

4-6 months

7-9 months

7-9 months
10-12 months
10-12 months
 > 12 months
 > 12 months
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9. If there is no improvement in the depressive symptoms of the child and/or adolescent, after reaching the
antidepressant’s tolerated maximum prescribed dosage (assuming no adverse events), how long do you
continue to prescribe the drug before considering another treatment approach? (Check one)
Child (5-12 years)
 < 2 weeks
2 – 4 weeks
5 – 6 weeks
7 – 8 weeks
9 –10 weeks
> 10 weeks

Adolescent (13-18 years)
 < 2 weeks
2 – 4 weeks
5 – 6 weeks
7 – 8 weeks
9 –10 weeks
> 10 weeks

10. If there is no improvement in depressive symptoms with the first-line antidepressant, what would you
typically prescribe as your next step in outpatient treatment for this child and/or adolescent? (Check one)
Child (5-12 years)
Augment antidepressant therapy
Switch to a different antidepressant
Augment with counseling/psychotherapy

Adolescent (13-18 years)
Augment antidepressant therapy
Switch to a different antidepressant
Augment with counseling/psychotherapy

Other treatment, please specify


Other treatment, please specify


11. If you indicated above that you would augment antidepressant therapy or switch to a different
antidepressant, what would you typically prescribe as your second-line of antidepressant treatment for
this child and/or adolescent?
Child (5-12 years)

Adolescent (13-18 years)

nd

2 -Line
Antidepressant

_______________

_______________

12. If there is no improvement in depressive symptoms with the second-line antidepressant, what would you
typically prescribe as your third-line of antidepressant treatment for this child and/or adolescent?
Child (5-12 years)

Adolescent (13-18 years)

rd

3 -Line
Antidepressant

_______________

_______________

Section 3: Counseling/Psychotherapy
13. If you believe the child and/or adolescent should have counseling/psychotherapy, would you refer to a
counselor or psychotherapist or conduct the counseling/psychotherapy yourself? (Check one)
 Refer the child and/or adolescent to ________________________________
 Conduct my own therapy
 Do not utilize counseling/psychotherapy
14. If you refer a child and/or adolescent with MDD for counseling/psychotherapy treatment, please
indicate how far, in approximate miles, the patient would have to travel to visit a
counselor/psychotherapist. ____________________ Miles
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15. What type of counseling/psychotherapy, would you most likely recommend/utilize? (Check all that
apply)
Children (5-12 years)
Cognitive behavioral therapy
Family therapy
Interpersonal therapy
Patient education
Play therapy
Supportive counseling
Do not utilize counseling/psychotherapy
Other, Please Specify

Adolescents (13-18 years)
Cognitive behavioral therapy
Family therapy
Interpersonal therapy
Patient education
Play therapy
Supportive counseling
Do not utilize counseling/psychotherapy
Other, Please Specify

Section 4: Pharmacotherapy Monitoring of Outpatient Children and Adolescents
16. Check the primary mode of monitoring outpatient children and/or adolescents who are receiving an
antidepressant for MDD?
Children (5-12 years)
Individual patient office visit
Telephone contact
Patient medication group
Other, please specify


Adolescents (13-18 years)
Individual patient office visit
Telephone contact
Patient medication group
Other, please specify


17. Check the primary type of health care provider who conducts the monitoring?
Children (5-12 years)
Physician
Nurse
Counselor/Psychotherapist 
Pharmacist
Other, please specify


Adolescents (13-18 years)
Physician
Nurse
Counselor/Psychotherapist 
Pharmacist
Other, please specify


18. Check ALL types of monitoring conducted for outpatient children and/or adolescents taking an
antidepressant for MDD?
Children (5-12 years)
Monitor for adverse events
Monitor for suicidality
Conduct labwork 
Monitor clinical symptoms (e.g. sleep,
appetite, energy, activities) 
Other, please specify

Adolescents (13-18 years)
Monitor for adverse events
Monitor for suicidality
Conduct labwork 
Monitor clinical symptoms (e.g. sleep,
appetite, energy, activities) 
Other, please specify
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19. During the first month of treatment, check the most appropriate timeline you use, on average, to
monitor outpatient children and/or adolescents taking an antidepressant for MDD?
Children (5-12 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


Adolescents (13-18 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


20. During the second month of treatment, check the most appropriate timeline you use, on average, to
monitor outpatient children and/or adolescents taking an antidepressant for MDD?
Children (5-12 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


Adolescents (13-18 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


21. During the third month of treatment, check the most appropriate timeline you use, on average, to
monitor outpatient children and/or adolescents taking an antidepressant for MDD?
Children (5-12 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


Adolescents (13-18 years)
Two times per week
Once a week
Every 2 weeks
Every 3 weeks
Once a month
Greater than 1 month
Other, please specify


Please continue to the next page
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Section 5: Factors Influencing Your Decisions to Prescribe
22. Please circle the number that best represents the extent to which the following factors influence your
decision of whether or not to prescribe an antidepressant to a newly diagnosed child or adolescent with
MDD, in an outpatient setting (e.g. selecting an antidepressant versus some other type of treatment).

Not
Influential

Somewhat
Influential

Influential

Extremely
Influential

1

2

3

4

1

2

3

4

1

2

3

4

1
1
1

2
2
2

3
3
3

4
4
4

1
1

2
2

3
3

4
4

1

2

3

4

1
1

2
2

3
3

4
4

1
1
1

2
2
2

3
3
3

4
4
4

1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4

Patient's gender

1

2

3

4

Patient's insurance

1

2

3

4

Potential adverse effects

1

2

3

4

Sample drugs available
Severity of MDD symptoms
Suicidal thinking

1
1
1

2
2
2

3
3
3

4
4
4

Factor
Advertisements to physicians via journals
and/or mail
Availability of patient education materials
Clinical experience with prescribing
antidepressants
Co-existing conditions of patient (e.g.
obsessive compulsive disorder)
Comfort in managing MDD in youth
Direct-to-consumer advertising
Drug efficacy
Drug safety
Face-to-face detailing by medical
sciences liaison and/or pharmaceutical
representatives
Familiarity with an antidepressant being
prescribed
FDA approved
Formulary inclusion
Frequency of dosing
Generic form of drug available
Manufacturer provides free drugs to
indigent patients
Medication cost
Monitoring requirements
Parents’ education level
Parental use of antidepressants
Patient's ability to perform daily activities
Patient's age
Patient's family income
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Section 6: Demographic Information
23. Please indicate your gender:
 Male
 Female
24. Please indicate your age-group:
30 years or younger
31 to 40 years
41 to 50 years
51 to 60 years
61 years and older
25. Year of graduation from medical school: __________
26. Your primary practice site:
Hospital based: non-university-affiliated
Hospital based: university-affiliated
Private practice: solo, office-based
Private practice: group, office-based
Other, please specify _______________
27. In which state is your primary practice site located?

__________

28. Check the population of the community where your primary practice site is located?
 Less than 10,000
 10,000 - 24,999
 25,000 - 49,999
 50,000 -. 99,999
 100,000 - 249,999
 250,000 - 500,000
 500,000 - 999,999
 1 million or more
29. Please check all of your practice specialties:
 Adult psychiatry
 Child & adolescent psychiatry
 Family practice
 General practice
 Pediatrics
 Other, please specify _____________
30. Please check all of your board certifications:
 Adult psychiatry
 Child & adolescent psychiatry
 Family practice
 General practice
 Pediatrics
 Not board certified
 Other, please specify _____________
31. Average number of children (5 – 12 years) with MDD seen in your office. _________ per week
32. Average number of adolescents (13 – 18 years) with MDD seen in your office. ______ per week
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33. How long have you treated children and/or adolescents?
 One year or less
 Greater than one year to five years
 Greater than five years to 10 years
 Greater than 10 years
34. Are you aware of the U.S. FDA black box warning for antidepressant medication for children and/or
adolescents?
 Yes
 No
35. Has the U.S. FDA black box warning had any impact on your decision-making about treatment of
children and/or adolescents with MDD?
 Yes (Go to Question 36)
 No
36. Please describe any major changes you have made in
the treatment of MDD in children and/or adolescents as a
result of the FDA black box warning.
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________

Comments : Please use this space to provide additional comments.

THANK YOU FOR YOUR TIME AND ASSISTANCE!
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APPENDIX D

November 26, 2007

Dear Physician:
My name is Andrea Pfalzgraf, a Doctoral Candidate in the Department of Pharmaceutical
Systems and Policy at West Virginia University (WVU) School of Pharmacy. My dissertation
consists of conducting a national survey of pediatricians and child psychiatrists who may be
involved in treating children and/or adolescents with major depressive disorder in an outpatient
setting. This research study is designed to examine the prescribing behavior and the factors that
influence the prescribing behavior of antidepressant medication to children and adolescents with
major depressive disorder. The enclosed survey is designed to identify physicians who treat children
and adolescents with major depressive disorder and who would be willing to participate in the study.
The enclosed questionnaire will take only a few minutes to complete. Your participation is
voluntary and you are not required to answer every question in the survey. Your responses will be
kept as confidential as legally possible and will be analyzed and reported in aggregate form. .
If you choose to participate, please complete the survey and mail in the enclosed business reply
envelope. Any questions related to the questionnaire may be directed to Andrea Pfalzgraf, 412-2256845 or Dr. Ginger Scott at 304-293-1553. Thank you in advance for your valuable time and
information.

Sincerely,

Andrea Pfalzgraf, MPH
Doctoral Candidate

Virginia (Ginger) Scott, PhD, MS, RPh
Professor and Advisor

WVU IRB reviewed and acknowledged
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APPENDIX E
January 10, 2008
Dear Physician:
My name is Andrea Pfalzgraf, a Doctoral Candidate in the Department of Pharmaceutical
Systems and Policy at West Virginia University (WVU) School of Pharmacy. My dissertation
consists of conducting a national survey of pediatricians and child psychiatrists who may be
involved in treating children and/or adolescents with major depressive disorder in an outpatient
setting. This research study is designed to examine the prescribing behavior and the factors that
influence the prescribing behavior of antidepressant medication to children and adolescents with
major depressive disorder.
The enclosed questionnaire will take less than ten minutes to complete. Your participation is
voluntary and you are not required to answer every question in the survey. However, your input is
essential to determine antidepressant prescribing behavior of physicians and the factors that
influence the prescribing behavior of physicians in children and adolescents with major depressive
disorder in an outpatient setting. Your responses will be kept as confidential as legally possible and
will be analyzed and reported in aggregate form.
If you choose to participate, please complete the survey and mail in the enclosed business reply
envelope. Any questions related to the questionnaire may be directed to Andrea Pfalzgraf, 412-2256845 or Dr. Ginger Scott at 304-293-1553. Thank you in advance for your valuable time and
information.
Sincerely,

Andrea Pfalzgraf, MPH
Doctoral Candidate

Virginia (Ginger) Scott, PhD, MS, RPh
Professor and Advisor
WVU IRB reviewed and acknowledged
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APPENDIX F
January 10, 2008
Dear Physician:
Recently you indicated you would be willing to participate in a survey that is an integral part of
my dissertation, as a Doctoral Candidate in the Department of Pharmaceutical Systems and Policy at
West Virginia University (WVU) School of Pharmacy. My dissertation consists of conducting a
national survey of pediatricians and child psychiatrists who may be involved in treating children
and/or adolescents with major depressive disorder in an outpatient setting. This research study is
designed to examine the prescribing behavior and the factors that influence the prescribing behavior
of antidepressant medication to children and adolescents with major depressive disorder.
The enclosed questionnaire will take less than ten minutes to complete. Your participation is
voluntary and you are not required to answer every question in the survey. However, your input is
essential to determine antidepressant prescribing behavior of physicians and the factors that
influence the prescribing behavior of physicians in children and adolescents with major depressive
disorder in an outpatient setting. Your responses will be kept as confidential as legally possible and
will be analyzed and reported in aggregate form.
Thank you for volunteering to participate in this study. Please complete the survey and mail in
the enclosed business reply envelope. Any questions related to the questionnaire may be directed to
Andrea Pfalzgraf, 412-225-6845 or Dr. Ginger Scott at 304-293-1553. Thank you in advance for
your valuable time and information.

Sincerely,

Andrea Pfalzgraf, MPH
Doctoral Candidate

Virginia (Ginger) Scott, PhD, MS, RPh
Professor and Advisor

WVU IRB reviewed and acknowledged
Digitally signed by John H. Hagen
DN: cn=John H. Hagen, o=West
Virginia University Libraries,
ou=Acquisitions Department,
email=John.Hagen@mail.wvu.edu,
c=US
Reason: I am approving this
document.
Date: 2009.04.30 16:19:39 -04'00'
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